{"docstore/data": {"fb30f01d-f1da-4b6c-af85-8e350e254872": {"__data__": {"id_": "fb30f01d-f1da-4b6c-af85-8e350e254872", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. ", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f7b529e-12d8-4900-b952-9073dc122dc9", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. ", "original_text": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year. "}, "hash": "d93e3da80e06f31a5b5a7d9b9f085a0b320f118640f528a8ef000667e419b0cf", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion. ", "start_char_idx": 0, "end_char_idx": 637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f7b529e-12d8-4900-b952-9073dc122dc9": {"__data__": {"id_": "1f7b529e-12d8-4900-b952-9073dc122dc9", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. ", "original_text": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb30f01d-f1da-4b6c-af85-8e350e254872", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. ", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "594e42c113535404ffd4c0ff1004e67fac743ec39b9b8aca60d8e4bf8cb26ac0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c935420a-5b2a-49d7-a67e-4b49593ccb0b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n", "original_text": "On the basis of U.S. "}, "hash": "512811f95ff5c0e7c8af9405ddf2e5bdd13cf3e3721cf38e15a88f29d7e52073", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year. ", "start_char_idx": 637, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c935420a-5b2a-49d7-a67e-4b49593ccb0b": {"__data__": {"id_": "c935420a-5b2a-49d7-a67e-4b49593ccb0b", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f7b529e-12d8-4900-b952-9073dc122dc9", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. ", "original_text": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc7520b657eb0f4781442dc43e63364046fe211aab3a5fdcf6d4b3169ad1cfc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8998fb25-1e69-4c19-a1b0-7d4ef5172064", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. "}, "hash": "e5acb7658ed2d1ce5e3a1faae9c6c13dc6831ef26ee91761e56ec61b1d1690b3", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 707, "end_char_idx": 728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8998fb25-1e69-4c19-a1b0-7d4ef5172064": {"__data__": {"id_": "8998fb25-1e69-4c19-a1b0-7d4ef5172064", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c935420a-5b2a-49d7-a67e-4b49593ccb0b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f911794736036d3ac6618a795022fc4a04a6f16693ab156e7a3bc5dd088c72a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3607aeac-91ec-4d39-812c-96a8d51d323a", "node_type": "1", "metadata": {"window": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. "}, "hash": "21abe95419c565e28b39be053d3107a159f8a045a1289371a261fe0f47d4eb99", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. ", "start_char_idx": 728, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3607aeac-91ec-4d39-812c-96a8d51d323a": {"__data__": {"id_": "3607aeac-91ec-4d39-812c-96a8d51d323a", "embedding": null, "metadata": {"window": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8998fb25-1e69-4c19-a1b0-7d4ef5172064", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n", "original_text": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fe9816cace845a6267c97d574b8681c82c88449da69831a496958ba725d0788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63d75c4-d735-4983-98ec-e655c9d3ca3d", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. ", "original_text": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n"}, "hash": "5a53a5bcb10f65cf9c381c11226f8e4eaa25eb3b6e3be6a869c4d9e5a4ae83b1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. ", "start_char_idx": 910, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63d75c4-d735-4983-98ec-e655c9d3ca3d": {"__data__": {"id_": "f63d75c4-d735-4983-98ec-e655c9d3ca3d", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. ", "original_text": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3607aeac-91ec-4d39-812c-96a8d51d323a", "node_type": "1", "metadata": {"window": "Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "original_text": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1225d4da4d3550f1d01543840b1aaf7438722658bee5274958cc548a08cb093", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cb7553f-8fbb-4ed1-8189-d1c168cac871", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. ", "original_text": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n"}, "hash": "c96e059b2b052545bbe3c312f2b4daaff6f494b652ac66eab10d461314cb1471", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n", "start_char_idx": 1060, "end_char_idx": 1136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cb7553f-8fbb-4ed1-8189-d1c168cac871": {"__data__": {"id_": "3cb7553f-8fbb-4ed1-8189-d1c168cac871", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. ", "original_text": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63d75c4-d735-4983-98ec-e655c9d3ca3d", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. ", "original_text": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bae15cc6d478b2dc570bec6c8e67fe15ea0b498388d0c57616c1fee8b1f21bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d4b2432-0911-4127-a716-5bc41001bac3", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n", "original_text": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n"}, "hash": "83ce09ee00c8777fc241233e31c78e18d8a70e5eaff6628c8c9cb79ab9c32855", "class_name": "RelatedNodeInfo"}}, "text": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n", "start_char_idx": 1136, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d4b2432-0911-4127-a716-5bc41001bac3": {"__data__": {"id_": "4d4b2432-0911-4127-a716-5bc41001bac3", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n", "original_text": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cb7553f-8fbb-4ed1-8189-d1c168cac871", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter.  Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. ", "original_text": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8c12b883da51cd6ee88f7b9f67b09b526ccbd058a720efb50bd98a4e3a94532", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbd13a51-c9d3-4545-85ca-d93b0a927887", "node_type": "1", "metadata": {"window": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n", "original_text": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. "}, "hash": "cc3a0250c69e45c98d16439dcbeeeb9f456ae9c57e71d5291a9cc3dc7518ae9a", "class_name": "RelatedNodeInfo"}}, "text": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "start_char_idx": 1268, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbd13a51-c9d3-4545-85ca-d93b0a927887": {"__data__": {"id_": "fbd13a51-c9d3-4545-85ca-d93b0a927887", "embedding": null, "metadata": {"window": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n", "original_text": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d4b2432-0911-4127-a716-5bc41001bac3", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-\nGAAP measure that excludes items described below, increased 26.5 percent to $2.39 in the fiscal fourth quarter.  For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n", "original_text": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce531fa48ba2b070a2837889db8ded5ce13a8ebdcf9476cd97432aa22ef37ee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e9303fe-4dde-493b-ad56-86c67d9bad00", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. "}, "hash": "c265a7b12e1cdf02581a37792c225746dcd9ddbc3d4f493705d64aaad4630b3e", "class_name": "RelatedNodeInfo"}}, "text": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. ", "start_char_idx": 1600, "end_char_idx": 1747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e9303fe-4dde-493b-ad56-86c67d9bad00": {"__data__": {"id_": "3e9303fe-4dde-493b-ad56-86c67d9bad00", "embedding": null, "metadata": {"window": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbd13a51-c9d3-4545-85ca-d93b0a927887", "node_type": "1", "metadata": {"window": "For fiscal year 2021,\nadjusted diluted EPS increased 17.2 percent to $9.26.\n \u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n", "original_text": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9aaa016b6deaf45253314fdff84cce442574f976b5ddbdf1ac026792feeea25e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf807aaf-a818-44cf-95e7-065c6667df16", "node_type": "1", "metadata": {"window": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "Collis continued.\n"}, "hash": "139dd88a8628547a2a941d6b854f2946e3d554b3cf9b29b415accde06d4a0a45", "class_name": "RelatedNodeInfo"}}, "text": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. ", "start_char_idx": 1747, "end_char_idx": 1968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf807aaf-a818-44cf-95e7-065c6667df16": {"__data__": {"id_": "cf807aaf-a818-44cf-95e7-065c6667df16", "embedding": null, "metadata": {"window": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "Collis continued.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e9303fe-4dde-493b-ad56-86c67d9bad00", "node_type": "1", "metadata": {"window": "\u201cAmerisourceBergen delivered strong growth in our 2021 fiscal year and took key steps to further enhance our strategic positioning.\n The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42876d0fe3c33a82866d76229835bc396045e3dd2daaecc3c7362435473ee33c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "790778c9-d0de-49a5-9472-56818c0dd008", "node_type": "1", "metadata": {"window": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "\"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n"}, "hash": "b3ef4a210676d78de29ed1cd44c4e7b0ca1738e312fe0e61846a4e4016a5f3be", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued.\n", "start_char_idx": 1968, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "790778c9-d0de-49a5-9472-56818c0dd008": {"__data__": {"id_": "790778c9-d0de-49a5-9472-56818c0dd008", "embedding": null, "metadata": {"window": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "\"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf807aaf-a818-44cf-95e7-065c6667df16", "node_type": "1", "metadata": {"window": "The investments we have made in our business and team members support AmerisourceBergen's ability to help advance healthcare\nthrough our differentiated capabilities for manufacturers globally and solutions for healthcare providers locally,\" said Steven H.\nCollis, Chairman, President & Chief Executive Officer of AmerisourceBergen.\n \"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "Collis continued.\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18dda8be73653b0005333e030d63c4287228483e1d59b2e9a701c33409c7c5ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09101624-2e97-4fcd-bf5a-539db64fbd57", "node_type": "1", "metadata": {"window": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1"}, "hash": "208310c3afc2fc581c026867148b0a842a6eb3774c12fb30be77b2d4ca6687e5", "class_name": "RelatedNodeInfo"}}, "text": "\"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n", "start_char_idx": 1986, "end_char_idx": 2160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09101624-2e97-4fcd-bf5a-539db64fbd57": {"__data__": {"id_": "09101624-2e97-4fcd-bf5a-539db64fbd57", "embedding": null, "metadata": {"window": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "867b5a13-688e-4a45-97ba-c3feb7565389", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a06184ae5e55e0a97f25b2efde7ba1e2affd7c635d54c327103fcb019dd9c23", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "790778c9-d0de-49a5-9472-56818c0dd008", "node_type": "1", "metadata": {"window": "\"I am proud of how we have lived our purpose with our customers, partners and team members throughout these challenging times\nfor our communities.  As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "\"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ef826fdd66a408092dbe92e3e37fc951dc4760c3d1d92dba089fca0fdab7df7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c920032-d067-417e-b8f3-bd9e316ac195", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. "}, "hash": "4ea717b852074046cabe1acd35cf9e0dac4f10c650960069ba673d148d4c3747", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "start_char_idx": 2160, "end_char_idx": 2459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c920032-d067-417e-b8f3-bd9e316ac195": {"__data__": {"id_": "3c920032-d067-417e-b8f3-bd9e316ac195", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09101624-2e97-4fcd-bf5a-539db64fbd57", "node_type": "1", "metadata": {"window": "As we look to capitalize on a year of significant advancement, we are well positioned by our strong customer\nbase, leadership in specialty, commitment to innovation and execution, and focus on corporate stewardship,\" Mr.  Collis continued.\n \"Our long-term, sustainable growth is powered by our talent and culture, and we are guided by our purpose of being united in our\nresponsibility to create healthier futures.\"\n Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "original_text": "Four th Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0GAAP Adjust ed (Non-\nGAAP)\nRevenue $58.9B $58.9B\nGross Pr ofit $2.1B $2.0B\nOperating Expenses $1.5B $1.3B\nOperating Income $562M $694M\nInterest Expense, Net $55M $55M\nEffectiv e Tax Rat e 21.2% 20.3%\nNet Income A ttributable t o\nABC $438M $504M\n1", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b06c3c3b93f4a44f3a738b39578807531010cb82eab77e768c23714f94bbc91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e78cd766-657e-48b7-94a8-8a978c260eb6", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "2fcfb78304ac9b2cb3bb9669ef2af7b90f995d082356e6aaa6d4d7f5b1871ab3", "class_name": "RelatedNodeInfo"}}, "text": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "start_char_idx": 0, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e78cd766-657e-48b7-94a8-8a978c260eb6": {"__data__": {"id_": "e78cd766-657e-48b7-94a8-8a978c260eb6", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c920032-d067-417e-b8f3-bd9e316ac195", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14bcd4e0f3e059a03728d3b032cbcdebe6330a05a678fb2b8a34c5619e03a76a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "379d1b3e-41ca-4e49-8b27-314ef8a01980", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n"}, "hash": "696589b4303d950b0c2f405d876e694029eea166d35642d4817c380d741eceba", "class_name": "RelatedNodeInfo"}}, "text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 222, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "379d1b3e-41ca-4e49-8b27-314ef8a01980": {"__data__": {"id_": "379d1b3e-41ca-4e49-8b27-314ef8a01980", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e78cd766-657e-48b7-94a8-8a978c260eb6", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1fb7e27615c70b4f6db60911ec2fea5573dffb857544106b159c3c4ea3c2946", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7244cccb-bb8f-4ceb-a1d3-3ecfecb506eb", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "6a01c7a2b506ed068fb50bb7f48ce18657ce13038467f88ebd9aed359c954757", "class_name": "RelatedNodeInfo"}}, "text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n", "start_char_idx": 314, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7244cccb-bb8f-4ceb-a1d3-3ecfecb506eb": {"__data__": {"id_": "7244cccb-bb8f-4ceb-a1d3-3ecfecb506eb", "embedding": null, "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "379d1b3e-41ca-4e49-8b27-314ef8a01980", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "original_text": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad66f5663f51abef849dbd86f0f05da2cb1e9b4a3df0e817d8a28663ad3acfda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "965afa94-7a1c-4230-bfdc-510ed048ff49", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. "}, "hash": "692be4946e299fc007da924edba848b4df7161125009f513b9c4e562347c5c98", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 533, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "965afa94-7a1c-4230-bfdc-510ed048ff49": {"__data__": {"id_": "965afa94-7a1c-4230-bfdc-510ed048ff49", "embedding": null, "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7244cccb-bb8f-4ceb-a1d3-3ecfecb506eb", "node_type": "1", "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n", "original_text": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b00397bbd86264e28450ac896f0124eded1c46fe5fb29d16155362237254e3fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e19e0b62-bc01-44ff-acb3-a9f7ddf999ae", "node_type": "1", "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. ", "original_text": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. "}, "hash": "277d42ed06d09ca427ff6cbf841f2e653146ddbea29aefbb02ec0f049967c62c", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 919, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e19e0b62-bc01-44ff-acb3-a9f7ddf999ae": {"__data__": {"id_": "e19e0b62-bc01-44ff-acb3-a9f7ddf999ae", "embedding": null, "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. ", "original_text": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "965afa94-7a1c-4230-bfdc-510ed048ff49", "node_type": "1", "metadata": {"window": "In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ec7cb3bdacb31fb6c672da1c1c384303715188d3cc2b9b53ca903e11e20c8cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9d74e9b-cec7-435b-9c0f-aa44fba55d19", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n", "original_text": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n"}, "hash": "a48190c2ac35bafdd64fa6fcff019bf0bfb54b350be2af93731c81d58610ab97", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "start_char_idx": 1080, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9d74e9b-cec7-435b-9c0f-aa44fba55d19": {"__data__": {"id_": "f9d74e9b-cec7-435b-9c0f-aa44fba55d19", "embedding": null, "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n", "original_text": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e19e0b62-bc01-44ff-acb3-a9f7ddf999ae", "node_type": "1", "metadata": {"window": "For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. ", "original_text": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bfefc1f14545ac915a2e7f5cdfbca9a7697da0417d8e3fb6652547184092ce43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eed55b2-7c3c-4403-9c7e-fe6c7bd1cc8d", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. "}, "hash": "816e641a1802c961ce375e38846aabeeff734f77990fe17c2c9119f547314267", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n", "start_char_idx": 1274, "end_char_idx": 1607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eed55b2-7c3c-4403-9c7e-fe6c7bd1cc8d": {"__data__": {"id_": "8eed55b2-7c3c-4403-9c7e-fe6c7bd1cc8d", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9d74e9b-cec7-435b-9c0f-aa44fba55d19", "node_type": "1", "metadata": {"window": "Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n", "original_text": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68afeb572ee097d4ddb79f5771315dff4efc10adb78bf141a61f2afed029c236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc57206b-b2af-4130-a874-898b9f690cf0", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n", "original_text": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. "}, "hash": "84e49fb6c4f6aadce02d58a1f18ddf2c9f634ddd4da508d7689ff5617fe1d41a", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. ", "start_char_idx": 1607, "end_char_idx": 1765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc57206b-b2af-4130-a874-898b9f690cf0": {"__data__": {"id_": "cc57206b-b2af-4130-a874-898b9f690cf0", "embedding": null, "metadata": {"window": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n", "original_text": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eed55b2-7c3c-4403-9c7e-fe6c7bd1cc8d", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the fiscal 2021 fourth quarter was $2.1 billion, a 53.6 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. ", "original_text": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50d7de1596560f2a76ba86405312c7129a742fe84a05b54546ec14cc5e85de6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ab6b56c-eeff-45ee-9267-5489473452bd", "node_type": "1", "metadata": {"window": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n"}, "hash": "807edd2ca9f2ce650131bea61ccb280c5b72e5464135a076eb021a723dc237f7", "class_name": "RelatedNodeInfo"}}, "text": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. ", "start_char_idx": 1765, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ab6b56c-eeff-45ee-9267-5489473452bd": {"__data__": {"id_": "3ab6b56c-eeff-45ee-9267-5489473452bd", "embedding": null, "metadata": {"window": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc57206b-b2af-4130-a874-898b9f690cf0", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by increases in gross profit in Other, which was\nprimarily driven by the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n", "original_text": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c372770ab3ef276c9b044ecad87c92ca69396cc2f58c97c24a8fa5c1e5a8d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a47c259-7683-4031-b5f9-fad81f6a2dce", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. ", "original_text": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. "}, "hash": "3f1b57820ef8843ae193e05e3f4eb5d7461b582a7517fddde7b59b90c0826514", "class_name": "RelatedNodeInfo"}}, "text": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n", "start_char_idx": 1970, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a47c259-7683-4031-b5f9-fad81f6a2dce": {"__data__": {"id_": "4a47c259-7683-4031-b5f9-fad81f6a2dce", "embedding": null, "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. ", "original_text": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ab6b56c-eeff-45ee-9267-5489473452bd", "node_type": "1", "metadata": {"window": "Gross profit as a\npercentage of revenue was 3.51 percent, an increase of 77 basis points from the prior year quarter primarily driven by the\nJune 2021 acquisition of Alliance Healthcare, an increase in sales of specialty products in Pharmaceutical Distribution Services,\nand growth in some of the Company's higher margin businesses.\n Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8b43fe1e9103ad8b8a28114d36c8083bfeff0e727f5bedeb32d5dc9e13a6cba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13d6a852-721d-4705-b93d-fbac9bc16fe3", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n"}, "hash": "417a5cd6cc94c2bdd033d653787fa364d0399424e917a9a8be09193088634d7e", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. ", "start_char_idx": 2187, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13d6a852-721d-4705-b93d-fbac9bc16fe3": {"__data__": {"id_": "13d6a852-721d-4705-b93d-fbac9bc16fe3", "embedding": null, "metadata": {"window": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a47c259-7683-4031-b5f9-fad81f6a2dce", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the fourth quarter of fiscal 2021, operating expenses were $1.5 billion compared to $7.5 billion in the\nsame period last fiscal year.  The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. ", "original_text": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71a6d632b549afdf4bffd215369cc25061dd15c12f367c0fd12f0c0af7b37e7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f062024a-ae59-440c-af9f-545fc7adfb18", "node_type": "1", "metadata": {"window": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "292bd84f2a4e9b0fb3e825dca6d63e5d09587badfa88dd54cdebd49c3021d6b7", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n", "start_char_idx": 2338, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f062024a-ae59-440c-af9f-545fc7adfb18": {"__data__": {"id_": "f062024a-ae59-440c-af9f-545fc7adfb18", "embedding": null, "metadata": {"window": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13d6a852-721d-4705-b93d-fbac9bc16fe3", "node_type": "1", "metadata": {"window": "The decrease in operating expenses was primarily due to the $6.6 billion legal expense accrual\nrecorded in the prior year quarter and was partially offset by the operating expenses of Alliance Healthcare.  Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n", "original_text": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8db0d2734cd4c47ab97dfbf23b3dbb0a491303fee1db46c79843fe1c08e69c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d996dcea-f310-428a-b81c-ea8dca640ceb", "node_type": "1", "metadata": {"window": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. "}, "hash": "e0a9236a15b24c54b83d16e1a28a90a8e599fc9988dacfb29e762a1d0b715913", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 2576, "end_char_idx": 2825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d996dcea-f310-428a-b81c-ea8dca640ceb": {"__data__": {"id_": "d996dcea-f310-428a-b81c-ea8dca640ceb", "embedding": null, "metadata": {"window": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f062024a-ae59-440c-af9f-545fc7adfb18", "node_type": "1", "metadata": {"window": "Operating\nexpenses as a percentage of revenue in the fiscal 2021 fourth quarter were 2.56 percent, compared to 15.15 percent for the\nsame period in the previous fiscal year primarily due to the items mentioned above.\n Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3390816f3993185da2dadb8eaae5eeb4f7e1dc1c234954848555c1941748b796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c37dd9b-c67a-41c5-ba86-f56c91c4b431", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.1 percent\nin the prior year quarter.\n"}, "hash": "8c15ce7b5f236a254ea21e6207bbbc43c34edc79eefee3e05381b6886cd2ceee", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. ", "start_char_idx": 2825, "end_char_idx": 2925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c37dd9b-c67a-41c5-ba86-f56c91c4b431": {"__data__": {"id_": "8c37dd9b-c67a-41c5-ba86-f56c91c4b431", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.1 percent\nin the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d996dcea-f310-428a-b81c-ea8dca640ceb", "node_type": "1", "metadata": {"window": "Operating Income (Loss):  In the fiscal 2021 fourth quarter, operating income (loss) was $0.6 billion versus $(6.1) billion in the\nprior year quarter.  Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4cdfaf5e2b4fca048949c80aef4942ad552be8c55e7874bc5213721d019c3b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d7e85db-b14d-42ad-a425-0f2efea7487f", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n"}, "hash": "cf2dd39a39509299a8112240e73080e761e98efc3c84b126b91b7bec1dade175", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 21.1 percent\nin the prior year quarter.\n", "start_char_idx": 2925, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d7e85db-b14d-42ad-a425-0f2efea7487f": {"__data__": {"id_": "8d7e85db-b14d-42ad-a425-0f2efea7487f", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c37dd9b-c67a-41c5-ba86-f56c91c4b431", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 0.95 percent in the fourth quarter of fiscal 2021,\ncompared to (12.41) percent for the same period in the previous fiscal year as a result of the previously mentioned legal\nexpense accrual.\n Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 21.1 percent\nin the prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "139211c5e9e2fc6f26d23cbfedf2c7eea93f3e1a0038205b15e81b1e0bac6e3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be3f9295-d91a-441b-9428-e4e5db0ff4da", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n"}, "hash": "d836069d764b6b156e298cbbb5e64b582fa1e1c87db6afb1c6f7bb36f0c05c00", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n", "start_char_idx": 2982, "end_char_idx": 3210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be3f9295-d91a-441b-9428-e4e5db0ff4da": {"__data__": {"id_": "be3f9295-d91a-441b-9428-e4e5db0ff4da", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d7e85db-b14d-42ad-a425-0f2efea7487f", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 fourth quarter, net interest expense of $54.6 million was up 57.3 percent versus the\nprior year quarter primarily due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "303d47e4ea1fbd0efc386d5ed9f06d349b2945df1e36adc2444d632f08644da7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e192c913-6afb-4f10-9cb4-99ea22052f07", "node_type": "1", "metadata": {"window": "This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "40af476410f8479bf2d7736ac32495971ca88596368208829d187887f611a719", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "start_char_idx": 3210, "end_char_idx": 3575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e192c913-6afb-4f10-9cb4-99ea22052f07": {"__data__": {"id_": "e192c913-6afb-4f10-9cb4-99ea22052f07", "embedding": null, "metadata": {"window": "This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be3f9295-d91a-441b-9428-e4e5db0ff4da", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 21.2 percent for the fourth quarter of fiscal 2021.  This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8d7d7e578b8b425b12e18ed0d653b2cd7ee18af9cd4afe6dce3b44291965446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e86c5902-6762-4d25-a692-2cd8e20f3d92", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n"}, "hash": "afa8aac27340b123d5a3fa482d5c5ce2e66e0765576d20ea2ed667ad7874f36e", "class_name": "RelatedNodeInfo"}}, "text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3575, "end_char_idx": 3694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e86c5902-6762-4d25-a692-2cd8e20f3d92": {"__data__": {"id_": "e86c5902-6762-4d25-a692-2cd8e20f3d92", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e192c913-6afb-4f10-9cb4-99ea22052f07", "node_type": "1", "metadata": {"window": "This compares to 21.1 percent\nin the prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77541aa9f629f0cafe2cc3b673978560bf02b761b31df84c93e4732a68a64c4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3d7f4c8-1097-40c5-ad0c-1ab503243bb9", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. "}, "hash": "1b92f65e20965c3106c93f1d0a03ff0640a7b8e234638aee84a9bf37d141487f", "class_name": "RelatedNodeInfo"}}, "text": "In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n", "start_char_idx": 3694, "end_char_idx": 4029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3d7f4c8-1097-40c5-ad0c-1ab503243bb9": {"__data__": {"id_": "e3d7f4c8-1097-40c5-ad0c-1ab503243bb9", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e86c5902-6762-4d25-a692-2cd8e20f3d92", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.08 in the fourth quarter of fiscal 2021 compared to $(23.74) in\nthe previous fiscal year fourth quarter, which was negatively impacted by the legal expense accrual.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da4752444dd16c79308e1b91b96ee0884a7b779e497f20cede3db878a21696a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "561543e4-57eb-4dc2-ae35-fafb4fea2386", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2"}, "hash": "6be6c751e467f025fddf60b2330b7e0533ad9b80d9a88b44679c0b1cec5117ce", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "start_char_idx": 4029, "end_char_idx": 4371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "561543e4-57eb-4dc2-ae35-fafb4fea2386": {"__data__": {"id_": "561543e4-57eb-4dc2-ae35-fafb4fea2386", "embedding": null, "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ef133143-d754-4537-a987-836ab2b9b35f", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f61d368149de5bc8e684a4c30d5a6b3bbaa34bbf5e0da04f19b0315db5f4516", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3d7f4c8-1097-40c5-ad0c-1ab503243bb9", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were 210.8\nmillion, a 3.3 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million Company\nshares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a0e8c9892650c7c28f7412254c6933ffaf24c034fc287adaadbc822b2cfd0ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "756efeac-0cb4-48eb-8e77-4c6154a8b486", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "original_text": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n"}, "hash": "24025e499da8af75964bba3356e6ae21eab9abf015424d0c3196b8e1786a18ef", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "start_char_idx": 4371, "end_char_idx": 4521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "756efeac-0cb4-48eb-8e77-4c6154a8b486": {"__data__": {"id_": "756efeac-0cb4-48eb-8e77-4c6154a8b486", "embedding": null, "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "original_text": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "561543e4-57eb-4dc2-ae35-fafb4fea2386", "node_type": "1", "metadata": {"window": "Four th Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the fourth quarter of fiscal 2021, revenue was\n$58.9 billion, up 19.6 percent compared to the same quarter in the previous fiscal year, reflecting an 8.4 percent increase in\nPharmaceutical Distribution Services revenue and a 286.8 percent increase in revenue within Other primarily driven by the\nacquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 fourth quarter was $2.0 billion, which was up 51.3 percent\ncompared to the same period in the previous fiscal year due to increases in gross profit in Other, which was primarily driven\nby the June 2021 Alliance Healthcare acquisition, and Pharmaceutical Distribution Services.  Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "original_text": "Adjusted gross profit as a\npercentage of revenue was 3.40 percent in the fiscal 2021 fourth quarter, an increase of 71 basis points when compared to\n2", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6149d071cf051923222ddb10dc545b8ccd9e762244f732f5210af78ee85e3f4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fe18875-008d-4559-b668-9ecf60062442", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n"}, "hash": "92a590258a0ad95d78157e930784ecf2c0149d3fc6b09db1a069585323bf66c0", "class_name": "RelatedNodeInfo"}}, "text": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "start_char_idx": 0, "end_char_idx": 225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fe18875-008d-4559-b668-9ecf60062442": {"__data__": {"id_": "4fe18875-008d-4559-b668-9ecf60062442", "embedding": null, "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "756efeac-0cb4-48eb-8e77-4c6154a8b486", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "original_text": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "431f4006dafa8a032f4eb59d8a2a5c222f58f9c2728a085bb43f4d2698526df4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d48a009-df3b-440c-9275-2b5e079ec444", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n"}, "hash": "65549bbd7aabc30c0307f7bac0f360f10fb345ce90b7952db6def5378185d377", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n", "start_char_idx": 225, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d48a009-df3b-440c-9275-2b5e079ec444": {"__data__": {"id_": "5d48a009-df3b-440c-9275-2b5e079ec444", "embedding": null, "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fe18875-008d-4559-b668-9ecf60062442", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n", "original_text": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7f625377a3e9925b34d2eae223f6ef1ce3b3a7560bff5249034d86c3ba08a7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "207d9c4b-9dc7-4ffe-b3da-6391f8c5a28f", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. "}, "hash": "c95e1e519b885c6806f63ef83071272c9f1c88ae5a7397aa40b72ae6fdfc9b6c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "start_char_idx": 598, "end_char_idx": 833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "207d9c4b-9dc7-4ffe-b3da-6391f8c5a28f": {"__data__": {"id_": "207d9c4b-9dc7-4ffe-b3da-6391f8c5a28f", "embedding": null, "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d48a009-df3b-440c-9275-2b5e079ec444", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8eea98182cbd8b302e18ffc7f0bfdcd50d2f9182a2e5bba88e6402eb41d35e94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "084b6942-30fc-4756-b411-428ed01fe9af", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n", "original_text": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n"}, "hash": "fe6fb13d209932d500c543987e93d2bc44ddde5cd1cf01c2adbbe6ba978784ae", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "start_char_idx": 833, "end_char_idx": 1143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "084b6942-30fc-4756-b411-428ed01fe9af": {"__data__": {"id_": "084b6942-30fc-4756-b411-428ed01fe9af", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n", "original_text": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "207d9c4b-9dc7-4ffe-b3da-6391f8c5a28f", "node_type": "1", "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "046b7cc57d01b14c71e8ab6aed5fa9978a19dfabdd2febfb4a6112187b78b09a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aef7bca5-028c-4f72-9962-5de4ae26b43d", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "b21d4e364048ea5500f67dc696835df14d9f846e0c721846dab6d52e30c3eed4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n", "start_char_idx": 1143, "end_char_idx": 1383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aef7bca5-028c-4f72-9962-5de4ae26b43d": {"__data__": {"id_": "aef7bca5-028c-4f72-9962-5de4ae26b43d", "embedding": null, "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "084b6942-30fc-4756-b411-428ed01fe9af", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n", "original_text": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c258bd457f8d45b8184b99ef8094b9205457a8abdd7be8a3a282c581b0897395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0fbecbb-bcee-4f98-ad9f-58ed67e70ea7", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "original_text": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "dd2c514615bb408bfbfcb7d45cf5b1933e3616f5f2eab4546ba9e36291a7bfb1", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1383, "end_char_idx": 1482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0fbecbb-bcee-4f98-ad9f-58ed67e70ea7": {"__data__": {"id_": "b0fbecbb-bcee-4f98-ad9f-58ed67e70ea7", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "original_text": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aef7bca5-028c-4f72-9962-5de4ae26b43d", "node_type": "1", "metadata": {"window": "Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbb05eff04c435033737bfcfeab125aaff49b304527260b20e284c8450705521", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9af23843-2920-4ed9-995e-3052c019dcb0", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n"}, "hash": "43aff20c0aa661448f59bac415b051feeddf86cba0631fb2ebfc8513d131eaf0", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 1482, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9af23843-2920-4ed9-995e-3052c019dcb0": {"__data__": {"id_": "9af23843-2920-4ed9-995e-3052c019dcb0", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0fbecbb-bcee-4f98-ad9f-58ed67e70ea7", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income.  Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "original_text": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ae84e6b192906c559cb04cd945136e85eba4d2a06a9c4fa7563e55dbf11fc05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d02beb8c-7177-4768-864d-ba41f9e38fba", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n"}, "hash": "1e0a0841e7fd2cc3219aa8b8f9fa6f21f7c93214a9ae2a3003bc62fa3e786250", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n", "start_char_idx": 1707, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d02beb8c-7177-4768-864d-ba41f9e38fba": {"__data__": {"id_": "d02beb8c-7177-4768-864d-ba41f9e38fba", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9af23843-2920-4ed9-995e-3052c019dcb0", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue\nwas 1.18 percent in the fiscal 2021 fourth quarter, an increase of 10 basis points when compared to the prior year quarter\nprimarily due to the June 2021 Alliance Healthcare acquisition.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "244dfe660c0cb48ee68df71ccd0b89bb3fe74c9752554bc845599550d0adb5e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f326c2a-aeb5-425c-a770-b0bc83b90be5", "node_type": "1", "metadata": {"window": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "original_text": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n"}, "hash": "4df6ed7b09790bc4f1c276c8d77f5d77ac92ff37a04b3299906184123fa3bb82", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n", "start_char_idx": 1983, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f326c2a-aeb5-425c-a770-b0bc83b90be5": {"__data__": {"id_": "3f326c2a-aeb5-425c-a770-b0bc83b90be5", "embedding": null, "metadata": {"window": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "original_text": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d02beb8c-7177-4768-864d-ba41f9e38fba", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc388b95d21eda60ebf47ea5922d10398dcc4c7b0046d1a52b118d27520b9bb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c84c170f-8da4-4c98-8cb1-3fed24c6c5dd", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. "}, "hash": "d126ed0e9b2fe0d56f8f233e0feeb0bf30a88e650c7896fd10fd6edc0e0098f8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "start_char_idx": 2323, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c84c170f-8da4-4c98-8cb1-3fed24c6c5dd": {"__data__": {"id_": "c84c170f-8da4-4c98-8cb1-3fed24c6c5dd", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f326c2a-aeb5-425c-a770-b0bc83b90be5", "node_type": "1", "metadata": {"window": "In the fiscal 2021 fourth\nquarter, net interest expense of $54.6 million was up 57.3 percent versus the prior year quarter primarily due to an increase in\ndebt as a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "original_text": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35bed031b01a349504b97c773926ced039ed8c4046453d4fc4d7506235e29611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c10f97f-cb4f-49b5-b83e-5c0649c6a3db", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n", "original_text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). "}, "hash": "0968163712105ea70c260839cdddb816798cbc99a8aa2df82c1346fa21a41445", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "start_char_idx": 2697, "end_char_idx": 3029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c10f97f-cb4f-49b5-b83e-5c0649c6a3db": {"__data__": {"id_": "4c10f97f-cb4f-49b5-b83e-5c0649c6a3db", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n", "original_text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c84c170f-8da4-4c98-8cb1-3fed24c6c5dd", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 20.3 percent for the fourth quarter of fiscal 2021 compared to\n21.7 percent in the prior year quarter as a result of the Company's change in mix of domestic and international income in the\nrespective quarters.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9e6cb4fb054bb40c67eda67dcba50ff26daf7b754940286452f17d39aebad43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f5a4254-8529-43c4-ae60-f130339d9c55", "node_type": "1", "metadata": {"window": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. ", "original_text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n"}, "hash": "ee392457a3645899ba6d453defea04557f653d451252132cc58dbfaa67ceba04", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "start_char_idx": 3029, "end_char_idx": 3256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f5a4254-8529-43c4-ae60-f130339d9c55": {"__data__": {"id_": "2f5a4254-8529-43c4-ae60-f130339d9c55", "embedding": null, "metadata": {"window": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. ", "original_text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c10f97f-cb4f-49b5-b83e-5c0649c6a3db", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 26.5 percent to $2.39 in the fourth quarter\nof fiscal 2021 compared to $1.89 in the previous fiscal year fourth quarter, driven by the increase in adjusted operating\nincome and partially offset by higher net interest expense and a higher diluted share count.\n Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n", "original_text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "437a10dc4fe219549e5dffc117cbd9dbfad251661278792c6be75499c4a12761", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d35afe02-f45c-4362-85a5-ed9233d4d6d0", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n"}, "hash": "37f2abf3e17f011b5435858787f42f51cd60b59da04f0a2a0be7837d020e2c22", "class_name": "RelatedNodeInfo"}}, "text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "start_char_idx": 3256, "end_char_idx": 3401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d35afe02-f45c-4362-85a5-ed9233d4d6d0": {"__data__": {"id_": "d35afe02-f45c-4362-85a5-ed9233d4d6d0", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f5a4254-8529-43c4-ae60-f130339d9c55", "node_type": "1", "metadata": {"window": "Adjusted Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the fourth quarter of fiscal 2021 were\n210.8 million, a 2.2 percent increase versus the prior fiscal year fourth quarter resulting from the issuance of 2 million\nCompany shares to Walgreens for the acquisition of Alliance Healthcare, stock option exercises, and restricted stock vesting.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. ", "original_text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09145f82922da357a1aff7db6c1cd66b5e51e73cce059486b1297282d12115d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "384803c5-197d-460c-b65e-00191d4880aa", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n"}, "hash": "307eb7bfce942c13caa457d1c333c30bb741c425e70f5a8e93a2860a977e4e93", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n", "start_char_idx": 3401, "end_char_idx": 3705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "384803c5-197d-460c-b65e-00191d4880aa": {"__data__": {"id_": "384803c5-197d-460c-b65e-00191d4880aa", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d35afe02-f45c-4362-85a5-ed9233d4d6d0", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d10af6ea5784cf275364ebf6850571e47bafa1e1d0ce136465682a2443e737d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1d0f6ef-590d-4cf9-980b-111d3f00d96d", "node_type": "1", "metadata": {"window": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. "}, "hash": "771171c956579940965bcb4285175ad57b5f99d37c29fa7b092916b56a1f69c8", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n", "start_char_idx": 3705, "end_char_idx": 3980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1d0f6ef-590d-4cf9-980b-111d3f00d96d": {"__data__": {"id_": "d1d0f6ef-590d-4cf9-980b-111d3f00d96d", "embedding": null, "metadata": {"window": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "384803c5-197d-460c-b65e-00191d4880aa", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ca865184abb652170ff648f94f709bcda75d2ff54b8d605121bc522ce2ceb6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aad6b1da-2478-43c4-87f1-965bcf57e72e", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n"}, "hash": "ee4050c4a57b9d4dbb224fd7edf1db1199f2b0b142f85f561b24e2970c293b12", "class_name": "RelatedNodeInfo"}}, "text": "Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. ", "start_char_idx": 3980, "end_char_idx": 4270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aad6b1da-2478-43c4-87f1-965bcf57e72e": {"__data__": {"id_": "aad6b1da-2478-43c4-87f1-965bcf57e72e", "embedding": null, "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1d0f6ef-590d-4cf9-980b-111d3f00d96d", "node_type": "1", "metadata": {"window": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier. ", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3427bcee89c894d2a3ac466c6ccff73fc85094c6f58089b5fbe08f2aaf418a88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "875239ee-3226-4c2a-9732-011b840b509e", "node_type": "1", "metadata": {"window": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Fiscal Y ear 2021 Summar y Results\n3"}, "hash": "06fcc04c29c60e3125814caafdc4a44e9fb86ca96cf6899be75a0855c405f74d", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n", "start_char_idx": 4270, "end_char_idx": 4422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "875239ee-3226-4c2a-9732-011b840b509e": {"__data__": {"id_": "875239ee-3226-4c2a-9732-011b840b509e", "embedding": null, "metadata": {"window": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Fiscal Y ear 2021 Summar y Results\n3", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "602b3ddcd0870a6fbda8f9ed544555fe5b95d5c5df02c0ac327a315136796b3b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aad6b1da-2478-43c4-87f1-965bcf57e72e", "node_type": "1", "metadata": {"window": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $51.2 billion, an increase of 8.4 percent compared to the same quarter in the prior\nfiscal year primarily due to increased sales of specialty products, including COVID-19 treatments, and overall market growth.\n Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7460a7af9f20555c08f64a108b0be02004721d5bf70396fe46f3618b443e74ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e5b973f-40d1-45bd-a92c-0463c88fe21d", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year. "}, "hash": "b3b3bf5b50898f069aa027bcf1a5e61cf5460e4a3b6f8d88244fcdc88872279d", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Summar y Results\n3", "start_char_idx": 4422, "end_char_idx": 4458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e5b973f-40d1-45bd-a92c-0463c88fe21d": {"__data__": {"id_": "3e5b973f-40d1-45bd-a92c-0463c88fe21d", "embedding": null, "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "875239ee-3226-4c2a-9732-011b840b509e", "node_type": "1", "metadata": {"window": "Segment operating income of $472.1 million in the fourth quarter of fiscal 2021 was up 10.9 percent compared to the same period\nin the previous fiscal year as a result of strong performance across our distribution businesses, including increased sales of specialty\nproducts.\n Other\nRevenue in Other was $7.7 billion in the fourth quarter of fiscal 2021, an increase of 286.8 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, ABCS,\nand World Courier.  Operating income in Other increased 113.6 percent to $223.3 million in the fourth quarter of fiscal 2021 due to\nthe acquisition of Alliance Healthcare.\n Fiscal Y ear 2021 Summar y Results\n3", "original_text": "Fiscal Y ear 2021 Summar y Results\n3", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88b835a977d13d658359585fef1527d06e7f063e3c3b2affd9a8f34fcd5b2897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ebd2cd2-4c90-4aac-bc9c-323419faa1d5", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. ", "original_text": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion. "}, "hash": "474c356421ce1dc62974ed48dbcdb451d9d94908db261f753a774a3e688bcd4d", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year. ", "start_char_idx": 0, "end_char_idx": 464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ebd2cd2-4c90-4aac-bc9c-323419faa1d5": {"__data__": {"id_": "9ebd2cd2-4c90-4aac-bc9c-323419faa1d5", "embedding": null, "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. ", "original_text": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e5b973f-40d1-45bd-a92c-0463c88fe21d", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d79697ab6a3edb91f4f0db41479cf2051c4dccbd972d469feef5940823e16a06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31794ee6-9386-4bd8-9a44-403ca2874b10", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n", "original_text": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n"}, "hash": "adce1614b2bdd6dd04af4e4b26f7646875fabec8dff3cee8743e83ac5244f47c", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion. ", "start_char_idx": 464, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31794ee6-9386-4bd8-9a44-403ca2874b10": {"__data__": {"id_": "31794ee6-9386-4bd8-9a44-403ca2874b10", "embedding": null, "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n", "original_text": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ebd2cd2-4c90-4aac-bc9c-323419faa1d5", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. ", "original_text": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96885db339ca0d0edde8480ffe4fd9136a627146c4ed7f92747a11b6d8217fea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a4b724-3b44-41c5-a7ad-a90aad28e4ee", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. ", "original_text": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. "}, "hash": "ba7bd2e2692680f236680045942b85d51cf1e4d78e1837dcc8f2f6bd595c465f", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n", "start_char_idx": 536, "end_char_idx": 904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a4b724-3b44-41c5-a7ad-a90aad28e4ee": {"__data__": {"id_": "54a4b724-3b44-41c5-a7ad-a90aad28e4ee", "embedding": null, "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. ", "original_text": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31794ee6-9386-4bd8-9a44-403ca2874b10", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n", "original_text": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cea04415a9425f49c999dca83b1f7bd974bd180ca8f612bfc092931843c68b2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6706c029-ff73-457a-835b-e9f981d44962", "node_type": "1", "metadata": {"window": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. ", "original_text": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. "}, "hash": "d7937c8837f1e8682c76c56ecb90e6932a6b0c306941995efc9000455592c2b1", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 904, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6706c029-ff73-457a-835b-e9f981d44962": {"__data__": {"id_": "6706c029-ff73-457a-835b-e9f981d44962", "embedding": null, "metadata": {"window": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. ", "original_text": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a4b724-3b44-41c5-a7ad-a90aad28e4ee", "node_type": "1", "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. ", "original_text": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fbbe9723772dcf0a9a00c5564c0873967a5e654d8533e930a01c87a5186f171", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec78b49-8624-4ca1-882f-2684358d889e", "node_type": "1", "metadata": {"window": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n"}, "hash": "5428e6a578008c14d15a43ef743bd2ede77b6414fd9f80b2b81715c7930e3673", "class_name": "RelatedNodeInfo"}}, "text": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. ", "start_char_idx": 1133, "end_char_idx": 1231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ec78b49-8624-4ca1-882f-2684358d889e": {"__data__": {"id_": "0ec78b49-8624-4ca1-882f-2684358d889e", "embedding": null, "metadata": {"window": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6706c029-ff73-457a-835b-e9f981d44962", "node_type": "1", "metadata": {"window": "Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. ", "original_text": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac30fd3ae41a17c080c5c9224205eace833c1b2eac49e0833c83817806e79369", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef08a182-1208-44d4-99d8-ecb5329e9645", "node_type": "1", "metadata": {"window": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. "}, "hash": "706e2cd3f0f2356fde1303d5c1128898c91caa234f60f30417d637ed068b506f", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n", "start_char_idx": 1231, "end_char_idx": 1353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef08a182-1208-44d4-99d8-ecb5329e9645": {"__data__": {"id_": "ef08a182-1208-44d4-99d8-ecb5329e9645", "embedding": null, "metadata": {"window": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec78b49-8624-4ca1-882f-2684358d889e", "node_type": "1", "metadata": {"window": "Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. ", "original_text": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96b34ed9c2a282fbc2a2cced4d535834898c4fa0762f4107642477534cc9757e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53ae9695-3a38-4960-9b51-78e356d9e94f", "node_type": "1", "metadata": {"window": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. ", "original_text": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. "}, "hash": "70ab61aba148e4da0f9571817005dccdc0fe2b79d55ef097663b6d259aed4ec0", "class_name": "RelatedNodeInfo"}}, "text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. ", "start_char_idx": 1353, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53ae9695-3a38-4960-9b51-78e356d9e94f": {"__data__": {"id_": "53ae9695-3a38-4960-9b51-78e356d9e94f", "embedding": null, "metadata": {"window": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. ", "original_text": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef08a182-1208-44d4-99d8-ecb5329e9645", "node_type": "1", "metadata": {"window": "Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare.  Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. ", "original_text": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70d49885b92434f883eb49d4427ce6bf6dc8a8708309c1a81f957e0bbcee5b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc0362f0-477c-4742-890e-f231a740f8df", "node_type": "1", "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. ", "original_text": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. "}, "hash": "fea5486278dd547d14014f1d993bfd6b875f9901db5127ba34aaee527a8dfa56", "class_name": "RelatedNodeInfo"}}, "text": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. ", "start_char_idx": 1635, "end_char_idx": 1707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc0362f0-477c-4742-890e-f231a740f8df": {"__data__": {"id_": "dc0362f0-477c-4742-890e-f231a740f8df", "embedding": null, "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. ", "original_text": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53ae9695-3a38-4960-9b51-78e356d9e94f", "node_type": "1", "metadata": {"window": "Operating income increased 145.8\npercent due to lower operating expenses and higher gross profit.  Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. ", "original_text": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29b49c8f8712026fc3f8978c32f253dfefe12c1a7b9663bd68c2878d946ddff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4dc5b5b-f95d-43f8-bed7-9f433dc6a186", "node_type": "1", "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n", "original_text": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. "}, "hash": "7f9de9d7b5d8ba01b94b18c3005cd5c91dc0b55f01751d2cbcf9adb77d1c9ee2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. ", "start_char_idx": 1707, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4dc5b5b-f95d-43f8-bed7-9f433dc6a186": {"__data__": {"id_": "b4dc5b5b-f95d-43f8-bed7-9f433dc6a186", "embedding": null, "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n", "original_text": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc0362f0-477c-4742-890e-f231a740f8df", "node_type": "1", "metadata": {"window": "Diluted weighted average shares outstanding in fiscal 2021 were\n208.5 million, up 1.8 percent from the prior fiscal year.\n Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. ", "original_text": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "889bf53131f71321c313d2dcdef1f8a75e849fbe9fc14a375fe6230a363390d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99307616-cfba-4bd7-a402-44cc95de6c03", "node_type": "1", "metadata": {"window": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. ", "original_text": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. "}, "hash": "c7f1d0a9787442a0216b156660eb77ed923595a4a8c178d83af171f78df64e79", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 1987, "end_char_idx": 2121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99307616-cfba-4bd7-a402-44cc95de6c03": {"__data__": {"id_": "99307616-cfba-4bd7-a402-44cc95de6c03", "embedding": null, "metadata": {"window": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. ", "original_text": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4dc5b5b-f95d-43f8-bed7-9f433dc6a186", "node_type": "1", "metadata": {"window": "Summary Fiscal Year Adjusted (non-GAAP) Results\nIn fiscal year 2021, adjusted diluted EPS was $9.26, an increase of 17.2 percent over the prior fiscal year due to an increase in\noperating income, and was partially offset by higher interest expense and a higher diluted share count.  Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n", "original_text": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf878592ac07fa62071b8d5244dee3b86218c68998b83e166c5fe3a1853e1c8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f70ed0d-cef5-40af-af94-d4a359622daf", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. "}, "hash": "369bea8b107b4274f52e6f137ba5ec122889fa6e3613158e0d126d1da5b36f73", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. ", "start_char_idx": 2121, "end_char_idx": 2415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f70ed0d-cef5-40af-af94-d4a359622daf": {"__data__": {"id_": "8f70ed0d-cef5-40af-af94-d4a359622daf", "embedding": null, "metadata": {"window": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99307616-cfba-4bd7-a402-44cc95de6c03", "node_type": "1", "metadata": {"window": "Revenue increased 12.7\npercent from last fiscal year to $214.0 billion.  Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. ", "original_text": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "860ddfc829af44856f4f9ce3a3ab890e34062b17583f596c8289c19c6777c7d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee0a1cc0-d4a4-40bf-9753-8bd4e9a26e3b", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n"}, "hash": "6fa84f42f87e2f602ead2346280bfa1598f4e5445e9fb0e14533296bfc1921a2", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. ", "start_char_idx": 2415, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee0a1cc0-d4a4-40bf-9753-8bd4e9a26e3b": {"__data__": {"id_": "ee0a1cc0-d4a4-40bf-9753-8bd4e9a26e3b", "embedding": null, "metadata": {"window": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f70ed0d-cef5-40af-af94-d4a359622daf", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased by $1.4 billion, or 25.9 percent, from the prior fiscal\nyear to $6.6 billion due to the increases in gross profit within Other, primarily due to the impact of the June 2021 Alliance Healthcare\nacquisition, and Pharmaceutical Distribution Services.  Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd7a7839caae34db401960cea88998899e20b7503fcdaeb4851da0e956baf37c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43024462-fd14-4eaf-b70a-dde807c655ac", "node_type": "1", "metadata": {"window": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. "}, "hash": "eb17240bff9c264b14ddda6772eb21e334a8bc2736556c25d369e85f05e2dfbb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n", "start_char_idx": 2508, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43024462-fd14-4eaf-b70a-dde807c655ac": {"__data__": {"id_": "43024462-fd14-4eaf-b70a-dde807c655ac", "embedding": null, "metadata": {"window": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee0a1cc0-d4a4-40bf-9753-8bd4e9a26e3b", "node_type": "1", "metadata": {"window": "Adjusted operating expenses increased 30.2 percent to $3.9 billion primarily\ndue to the June 2021 acquisition of Alliance Healthcare.  Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6c663f5ce40a060233075a20da3f7f68c6a559762c8f71947115e7a81b845a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "120c3c89-fc3e-4d70-abf6-8fa4c8465ea1", "node_type": "1", "metadata": {"window": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4"}, "hash": "e9dd74452223f4af0ffa70a7f66d25562a3bf58df9de694402b04da1ab32d0f0", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. ", "start_char_idx": 2638, "end_char_idx": 2763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "120c3c89-fc3e-4d70-abf6-8fa4c8465ea1": {"__data__": {"id_": "120c3c89-fc3e-4d70-abf6-8fa4c8465ea1", "embedding": null, "metadata": {"window": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3bfc40f81aa3809625b671a9c11c61e96b2754ec06724bf6784fd2f731ef5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43024462-fd14-4eaf-b70a-dde807c655ac", "node_type": "1", "metadata": {"window": "Adjusted operating income increased 20.1 percent to $2.6 billion due to the\nincrease in gross profit associated with the June 2021 acquisition of Alliance Healthcare and increased sales of specialty products,\nincluding COVID-19 therapies, and was partially offset by higher operating expenses.  Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d57bfb9a64844190bafd4eb4b3513f0631e427db75d51e7cd0ccf23a64e0a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e1b2584-254d-4682-9222-f17693a6a6a6", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "original_text": "Silver certification for the headquarters. "}, "hash": "6e67ad06b5a1a0698785e077d571ee46dd625a5047edd3015df6a39536df0a16", "class_name": "RelatedNodeInfo"}}, "text": "As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "start_char_idx": 2763, "end_char_idx": 2920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e1b2584-254d-4682-9222-f17693a6a6a6": {"__data__": {"id_": "9e1b2584-254d-4682-9222-f17693a6a6a6", "embedding": null, "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "original_text": "Silver certification for the headquarters. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "120c3c89-fc3e-4d70-abf6-8fa4c8465ea1", "node_type": "1", "metadata": {"window": "Adjusted operating income margin increased 8\nbasis points from 1.16 percent to 1.24 percent.  Adjusted diluted weighted average shares outstanding in fiscal 2021 was 208.5\nmillion, up 0.9 percent from the prior fiscal year.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen opened its new global headquarters in Conshohocken, Pennsylvania.  As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "original_text": "As a part of AmerisourceBergen\u2019s\nefforts to promote sustainability, the company is actively pursuing a Leadership in Energy and Environmental Design (LEED)\n4", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da31d50e42294c92e3bef75549f66b9e4875911870fd26844eeada4637feb1c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c55ba0a-3c1d-4c7b-bbc4-5dfe5bb15b17", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n", "original_text": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n"}, "hash": "e2c2986e58b9c7e03103b98c7e18b8bb1b74e65eda06474d686248e27a7f9537", "class_name": "RelatedNodeInfo"}}, "text": "Silver certification for the headquarters. ", "start_char_idx": 0, "end_char_idx": 43, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c55ba0a-3c1d-4c7b-bbc4-5dfe5bb15b17": {"__data__": {"id_": "6c55ba0a-3c1d-4c7b-bbc4-5dfe5bb15b17", "embedding": null, "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n", "original_text": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e1b2584-254d-4682-9222-f17693a6a6a6", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "original_text": "Silver certification for the headquarters. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fc73e2a3991397730f5b917fb7fd107fc10e8a6e72d1a2dc02264f5b869aa7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd76d5d5-6bbb-438f-a38f-2c8c540d76c6", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. ", "original_text": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives. "}, "hash": "b2f964dd967994abd32b77871bfaa5706c93300e3fe846fa51820b4de1faf104", "class_name": "RelatedNodeInfo"}}, "text": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n", "start_char_idx": 43, "end_char_idx": 206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd76d5d5-6bbb-438f-a38f-2c8c540d76c6": {"__data__": {"id_": "bd76d5d5-6bbb-438f-a38f-2c8c540d76c6", "embedding": null, "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. ", "original_text": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c55ba0a-3c1d-4c7b-bbc4-5dfe5bb15b17", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n", "original_text": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec962f45fc68a08e735d576343d681fff6dfcd00757d308b735c8c76a7321829", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa7306db-b25b-4060-a4ba-cc6e143ac726", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n", "original_text": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. "}, "hash": "812dacd5e9ce4eec53e79bebe1c5523b6c0c0de6ce2f13df35c28d57fd70b0e3", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives. ", "start_char_idx": 206, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa7306db-b25b-4060-a4ba-cc6e143ac726": {"__data__": {"id_": "fa7306db-b25b-4060-a4ba-cc6e143ac726", "embedding": null, "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n", "original_text": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd76d5d5-6bbb-438f-a38f-2c8c540d76c6", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. ", "original_text": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "980eaa90183f23ebb396b1f531fc41239ecf2796a92e8dd1af9f797090efc9b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fdf6ccc-0030-4195-a743-81aa10d81caa", "node_type": "1", "metadata": {"window": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. ", "original_text": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n"}, "hash": "25b52f72e615f0d9e7f267909c847aba33927c3a941ce76123ed030a6c153633", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "start_char_idx": 368, "end_char_idx": 492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fdf6ccc-0030-4195-a743-81aa10d81caa": {"__data__": {"id_": "8fdf6ccc-0030-4195-a743-81aa10d81caa", "embedding": null, "metadata": {"window": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. ", "original_text": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa7306db-b25b-4060-a4ba-cc6e143ac726", "node_type": "1", "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n", "original_text": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bce0f4b2cc5d3ce83133191185867af240e121a7fb9ea9eaf4beb10af12e68c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9762429a-5182-4ec7-bfbc-6de5ac38af73", "node_type": "1", "metadata": {"window": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n", "original_text": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. "}, "hash": "fad9a39f0f19f528999df9d9577be90b52155134bbec7746e3a7637ea1085be1", "class_name": "RelatedNodeInfo"}}, "text": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n", "start_char_idx": 492, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9762429a-5182-4ec7-bfbc-6de5ac38af73": {"__data__": {"id_": "9762429a-5182-4ec7-bfbc-6de5ac38af73", "embedding": null, "metadata": {"window": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n", "original_text": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fdf6ccc-0030-4195-a743-81aa10d81caa", "node_type": "1", "metadata": {"window": "At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. ", "original_text": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d29348a8c19e897cdd7551542c2f73db40be24d75a3b17364b7d5b025b0780f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e97e069b-a11e-4f06-862d-6b47f84aa8ed", "node_type": "1", "metadata": {"window": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. ", "original_text": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n"}, "hash": "54b28c2be9196e310543a2825893f2d24633015550ff650ee1aa920e8b050f80", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. ", "start_char_idx": 639, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e97e069b-a11e-4f06-862d-6b47f84aa8ed": {"__data__": {"id_": "e97e069b-a11e-4f06-862d-6b47f84aa8ed", "embedding": null, "metadata": {"window": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. ", "original_text": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9762429a-5182-4ec7-bfbc-6de5ac38af73", "node_type": "1", "metadata": {"window": "AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n", "original_text": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b441a6832715efc78c3e3d6f16ecdb286441db49967720920011d590eda8fb7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7354e0e3-fc85-4b71-affb-265d0dc5a18b", "node_type": "1", "metadata": {"window": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n", "original_text": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. "}, "hash": "903ec4b094522abd8dfb867fd6bc64da7bd2e31cf286aed41ef3fa5dfaca93ca", "class_name": "RelatedNodeInfo"}}, "text": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n", "start_char_idx": 815, "end_char_idx": 1063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7354e0e3-fc85-4b71-affb-265d0dc5a18b": {"__data__": {"id_": "7354e0e3-fc85-4b71-affb-265d0dc5a18b", "embedding": null, "metadata": {"window": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n", "original_text": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e97e069b-a11e-4f06-862d-6b47f84aa8ed", "node_type": "1", "metadata": {"window": "AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent.  The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. ", "original_text": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d2036261516b2b3b8362612f56a98f3bfc4dc6c2603f80c477ab380ca301d0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fba6cd3-5990-416a-9dbf-53815e60ee72", "node_type": "1", "metadata": {"window": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n"}, "hash": "4dd673cec10539213538e622970dedc3af23e530df5b18c4065cd013e80bd02f", "class_name": "RelatedNodeInfo"}}, "text": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. ", "start_char_idx": 1063, "end_char_idx": 1322, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fba6cd3-5990-416a-9dbf-53815e60ee72": {"__data__": {"id_": "4fba6cd3-5990-416a-9dbf-53815e60ee72", "embedding": null, "metadata": {"window": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7354e0e3-fc85-4b71-affb-265d0dc5a18b", "node_type": "1", "metadata": {"window": "The competencies focus on key areas including diversity, equity, and\ninclusion, collaboration, innovation and executional excellence, and purpose.\n AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n", "original_text": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5df0101b289a7e25c98be7ba5c3a265e491c1fbf26e433006b7d91a239800c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab98b000-1edd-4533-ad9d-6f19e2bb8230", "node_type": "1", "metadata": {"window": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. "}, "hash": "457d392af8efa5a7eb47e11544a62544f4cc93437e6426e3e13042b91a085c65", "class_name": "RelatedNodeInfo"}}, "text": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n", "start_char_idx": 1322, "end_char_idx": 1523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab98b000-1edd-4533-ad9d-6f19e2bb8230": {"__data__": {"id_": "ab98b000-1edd-4533-ad9d-6f19e2bb8230", "embedding": null, "metadata": {"window": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fba6cd3-5990-416a-9dbf-53815e60ee72", "node_type": "1", "metadata": {"window": "AmerisourceBergen hosted its second annual ThinkLive Trade virtual event, a three-day online summit geared toward brand,\nspecialty, generic and consumer-product manufacturers.  The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ad7f6ef7d83a6289250021bbd3cf5bcc3a3e6a512ddc20a055f438a2c603903", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce3a1be3-958f-45f5-b271-e29b1a4fef68", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n"}, "hash": "0ddb3f9cb9b75ee6327c80e07283742c2b5e5efcd0cc8e403741379e743ff1ce", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. ", "start_char_idx": 1523, "end_char_idx": 1724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce3a1be3-958f-45f5-b271-e29b1a4fef68": {"__data__": {"id_": "ce3a1be3-958f-45f5-b271-e29b1a4fef68", "embedding": null, "metadata": {"window": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab98b000-1edd-4533-ad9d-6f19e2bb8230", "node_type": "1", "metadata": {"window": "The event centered on challenges and considerations that\nmanufacturers face when bringing products to market, and how AmerisourceBergen works with its partners to drive supply\nchain sophistication, maximize patient access, and move health forward.\n The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88891445d30008f3a500a3400a8c886c6c82db5a5f3db8d7cfdfc0fbd6364aa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb1d23e9-9184-4308-b208-981f88fe29b3", "node_type": "1", "metadata": {"window": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. "}, "hash": "deb856586d7ec30508f3244ed62cc4eff1f6d3fa732fb5575ffb57771bfedcb4", "class_name": "RelatedNodeInfo"}}, "text": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n", "start_char_idx": 1724, "end_char_idx": 1881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb1d23e9-9184-4308-b208-981f88fe29b3": {"__data__": {"id_": "cb1d23e9-9184-4308-b208-981f88fe29b3", "embedding": null, "metadata": {"window": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce3a1be3-958f-45f5-b271-e29b1a4fef68", "node_type": "1", "metadata": {"window": "The AmerisourceBergen Foundation hosted more than 50 nonprofit partners and peers at its third annual Grantee and\nNonprofit Partner Conference to share best practices, facilitate collaboration, and foster long-term relationships that create\nsustained change.  The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bffad5cf2b00682039de52601085a4158782a8b46dd3bc39974148e24eed06f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56c00853-cc51-46db-a4c9-2efd0f78e5ec", "node_type": "1", "metadata": {"window": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. ", "original_text": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. "}, "hash": "201cd659424ef54584e79cdf35a0dc1aff19dd169c8ac61fa0189ac6ab67b9df", "class_name": "RelatedNodeInfo"}}, "text": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 1881, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56c00853-cc51-46db-a4c9-2efd0f78e5ec": {"__data__": {"id_": "56c00853-cc51-46db-a4c9-2efd0f78e5ec", "embedding": null, "metadata": {"window": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. ", "original_text": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb1d23e9-9184-4308-b208-981f88fe29b3", "node_type": "1", "metadata": {"window": "The virtual event focused on developing strategies to address urgent needs in response to the COVID-19\npandemic as well as longstanding issues, including health equity and global access to healthcare.\n Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1f190af04c545e3dc76c6c129c6347a1e20dfde51785a503dff8315d17019b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b047f95-bb82-47de-8572-c2fd2e3913b1", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. "}, "hash": "95efe20ccf3dc641d7e7262fe577236d5cb575b227b2bd16b198245f7db43e30", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. ", "start_char_idx": 2107, "end_char_idx": 2269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b047f95-bb82-47de-8572-c2fd2e3913b1": {"__data__": {"id_": "2b047f95-bb82-47de-8572-c2fd2e3913b1", "embedding": null, "metadata": {"window": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56c00853-cc51-46db-a4c9-2efd0f78e5ec", "node_type": "1", "metadata": {"window": "Dividend Declaration\nIn November 2021, the Company's Board of Directors declared a quarterly dividend of $0.46 per common share, an increase in its\nquarterly dividend rate from $0.44 per common share.  The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. ", "original_text": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f73f522a1af3bfa91c08d152042682a7ba3a1c6d2d27c7ed014e63f148cf5394", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6353406-e8d1-426f-b6d5-d4663107d977", "node_type": "1", "metadata": {"window": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. ", "original_text": "U.S. "}, "hash": "bdf26fce44bad32fd62f46778fb819fdea2f0a75e31fa7f450d3c2f4dec9a5d4", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "start_char_idx": 2269, "end_char_idx": 2330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6353406-e8d1-426f-b6d5-d4663107d977": {"__data__": {"id_": "f6353406-e8d1-426f-b6d5-d4663107d977", "embedding": null, "metadata": {"window": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. ", "original_text": "U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b047f95-bb82-47de-8572-c2fd2e3913b1", "node_type": "1", "metadata": {"window": "The quarterly dividend of $0.46 per common share will be payable November\n29, 2021, to stockholders of record at the close of business on November 15, 2021.\n New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88b752f348c9e15542ccad0969cd0ecbe01922855a6b777aadf0339d95b59463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5e5f054-e22c-4bbe-af01-53d9bb0be147", "node_type": "1", "metadata": {"window": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. ", "original_text": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. "}, "hash": "852d6f7e09d60e9053164a5bd28d685b32b1a05ea09a58901b46826e703042c0", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 2264, "end_char_idx": 2269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5e5f054-e22c-4bbe-af01-53d9bb0be147": {"__data__": {"id_": "d5e5f054-e22c-4bbe-af01-53d9bb0be147", "embedding": null, "metadata": {"window": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. ", "original_text": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6353406-e8d1-426f-b6d5-d4663107d977", "node_type": "1", "metadata": {"window": "New R epor table Segments\nRecently, AmerisourceBergen undertook a strategic evaluation of its reporting structure to reflect its expanded international\npresence as a result of the June 2021 acquisition of Alliance Healthcare.  As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. ", "original_text": "U.S. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d0fb90e7546950fc049d453d1585e00a51fa716d0513e29275f27d4929014e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b279f48-9eba-4908-9cbe-0b25a454c44e", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other. ", "original_text": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. "}, "hash": "7e026701c93cdd5dcd48c960349d34f843a9bce99e8051d6fbe2f1d328e8c0e2", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. ", "start_char_idx": 2335, "end_char_idx": 2504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b279f48-9eba-4908-9cbe-0b25a454c44e": {"__data__": {"id_": "4b279f48-9eba-4908-9cbe-0b25a454c44e", "embedding": null, "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other. ", "original_text": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5e5f054-e22c-4bbe-af01-53d9bb0be147", "node_type": "1", "metadata": {"window": "As a result of this review, beginning in the first quarter of\nfiscal 2022, the Company has re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. ", "original_text": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "281ea96f2695201884ae8a5953236da415d9b92a2ca63ba3c1a69e1f06e3a3b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42f8a8ee-e3d4-46c9-8000-e3926f469077", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n", "original_text": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. "}, "hash": "3f843efe3d3c9bc42d76e5cb00de7409133c35409910dfd45eb31c1cf533380c", "class_name": "RelatedNodeInfo"}}, "text": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. ", "start_char_idx": 2504, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42f8a8ee-e3d4-46c9-8000-e3926f469077": {"__data__": {"id_": "42f8a8ee-e3d4-46c9-8000-e3926f469077", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n", "original_text": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b279f48-9eba-4908-9cbe-0b25a454c44e", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other. ", "original_text": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c66eca93307e7cf6cc543ecb4450becc3d2300924a7bc673b475b0ef7faf3f81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d74637ad-a228-477e-891b-56441e50467e", "node_type": "1", "metadata": {"window": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. "}, "hash": "3b3dda87ba4c9ed0f7f14d4da746f5aeeefefed9f1c5bab22a2bea63f14158c1", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. ", "start_char_idx": 2571, "end_char_idx": 2704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d74637ad-a228-477e-891b-56441e50467e": {"__data__": {"id_": "d74637ad-a228-477e-891b-56441e50467e", "embedding": null, "metadata": {"window": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42f8a8ee-e3d4-46c9-8000-e3926f469077", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n", "original_text": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "170178b1df77c3d0d52b90f9cf0321bdd0a385dd15267ce0198017ae43b64494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a758d1f9-73ee-48dd-9238-357ea32d5adc", "node_type": "1", "metadata": {"window": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Profarma Specialty had previously been reported in Other. "}, "hash": "ca556fc1bca752d8f27b384e1abfa40f799a4881a4d1c5f5a80d425fff96a680", "class_name": "RelatedNodeInfo"}}, "text": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. ", "start_char_idx": 2704, "end_char_idx": 2806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a758d1f9-73ee-48dd-9238-357ea32d5adc": {"__data__": {"id_": "a758d1f9-73ee-48dd-9238-357ea32d5adc", "embedding": null, "metadata": {"window": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Profarma Specialty had previously been reported in Other. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d74637ad-a228-477e-891b-56441e50467e", "node_type": "1", "metadata": {"window": "Healthcare Solutions will consist of the legacy Pharmaceutical Distribution Services\nreportable segment (excluding Profarma Distribuidora de Produtos Farmac\u00eauticos S.A.  (\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3279987c321433ba5bbbdc8344da64494bf06b48a2950caf2d6c06eaab5a70f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb79b495-32fc-482b-90aa-598d0eb81639", "node_type": "1", "metadata": {"window": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. ", "original_text": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n"}, "hash": "ed9e2f6975a8529ed94c3d51335224eec0cc5db9764e800f60da4121a5785c5b", "class_name": "RelatedNodeInfo"}}, "text": "Profarma Specialty had previously been reported in Other. ", "start_char_idx": 2806, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb79b495-32fc-482b-90aa-598d0eb81639": {"__data__": {"id_": "fb79b495-32fc-482b-90aa-598d0eb81639", "embedding": null, "metadata": {"window": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. ", "original_text": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a758d1f9-73ee-48dd-9238-357ea32d5adc", "node_type": "1", "metadata": {"window": "(\"Profarma\")), MWI Animal Health, Xcenda,\nLash Group, and ICS 3PL.  International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "Profarma Specialty had previously been reported in Other. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9713b9b63502307bfe369773b1845b4525b75c70ff074e1b24fca305c1320fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95eff09d-de36-415f-8385-b84687fa7538", "node_type": "1", "metadata": {"window": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. "}, "hash": "2ceef7266f621b7f7d0245546fbcffeafd5c4449ac70a1cca5c74c48a2a67700", "class_name": "RelatedNodeInfo"}}, "text": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n", "start_char_idx": 2864, "end_char_idx": 2973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95eff09d-de36-415f-8385-b84687fa7538": {"__data__": {"id_": "95eff09d-de36-415f-8385-b84687fa7538", "embedding": null, "metadata": {"window": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb79b495-32fc-482b-90aa-598d0eb81639", "node_type": "1", "metadata": {"window": "International Healthcare Solutions will consist of Alliance Healthcare, World Courier, Innomar, and\nProfarma and Profarma Specialty.  Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. ", "original_text": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49c0ebde439933a75fa4dd09e85b078802757e8a0c52dd44db4373c28452d8d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94a0e509-3b4f-4a0f-88f4-c5bb82800bf5", "node_type": "1", "metadata": {"window": "Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "2f0138d93dc6d85bf73e7ce540198afef71f829480d6b8a7035180c8098d26f5", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 2973, "end_char_idx": 3218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94a0e509-3b4f-4a0f-88f4-c5bb82800bf5": {"__data__": {"id_": "94a0e509-3b4f-4a0f-88f4-c5bb82800bf5", "embedding": null, "metadata": {"window": "Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95eff09d-de36-415f-8385-b84687fa7538", "node_type": "1", "metadata": {"window": "Profarma had previously been included in the Pharmaceutical Distribution Services reportable\nsegment.  Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cc9c480832c276870acd6c84a61910c9867cc6a94b17db16ea421be17dfc33d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3e5d2bb-92cd-440d-a18f-fd9a9c386e64", "node_type": "1", "metadata": {"window": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. "}, "hash": "cbc33df18b9755d2d27e50d8108e22ba96bd8b3dcd0aec6cd11d07be38a7a0f1", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 3218, "end_char_idx": 3350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3e5d2bb-92cd-440d-a18f-fd9a9c386e64": {"__data__": {"id_": "f3e5d2bb-92cd-440d-a18f-fd9a9c386e64", "embedding": null, "metadata": {"window": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94a0e509-3b4f-4a0f-88f4-c5bb82800bf5", "node_type": "1", "metadata": {"window": "Profarma Specialty had previously been reported in Other.  Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. ", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54c5f97e13462dfa3c073246b2f54ac797f07b59ece21c0e4404674b93b98291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586fe25b-3095-4963-a638-495dad6cef1d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. "}, "hash": "ab18f7c30dfda8babb22fdbdaa76bae637ef07811695f836dc087312bf391605", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. ", "start_char_idx": 3350, "end_char_idx": 3550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586fe25b-3095-4963-a638-495dad6cef1d": {"__data__": {"id_": "586fe25b-3095-4963-a638-495dad6cef1d", "embedding": null, "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3e5d2bb-92cd-440d-a18f-fd9a9c386e64", "node_type": "1", "metadata": {"window": "Beginning in the first quarter of fiscal 2022, the Company will\nreport its results under this new structure.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9073c31054600cd5c76450c879673f38f7a57dc720c8a5081d75030bcd93ae5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c15b22-2847-42d1-ba9a-7cb63e1afb27", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. "}, "hash": "a963d787a6137d2f0c4ffff6dc3566b93079d709dc7162ae3f002a1b7edb1b1c", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. ", "start_char_idx": 3550, "end_char_idx": 3666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c15b22-2847-42d1-ba9a-7cb63e1afb27": {"__data__": {"id_": "e0c15b22-2847-42d1-ba9a-7cb63e1afb27", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586fe25b-3095-4963-a638-495dad6cef1d", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available and cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd56304db29a6be3d3c1fc283209c3f491a7e75e46990c29920b008b00608aa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee7cd545-8cc2-4442-820e-4be4818d245e", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n"}, "hash": "66c87ea20ac63557d2ecfb4154cfa5076b2c02dab1662ea5d71ad06a36a0f32d", "class_name": "RelatedNodeInfo"}}, "text": "The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. ", "start_char_idx": 3666, "end_char_idx": 3767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee7cd545-8cc2-4442-820e-4be4818d245e": {"__data__": {"id_": "ee7cd545-8cc2-4442-820e-4be4818d245e", "embedding": null, "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0c15b22-2847-42d1-ba9a-7cb63e1afb27", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f7414bfc190b6e4ab08eb8f5692f167d72d9ffbf98a063077a98f1c15a0220f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "425c26b9-a8f8-4e7d-b59a-49589dd2eea9", "node_type": "1", "metadata": {"window": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5"}, "hash": "2c0a0490be93f42030e528d5e17dd3c08ec169ea8e01ce88b979d980925646bf", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n", "start_char_idx": 3767, "end_char_idx": 4023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "425c26b9-a8f8-4e7d-b59a-49589dd2eea9": {"__data__": {"id_": "425c26b9-a8f8-4e7d-b59a-49589dd2eea9", "embedding": null, "metadata": {"window": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d5b9dc7ba6b077f2bf4baedc449501d33bb6db871feff27a490dad0df31e7e1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee7cd545-8cc2-4442-820e-4be4818d245e", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen has introduced its fiscal year 2022 financial guidance, which reflects growth in both of its new reportable\nsegments.  AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "654d27ac2f84ad120b06628c2835315c47e71d54d6712f9283873eb3003895a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd654a60-fa27-4868-9ba1-525a1478d578", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021. ", "original_text": "U.S. "}, "hash": "209e73b7886ae1342f373bafa6d4b4a48db735c48b087fbc68197b1a1e857c12", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "start_char_idx": 4023, "end_char_idx": 4131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd654a60-fa27-4868-9ba1-525a1478d578": {"__data__": {"id_": "fd654a60-fa27-4868-9ba1-525a1478d578", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021. ", "original_text": "U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "425c26b9-a8f8-4e7d-b59a-49589dd2eea9", "node_type": "1", "metadata": {"window": "AmerisourceBergen does not include unidentified capital allocation opportunities into its forward-looking guidance.  The\nCompany expects:\nRevenue growth in the high-single digit to low-double digit percent range;\nU.S.  Healthcare Solutions revenue in the range of $207 to $212 billion, representing growth of 2% to 5%;\nInternational Healthcare Solutions revenue of approximately $26 to $27 billion;\nAdjusted diluted earnings per share to be in the range of $10.50 to $10.80.\n Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "original_text": "Additional expectations include:\nAdjusted operating income growth in the mid- to high-teens percent range;\n5", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c1c7fa916720db59eb28a7636e9639f10a681a2eb5bcab104e784eccf54317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a6d7d22-08ab-4223-8914-f59f09f4c6f7", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n"}, "hash": "6c4f225b784c8c7c14d3c7e63bcc6ac21dd5ce966777306c4ea04d1cba954b20", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 0, "end_char_idx": 5, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a6d7d22-08ab-4223-8914-f59f09f4c6f7": {"__data__": {"id_": "6a6d7d22-08ab-4223-8914-f59f09f4c6f7", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd654a60-fa27-4868-9ba1-525a1478d578", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021. ", "original_text": "U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d13c3f6f8c4aee95187b48e5c38caaef729e331f8df03d0719b51edc63591cd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5fe2589-59ba-4bf4-ba5d-9bfe8743837b", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "904f3e2729aafa3a7a0eedbd2b309c3bebdd1627219fe08d3202ee5adef4cf93", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n", "start_char_idx": 5, "end_char_idx": 584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5fe2589-59ba-4bf4-ba5d-9bfe8743837b": {"__data__": {"id_": "a5fe2589-59ba-4bf4-ba5d-9bfe8743837b", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a6d7d22-08ab-4223-8914-f59f09f4c6f7", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75778c87c4065600583f7cc50cb5881bf8a71f71ae08b07a95bbbc330ab3b2bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcf5d784-5565-423b-a71d-31330ef9199a", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required. ", "original_text": "ET on November 4, 2021. "}, "hash": "c532d75be6a01a364bcd9ee425963b18d0f6a1a130aa7ae4f807922d9fb830db", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 584, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcf5d784-5565-423b-a71d-31330ef9199a": {"__data__": {"id_": "dcf5d784-5565-423b-a71d-31330ef9199a", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required. ", "original_text": "ET on November 4, 2021. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5fe2589-59ba-4bf4-ba5d-9bfe8743837b", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61ed3a85a483738fd676c427e209da7ca3b4999eae226a48551382dbedae3c41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d478b7e-8506-43ad-bdc0-115a218f0ad1", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "7c31ab00dccf14715dfc8d0dea5425825e4416afc26691ea8a4c2adc8ed10c87", "class_name": "RelatedNodeInfo"}}, "text": "ET on November 4, 2021. ", "start_char_idx": 699, "end_char_idx": 723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d478b7e-8506-43ad-bdc0-115a218f0ad1": {"__data__": {"id_": "4d478b7e-8506-43ad-bdc0-115a218f0ad1", "embedding": null, "metadata": {"window": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcf5d784-5565-423b-a71d-31330ef9199a", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required. ", "original_text": "ET on November 4, 2021. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13461f0c6cfefdbcb7277dfa3ac5641bb3290c05ab2db25b5c6675995da56be6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fb2257e-7424-4382-b47e-673ee1acb1de", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. "}, "hash": "300361136bd7aecf2c10870dfbef31e3d7a2daa5a2f1856730dee07a8c01caf1", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 723, "end_char_idx": 840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fb2257e-7424-4382-b47e-673ee1acb1de": {"__data__": {"id_": "7fb2257e-7424-4382-b47e-673ee1acb1de", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d478b7e-8506-43ad-bdc0-115a218f0ad1", "node_type": "1", "metadata": {"window": "Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "original_text": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42f4b278581a414bc2785111287f2fb6c5cd41135842722621b86f4fb8f0cabe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cec75c9b-d2f3-44af-aa08-c0bbcd18a5e7", "node_type": "1", "metadata": {"window": "ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is required. "}, "hash": "3542898d25623a0201d1573505f20c5ec463a25be5b4a4a0b938ddc8d3dcc147", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "start_char_idx": 840, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cec75c9b-d2f3-44af-aa08-c0bbcd18a5e7": {"__data__": {"id_": "cec75c9b-d2f3-44af-aa08-c0bbcd18a5e7", "embedding": null, "metadata": {"window": "ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is required. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fb2257e-7424-4382-b47e-673ee1acb1de", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "original_text": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "298f1a2e4fd748cf21d35d7f73af91fe4e13ae8443620273b916a186052d3f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db114988-20ec-4923-8d39-55f9c600cf41", "node_type": "1", "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . "}, "hash": "b022e4a8f3c1a30543c39ef151ebd08a17fe2a46dfed8e028b2b788c9862baae", "class_name": "RelatedNodeInfo"}}, "text": "No access code is required. ", "start_char_idx": 1079, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db114988-20ec-4923-8d39-55f9c600cf41": {"__data__": {"id_": "db114988-20ec-4923-8d39-55f9c600cf41", "embedding": null, "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cec75c9b-d2f3-44af-aa08-c0bbcd18a5e7", "node_type": "1", "metadata": {"window": "ET on November 4, 2021.  A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is required. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "734c2fef42bb084be333ad89bec94f83d6c1a2ddd374e0549638d5844c236412", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b957e00-d98b-4f26-af45-5ecdd245522c", "node_type": "1", "metadata": {"window": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n"}, "hash": "f84b80b4738000ebc672e4bd30729f277bf35692e41bbd7029c02a6f7c6e6e98", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 1107, "end_char_idx": 1204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b957e00-d98b-4f26-af45-5ecdd245522c": {"__data__": {"id_": "7b957e00-d98b-4f26-af45-5ecdd245522c", "embedding": null, "metadata": {"window": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db114988-20ec-4923-8d39-55f9c600cf41", "node_type": "1", "metadata": {"window": "A slide presentation for\ninvestors has also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "original_text": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com . ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a5bbd0e2a84934c5db0ac9814a2d1e6fa434f118985d059ee653159a9fc42ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a0ed1b9-9cda-4e36-989c-b4be2d08ab5f", "node_type": "1", "metadata": {"window": "No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "d20a12bf5141e231ce6396b4718faa1ae0173cabab528a6d90dd08d57b8b3383", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "start_char_idx": 1204, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a0ed1b9-9cda-4e36-989c-b4be2d08ab5f": {"__data__": {"id_": "3a0ed1b9-9cda-4e36-989c-b4be2d08ab5f", "embedding": null, "metadata": {"window": "No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b957e00-d98b-4f26-af45-5ecdd245522c", "node_type": "1", "metadata": {"window": "Participating in the conference call\nwill be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57d37305409153a477e15d31b42d09d5f35c912aeaebf175db96188593a67b54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c27b4d15-1441-4d37-9627-943c9a548f43", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. "}, "hash": "5b34a3ecd121ce228a1affba3dde474c8b3af7f28b9aa0412daa416f69963188", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1327, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c27b4d15-1441-4d37-9627-943c9a548f43": {"__data__": {"id_": "c27b4d15-1441-4d37-9627-943c9a548f43", "embedding": null, "metadata": {"window": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a0ed1b9-9cda-4e36-989c-b4be2d08ab5f", "node_type": "1", "metadata": {"window": "No access code is required.  The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48ed5e7c845f9542ed9bb56cc03d52fab5febad78a89a72a182a492d21279aa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fe81fe2-f846-4e36-a57e-695a13057a4d", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. "}, "hash": "c11105c3524f4b58654f9805f730f7f3ab3b82376fe4add9cdf8c44d1bcb4948", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "start_char_idx": 1397, "end_char_idx": 1567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fe81fe2-f846-4e36-a57e-695a13057a4d": {"__data__": {"id_": "1fe81fe2-f846-4e36-a57e-695a13057a4d", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c27b4d15-1441-4d37-9627-943c9a548f43", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the\nCompany\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "733d802fbdad04c923ed2e00fb82c9c3ec0713faf05dbc8e989126b302305708", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaa9c401-ba7e-4747-b819-71afd4032103", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "d0fb694dac17b5400c85c9d92ea8e12a03e70d2bf0851e8f44db74a87b38119c", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 1567, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaa9c401-ba7e-4747-b819-71afd4032103": {"__data__": {"id_": "aaa9c401-ba7e-4747-b819-71afd4032103", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fe81fe2-f846-4e36-a57e-695a13057a4d", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in\nadvance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n", "original_text": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1c908fb84abca8309bfb72a1549b8e71e2dcb40067a464ea947ada0b0582d56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ed10240-e264-4bb9-872f-5b322d59bc6c", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n", "original_text": "From outside the U.S., dial +1 (412) 317-0088. "}, "hash": "cb08c4d58ef62f5b468163a8cad98bf9d25ee8e68f4a6afee06ab1d31a626d15", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 1710, "end_char_idx": 1784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ed10240-e264-4bb9-872f-5b322d59bc6c": {"__data__": {"id_": "9ed10240-e264-4bb9-872f-5b322d59bc6c", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n", "original_text": "From outside the U.S., dial +1 (412) 317-0088. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaa9c401-ba7e-4747-b819-71afd4032103", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71e7ad5110a0efec4a358d6d6aa8c2befb5052319066a58af02a40b5d36b6794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64807305-2729-4c90-93c6-b1130a4db588", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The\naccess code for the replay is 10160671.\n"}, "hash": "355c174d0ca748c95b720131056ee9275c9db06f0a3cc388958cd20f9f80c475", "class_name": "RelatedNodeInfo"}}, "text": "From outside the U.S., dial +1 (412) 317-0088. ", "start_char_idx": 1784, "end_char_idx": 1831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64807305-2729-4c90-93c6-b1130a4db588": {"__data__": {"id_": "64807305-2729-4c90-93c6-b1130a4db588", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The\naccess code for the replay is 10160671.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ed10240-e264-4bb9-872f-5b322d59bc6c", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately two hours after the completion of the call and will remain available for 30 days.  The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n", "original_text": "From outside the U.S., dial +1 (412) 317-0088. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "948ca1784a87b0ae518c80068e74e0fa63d33955ec12ce2fbe2ed9dd06a57d12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66858b7d-a8fc-44c7-ab73-90c3deee1c89", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. "}, "hash": "09d029929d8b0b5c504b3696f1cf122ac1524dfbe05c2eb0f393ec889e729fdb", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the replay is 10160671.\n", "start_char_idx": 1831, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66858b7d-a8fc-44c7-ab73-90c3deee1c89": {"__data__": {"id_": "66858b7d-a8fc-44c7-ab73-90c3deee1c89", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64807305-2729-4c90-93c6-b1130a4db588", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately two hours after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "original_text": "The\naccess code for the replay is 10160671.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06e408431c00b85621a8b02b67b890a9da59179e2a54278f06b850fa142ba7b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffe44d94-ff88-460d-9eb9-25e274c392a4", "node_type": "1", "metadata": {"window": "From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Morgan Healthcare Conference, January 10-13, 2022.\n"}, "hash": "74c1e0cf2413fa8306c564549bd68f6aa1a05c1cec724eed4448c55979ab5682", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "start_char_idx": 1875, "end_char_idx": 2010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffe44d94-ff88-460d-9eb9-25e274c392a4": {"__data__": {"id_": "ffe44d94-ff88-460d-9eb9-25e274c392a4", "embedding": null, "metadata": {"window": "From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Morgan Healthcare Conference, January 10-13, 2022.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66858b7d-a8fc-44c7-ab73-90c3deee1c89", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d25ba6ee43a508cf32f19c0930ed559a724b32550fc68b09ee574a252dd0b420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ded6f19e-bdda-451c-a161-e3460d5c3edc", "node_type": "1", "metadata": {"window": "The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n"}, "hash": "e9644b5cdd49a36f7a85f62ba92e5dd4a0c1c5d9cb14e3cce1aec226ba08a3ae", "class_name": "RelatedNodeInfo"}}, "text": "Morgan Healthcare Conference, January 10-13, 2022.\n", "start_char_idx": 2010, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ded6f19e-bdda-451c-a161-e3460d5c3edc": {"__data__": {"id_": "ded6f19e-bdda-451c-a161-e3460d5c3edc", "embedding": null, "metadata": {"window": "The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffe44d94-ff88-460d-9eb9-25e274c392a4", "node_type": "1", "metadata": {"window": "From outside the U.S., dial +1 (412) 317-0088.  The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "Morgan Healthcare Conference, January 10-13, 2022.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "967f5a1eaebe5defd6eabeaf81877032e9ffc09bde7dd9728f22de2aa25d4475", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ad14ae5-78c1-4c1b-b1e1-697306b57784", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "d8546b76eaeb51cc70d6ab60a474cc0a2da8e73111eddf62c4f199d32c1da6ea", "class_name": "RelatedNodeInfo"}}, "text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "start_char_idx": 2061, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ad14ae5-78c1-4c1b-b1e1-697306b57784": {"__data__": {"id_": "4ad14ae5-78c1-4c1b-b1e1-697306b57784", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ded6f19e-bdda-451c-a161-e3460d5c3edc", "node_type": "1", "metadata": {"window": "The\naccess code for the replay is 10160671.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3369a45272821134bbd2e02548708498c5024f432efcfb97cf69994b8863845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1881e8ea-dd61-42ae-9a89-4b650383dd40", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. "}, "hash": "9ea549c27761ca1a7652dd86fc3775178f329219f2110a1984d3fe6d40227da5", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 2190, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1881e8ea-dd61-42ae-9a89-4b650383dd40": {"__data__": {"id_": "1881e8ea-dd61-42ae-9a89-4b650383dd40", "embedding": null, "metadata": {"window": "Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ad14ae5-78c1-4c1b-b1e1-697306b57784", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor conference in the coming months:\nJ.P.  Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "424e3920fddaead2e6a488a39aef5ce04896428167e37e7c40498ea583eb5dc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f139b735-fe95-4d3a-a9d4-d917a3c2328c", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). ", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "fe2e501dd49b421349c3d19c5d31e22cd635c5b77b6179eb60a0434fde62e700", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "start_char_idx": 2403, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f139b735-fe95-4d3a-a9d4-d917a3c2328c": {"__data__": {"id_": "f139b735-fe95-4d3a-a9d4-d917a3c2328c", "embedding": null, "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). ", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1881e8ea-dd61-42ae-9a89-4b650383dd40", "node_type": "1", "metadata": {"window": "Morgan Healthcare Conference, January 10-13, 2022.\n Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfe037fa2fda17964ce8543e200c213fc0a3c0c755cb458dbf2923588c4d9b14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2323456-5a46-4b34-9972-32b9c345b4ef", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. "}, "hash": "b6320c58e8408c3216317490b036e7d4d9a0e9cbdd047b90b3f182d547ab1a0b", "class_name": "RelatedNodeInfo"}}, "text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 2638, "end_char_idx": 2753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2323456-5a46-4b34-9972-32b9c345b4ef": {"__data__": {"id_": "d2323456-5a46-4b34-9972-32b9c345b4ef", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f139b735-fe95-4d3a-a9d4-d917a3c2328c", "node_type": "1", "metadata": {"window": "Please check the website for updates regarding the timing of the live presentation webcasts, if any, and for replay information.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). ", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "004c961a16720852536012ef061aa577d0782bb85f0a994f32c20c63a9a5564e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b9ff6c8-5bc1-49b4-a1fe-713d6aa44f3f", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "d8a04d6c2d442732b06e405dcfc209585fc03675d0ddcba8092bffe8a5e20acc", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "start_char_idx": 2753, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b9ff6c8-5bc1-49b4-a1fe-713d6aa44f3f": {"__data__": {"id_": "2b9ff6c8-5bc1-49b4-a1fe-713d6aa44f3f", "embedding": null, "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2323456-5a46-4b34-9972-32b9c345b4ef", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "688cc24013066067f7f368be74102823f063b8683df1fea9f784bcefe725264d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47a56e1c-24dd-4f2d-a075-275294d92258", "node_type": "1", "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). "}, "hash": "540fb98068de3725579fa27bdbb2d6e636e0303ba9b721a51652272d3ee79b79", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 2850, "end_char_idx": 2897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47a56e1c-24dd-4f2d-a075-275294d92258": {"__data__": {"id_": "47a56e1c-24dd-4f2d-a075-275294d92258", "embedding": null, "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b9ff6c8-5bc1-49b4-a1fe-713d6aa44f3f", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31d246757951d56e31cca5b373db3844eb7c72a7278b6a4cf7c925c2c39ed715", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22b88bf0-5ce6-4704-b47f-4740a7510825", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. "}, "hash": "e3d817b8fd3b4eb4153e1be0230648e949b91a6357b9d0709371acd5efced050", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). ", "start_char_idx": 2897, "end_char_idx": 3219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22b88bf0-5ce6-4704-b47f-4740a7510825": {"__data__": {"id_": "22b88bf0-5ce6-4704-b47f-4740a7510825", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47a56e1c-24dd-4f2d-a075-275294d92258", "node_type": "1", "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\"). ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f0002bbeea75a962d21e8dbbdebe743d2c54dc7edcd789fcf79270ee03d3415", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b625300-9268-49e4-9c10-ceb3bdb7e621", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "7d5924f39a2e412282101bf8ee21a270ec3a2050e9e76a5f6c9b43f1fe8dc747", "class_name": "RelatedNodeInfo"}}, "text": "Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. ", "start_char_idx": 3219, "end_char_idx": 3568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b625300-9268-49e4-9c10-ceb3bdb7e621": {"__data__": {"id_": "0b625300-9268-49e4-9c10-ceb3bdb7e621", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22b88bf0-5ce6-4704-b47f-4740a7510825", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "991178cf1a1116141651ad2818735622df3ce0dcb113bbc0c71eb433fdfec9f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2932a82-b061-4a94-bc2f-5e72a0f4942b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "These statements are not guarantees\n6"}, "hash": "31b3516a9674d1cba6e51d6f5c76763778a537a79ff69fdb170977f8feadc7e0", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 3568, "end_char_idx": 3730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2932a82-b061-4a94-bc2f-5e72a0f4942b": {"__data__": {"id_": "d2932a82-b061-4a94-bc2f-5e72a0f4942b", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "These statements are not guarantees\n6", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "82a918f5-ce90-40db-ae39-8a1966dfe496", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febe3cf2beba58e42af5261e2b0f9ad4955c31f24c9ae69725fc0ee07b88104b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b625300-9268-49e4-9c10-ceb3bdb7e621", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a12c249c62f0ef917e37a8c1d1c6de854e17504158758d09221a4e3f0c70f807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec1ac552-5033-4a20-8a42-81889826bdc5", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated. "}, "hash": "431b53c9629688f2b167ed6b0e5c2140cdb9f15c935787a3e26b948034d61d0a", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees\n6", "start_char_idx": 3730, "end_char_idx": 3767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec1ac552-5033-4a20-8a42-81889826bdc5": {"__data__": {"id_": "ec1ac552-5033-4a20-8a42-81889826bdc5", "embedding": null, "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4178326e-7085-471d-b59a-0a763f409150", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43b0dfe342803f799768e0178d5d21d56f5d3518f6299edd29783ccda38539c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2932a82-b061-4a94-bc2f-5e72a0f4942b", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the \"Securities Exchange Act\").  Words such as\n\"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\" \"sustain,\" \"synergy,\"\n\"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and similar expressions\nare intended to identify such forward-looking statements.  These statements are based on management's current expectations and\nare subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements are not guarantees\n6", "original_text": "These statements are not guarantees\n6", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cf49c8bea36fd5bbee1a791761bd669851c086b67a4478173c5c2d17c00ed36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb097874-cd20-4354-a0ba-aa7298b5cf69", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n", "original_text": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S. "}, "hash": "02940e394c6a5d5025024ef92e5db8761992089205bd325019263dd11a185cf4", "class_name": "RelatedNodeInfo"}}, "text": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated. ", "start_char_idx": 0, "end_char_idx": 163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb097874-cd20-4354-a0ba-aa7298b5cf69": {"__data__": {"id_": "bb097874-cd20-4354-a0ba-aa7298b5cf69", "embedding": null, "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n", "original_text": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4178326e-7085-471d-b59a-0a763f409150", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43b0dfe342803f799768e0178d5d21d56f5d3518f6299edd29783ccda38539c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec1ac552-5033-4a20-8a42-81889826bdc5", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58009914b277c65a726bbfe55bfd3f1f02fe2bdfa0d2d4805acd41270551854e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b892b8fa-976e-45e5-8b18-9993047d4a52", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally. "}, "hash": "f9a9b9e1c397885b7cfe751009da48683cb2fefe162f63778ded5b45d5e23b59", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S. ", "start_char_idx": 163, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b892b8fa-976e-45e5-8b18-9993047d4a52": {"__data__": {"id_": "b892b8fa-976e-45e5-8b18-9993047d4a52", "embedding": null, "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4178326e-7085-471d-b59a-0a763f409150", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43b0dfe342803f799768e0178d5d21d56f5d3518f6299edd29783ccda38539c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb097874-cd20-4354-a0ba-aa7298b5cf69", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n", "original_text": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "389adf2c9fe34ae9be39eebade41ee0bfb94cb74ccc7bcfe9af4c757dbf9e743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98a8f0f4-d3f9-4631-a82d-4e4cdabd68a3", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "0d9b74afd9ef1723b9df760b685bb62f9ab5ca9e4017064f1efe06307aedde44", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally. ", "start_char_idx": 3533, "end_char_idx": 5241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98a8f0f4-d3f9-4631-a82d-4e4cdabd68a3": {"__data__": {"id_": "98a8f0f4-d3f9-4631-a82d-4e4cdabd68a3", "embedding": null, "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4178326e-7085-471d-b59a-0a763f409150", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43b0dfe342803f799768e0178d5d21d56f5d3518f6299edd29783ccda38539c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b892b8fa-976e-45e5-8b18-9993047d4a52", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da39fb200c1f32142036fa033f6c04589b191ca27cbe03a24cb91f5599fda886", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51f7506e-ce6a-4e07-9634-a7cb36562ded", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n"}, "hash": "385d26031d1e6db9a00185890830567ef9a70bd85266d890ff8008165af749f2", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 5241, "end_char_idx": 5656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51f7506e-ce6a-4e07-9634-a7cb36562ded": {"__data__": {"id_": "51f7506e-ce6a-4e07-9634-a7cb36562ded", "embedding": null, "metadata": {"window": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4178326e-7085-471d-b59a-0a763f409150", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43b0dfe342803f799768e0178d5d21d56f5d3518f6299edd29783ccda38539c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98a8f0f4-d3f9-4631-a82d-4e4cdabd68a3", "node_type": "1", "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7541acf82041f6d4cda79c25db2f46b417070388dfa713303eded078eba9187b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1181f044-904a-4630-a399-d806fb2ee26a", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7"}, "hash": "a9555b4fec6912bda2c217c06e2d97881decfcb60af345a10621e7d354adc8bb", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n", "start_char_idx": 5656, "end_char_idx": 5805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1181f044-904a-4630-a399-d806fb2ee26a": {"__data__": {"id_": "1181f044-904a-4630-a399-d806fb2ee26a", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4178326e-7085-471d-b59a-0a763f409150", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c43b0dfe342803f799768e0178d5d21d56f5d3518f6299edd29783ccda38539c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51f7506e-ce6a-4e07-9634-a7cb36562ded", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "592727795ecbb4f8aabd6098ad27c54a427f1b0e4a7f878fa40fe5cd8d007662", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7751b9b7-0e73-4092-ab5c-8de8386dcebc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8"}, "hash": "9da1bf8fe91ef90897fbc6f9f1da2ede1da03341563433fb3080cb8b012453dd", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "start_char_idx": 5805, "end_char_idx": 5906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7751b9b7-0e73-4092-ab5c-8de8386dcebc": {"__data__": {"id_": "7751b9b7-0e73-4092-ab5c-8de8386dcebc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3c8bd45b-ac5e-4397-ba2c-82a897ddb832", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "768703d4a3f53ef66bacca6e9159224c28ea9a8579990fef672781014701b14c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1181f044-904a-4630-a399-d806fb2ee26a", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n7", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ea5c2658d2958e3ba3cecd94fbced703a3c05e901fa81ca33fea7f6a0de3f6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b7e517-1edc-4af8-8b79-d133f45427c2", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "original_text": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021. "}, "hash": "c59f3069c2d5392ae0ce4aa76ff9020700705eb4b1e70c9e9b813957d7d43dd8", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "start_char_idx": 0, "end_char_idx": 1261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b7e517-1edc-4af8-8b79-d133f45427c2": {"__data__": {"id_": "e3b7e517-1edc-4af8-8b79-d133f45427c2", "embedding": null, "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "original_text": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7751b9b7-0e73-4092-ab5c-8de8386dcebc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41fc0e3075a5926d3ca2c06ffdaf8c8cea5db04e01b6a75e23da23e7be39940d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49d971d2-88a4-48e0-a56c-d29a8d3e96a6", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n", "original_text": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n"}, "hash": "fee25281a3bc586c6d2797668aa0497fc6ae750c3c938e87d1ce3fbc418faea1", "class_name": "RelatedNodeInfo"}}, "text": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021. ", "start_char_idx": 0, "end_char_idx": 694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49d971d2-88a4-48e0-a56c-d29a8d3e96a6": {"__data__": {"id_": "49d971d2-88a4-48e0-a56c-d29a8d3e96a6", "embedding": null, "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n", "original_text": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b7e517-1edc-4af8-8b79-d133f45427c2", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "original_text": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9de934409c3da008008ffe23b81984d02bbe6af824b254927eb1bdd501999f22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f68b27f-cd78-408f-94e7-b66e66c5216b", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n", "original_text": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n"}, "hash": "fc91b5361f4c483b73bbd794e66375c4c3671846dadea75e2bbbaa81cef23c46", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n", "start_char_idx": 694, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f68b27f-cd78-408f-94e7-b66e66c5216b": {"__data__": {"id_": "5f68b27f-cd78-408f-94e7-b66e66c5216b", "embedding": null, "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n", "original_text": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49d971d2-88a4-48e0-a56c-d29a8d3e96a6", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n", "original_text": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93bb3b56a32c7a4409ed95a96178b75a058fcb6af6db79463cda64ed2189f2b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ca99a91-9ec2-4547-9c52-a19d609a876d", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. ", "original_text": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. "}, "hash": "85d77d96f1204217808173fd1b33f982302fb9d78ede5cfdd280eedea93246ca", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n", "start_char_idx": 1003, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ca99a91-9ec2-4547-9c52-a19d609a876d": {"__data__": {"id_": "7ca99a91-9ec2-4547-9c52-a19d609a876d", "embedding": null, "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. ", "original_text": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f68b27f-cd78-408f-94e7-b66e66c5216b", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n", "original_text": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3817a4f9bffdaed8a56009547a991c706cf1f88dc6643f7bb5564d36bf6b4b39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0642ca7-fdb7-474b-8686-8e7c35b4f139", "node_type": "1", "metadata": {"window": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n", "original_text": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n"}, "hash": "d793d9a5769b6880e9a5b7f68b16c716c314e884557548d7c135930225e9a8a7", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "start_char_idx": 1111, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0642ca7-fdb7-474b-8686-8e7c35b4f139": {"__data__": {"id_": "f0642ca7-fdb7-474b-8686-8e7c35b4f139", "embedding": null, "metadata": {"window": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n", "original_text": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ca99a91-9ec2-4547-9c52-a19d609a876d", "node_type": "1", "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. ", "original_text": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63448c01719e8f0e9120a62d289374234d5eef80fd0d5c12155ee6facdb08aad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c397fe2-faba-44ed-9362-c5e521721e3d", "node_type": "1", "metadata": {"window": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n"}, "hash": "f2594363f52c4bd0e9d1e8eb619d99cd8079a9e6d2adebccdce5e77c59ffe47d", "class_name": "RelatedNodeInfo"}}, "text": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n", "start_char_idx": 1560, "end_char_idx": 1967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c397fe2-faba-44ed-9362-c5e521721e3d": {"__data__": {"id_": "4c397fe2-faba-44ed-9362-c5e521721e3d", "embedding": null, "metadata": {"window": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0642ca7-fdb7-474b-8686-8e7c35b4f139", "node_type": "1", "metadata": {"window": "Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n", "original_text": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "552576feda9a312dfef73cd9df69877bc71f81ab1ef5af6628bb4c32334678db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbbcd649-aaf5-4715-9389-3fca9e3ac58f", "node_type": "1", "metadata": {"window": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. "}, "hash": "47ece726f468b07b1afeef78d50a7f6bb081cc4f3da68e746359f0e1f9e0ee89", "class_name": "RelatedNodeInfo"}}, "text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n", "start_char_idx": 1967, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbbcd649-aaf5-4715-9389-3fca9e3ac58f": {"__data__": {"id_": "fbbcd649-aaf5-4715-9389-3fca9e3ac58f", "embedding": null, "metadata": {"window": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c397fe2-faba-44ed-9362-c5e521721e3d", "node_type": "1", "metadata": {"window": "2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23e18335c6cd4a8c4bd8e4c4086cb78507e69f352a2b3efd7bd59c0ebebdad13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36463de1-266f-4432-b9c3-62289a600f09", "node_type": "1", "metadata": {"window": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n"}, "hash": "2ae1b8425c1112409e459564252aea33634c4861b7e20409f2db640b2c4dce5d", "class_name": "RelatedNodeInfo"}}, "text": "5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. ", "start_char_idx": 2259, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36463de1-266f-4432-b9c3-62289a600f09": {"__data__": {"id_": "36463de1-266f-4432-b9c3-62289a600f09", "embedding": null, "metadata": {"window": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbbcd649-aaf5-4715-9389-3fca9e3ac58f", "node_type": "1", "metadata": {"window": "3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021.  Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03f5ec303fd1adee43087aec251c837cfcbebd77beb151cbca2577d93708f0f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b77dcf-d40f-421c-a554-e978625ca37a", "node_type": "1", "metadata": {"window": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "9"}, "hash": "4f1add326339cff6725d71f79d289657d74531682f47d89e5aef37be4ad2eef2", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n", "start_char_idx": 2369, "end_char_idx": 2796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b77dcf-d40f-421c-a554-e978625ca37a": {"__data__": {"id_": "76b77dcf-d40f-421c-a554-e978625ca37a", "embedding": null, "metadata": {"window": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "9", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "df6e7762-f404-4def-be69-c71cef041775", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f55582b64753f061f8fbb9e74c20c9da22a72e9620ecb182b41bcec2a2682859", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36463de1-266f-4432-b9c3-62289a600f09", "node_type": "1", "metadata": {"window": "Includes $2.0 million of employee severance, a $6,606.9 million legal accrual and\n$28.5 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $4.2 million of other\ncosts in connection with business transformation efforts, acquisition-related deal and integration costs, and other restructuring\ninitiatives in the three months ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b6a48c362857b1fc7b35b4555bcb53323019bf06c84a99f3583d500261602e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f17d447d-76fd-401d-a53b-fdd9945d43ee", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10"}, "hash": "f7260dd24955a5b0f2c8c5f56db80c5442b165a62bbedb8607c8d9cecc4cbf18", "class_name": "RelatedNodeInfo"}}, "text": "9", "start_char_idx": 174, "end_char_idx": 175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f17d447d-76fd-401d-a53b-fdd9945d43ee": {"__data__": {"id_": "f17d447d-76fd-401d-a53b-fdd9945d43ee", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e17dd7f-08e3-40f8-be90-86760ea4bebb", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73338f069da31baf20866db404b088d40287abeed01478f9b530b4fc33b8ce59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b77dcf-d40f-421c-a554-e978625ca37a", "node_type": "1", "metadata": {"window": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $2.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended September 30, 2021.\n 5 Includes $9.8 million of expense relating to Swiss tax reform in the three months ended September 30, 2021.  Includes a $1,078.6\nmillion tax benefit relating to the $6.6 billion legal expense accrual in connection with opioid lawsuits, a $360.7 million tax benefit\nrelating to Swiss tax reform, and a $20.4 million adjustment to discrete tax benefits previously recognized primarily attributable to\nthe income tax deductions resulting from the permanent shutdown of the PharMEDium business in the three months ended\nSeptember 30, 2020.\n 9", "original_text": "9", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "216c6ed7db0d2126b7fe4097e6a5b84e76c5f6d1e18661e7bd9df1a758279609", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fb806e9-54d6-40df-84d1-718f4b40021f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021. "}, "hash": "e3003a79b2764fcde33b8e9931516a64350bbf5ebfcbb1d67d6681217e0decce", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "start_char_idx": 0, "end_char_idx": 1332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fb806e9-54d6-40df-84d1-718f4b40021f": {"__data__": {"id_": "4fb806e9-54d6-40df-84d1-718f4b40021f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021. ", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f17d447d-76fd-401d-a53b-fdd9945d43ee", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc64872949cfda0e983651b86175fb68653506b18e7c468a9e7dd21e61b40867", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c397843-1f60-4c93-8e72-2f120f53d7d3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n", "original_text": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n"}, "hash": "c6ec3d93b18cfe835695769cc8bf79c9dc541ab1dff010851d59a0577769838e", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021. ", "start_char_idx": 0, "end_char_idx": 794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c397843-1f60-4c93-8e72-2f120f53d7d3": {"__data__": {"id_": "6c397843-1f60-4c93-8e72-2f120f53d7d3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n", "original_text": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fb806e9-54d6-40df-84d1-718f4b40021f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021. ", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66861369cefe15edf6e8217e21708a2f244c1575015839504d7ec50ad12cb513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c316e041-05af-494d-a229-244a1396dfd4", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n", "original_text": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n"}, "hash": "d3c8c63e37c13bed54fe9dea695008cafdded93568bc566e50b1631d589f9b68", "class_name": "RelatedNodeInfo"}}, "text": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n", "start_char_idx": 794, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c316e041-05af-494d-a229-244a1396dfd4": {"__data__": {"id_": "c316e041-05af-494d-a229-244a1396dfd4", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n", "original_text": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c397843-1f60-4c93-8e72-2f120f53d7d3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n", "original_text": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a56d9ccc4e41761326def3c7f53f1123b7fcb81a97ec0bc1cc68a2d940637a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "490c4b03-ac21-4581-9729-6c2b488a80f2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. "}, "hash": "f308b8cfcdeef426a12271806ef208650a67c2592685f504a955cc98a4ec01d2", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n", "start_char_idx": 1162, "end_char_idx": 1431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "490c4b03-ac21-4581-9729-6c2b488a80f2": {"__data__": {"id_": "490c4b03-ac21-4581-9729-6c2b488a80f2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c316e041-05af-494d-a229-244a1396dfd4", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n", "original_text": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3066ed26b22d2510e53622aa90d22f87e7a181cbd14a5122d478ce5ccc16f009", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52f058f3-2c0a-4aaf-acc0-d4e7a545c275", "node_type": "1", "metadata": {"window": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n"}, "hash": "6f0bb6be935a0c0dfc4f757d8969a0ea411f2f5d14bf850d5ec1386e4106acc3", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "start_char_idx": 1431, "end_char_idx": 1884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52f058f3-2c0a-4aaf-acc0-d4e7a545c275": {"__data__": {"id_": "52f058f3-2c0a-4aaf-acc0-d4e7a545c275", "embedding": null, "metadata": {"window": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "490c4b03-ac21-4581-9729-6c2b488a80f2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3b8fb836aa2cbe7235c2e279ab0b9fad581ee4ed7f0beac333d9d36f07124d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c5d9cd3-7aec-4ac6-bf66-af8eea8fd1e3", "node_type": "1", "metadata": {"window": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n"}, "hash": "d4eb0d9e649f4a376eae67fd12d8b1ab4f39ceae4b062494e7d921b7037d4bd2", "class_name": "RelatedNodeInfo"}}, "text": "Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n", "start_char_idx": 1884, "end_char_idx": 2293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c5d9cd3-7aec-4ac6-bf66-af8eea8fd1e3": {"__data__": {"id_": "7c5d9cd3-7aec-4ac6-bf66-af8eea8fd1e3", "embedding": null, "metadata": {"window": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52f058f3-2c0a-4aaf-acc0-d4e7a545c275", "node_type": "1", "metadata": {"window": "Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2673ac9180944187705a849a4720c7c7836dddbb52d13937fae6ae61300eec2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1f44901-7ffa-40d3-aabf-d364b0085ad8", "node_type": "1", "metadata": {"window": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11"}, "hash": "7ca7eda36005665f5180b0977109ce6139a22d6006745a17b060290a7e2f0e00", "class_name": "RelatedNodeInfo"}}, "text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n", "start_char_idx": 2293, "end_char_idx": 2584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1f44901-7ffa-40d3-aabf-d364b0085ad8": {"__data__": {"id_": "a1f44901-7ffa-40d3-aabf-d364b0085ad8", "embedding": null, "metadata": {"window": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75e1b78396eff746fb99138759a497d89f237e45adcec729c91eccd89fbf85fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c5d9cd3-7aec-4ac6-bf66-af8eea8fd1e3", "node_type": "1", "metadata": {"window": "2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b54cbb11829299c1ad38c4e99164650a7ec6a90a8f050c4255da2fc1693f4445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "639567ee-9d9c-48f5-83c0-cebdf3cf86f0", "node_type": "1", "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021. "}, "hash": "411938eabf35b54f6be682a286a84308e8360e3d8dcf338ae30b4ff78dd61194", "class_name": "RelatedNodeInfo"}}, "text": "5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "start_char_idx": 2584, "end_char_idx": 2717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "639567ee-9d9c-48f5-83c0-cebdf3cf86f0": {"__data__": {"id_": "639567ee-9d9c-48f5-83c0-cebdf3cf86f0", "embedding": null, "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021. ", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76b776b5-ce01-4272-8686-5c0e44dc0f4a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffce6a8d67cca3c3b9de4d7103a3a4cf83df6a2b414df36d4c13c6a6b02cb2b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1f44901-7ffa-40d3-aabf-d364b0085ad8", "node_type": "1", "metadata": {"window": "3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021.  Includes $34.4 million of employee severance, a $6,606.9 million legal accrual and\n$115.4 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $50.6 million of\nother costs in connection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and\nintegration costs in the fiscal year ended September 30, 2020.\n 4 Includes a $64.7 million gain on the remeasurement of an equity investment, a $14.0 million impairment of a non-customer note\nreceivable, and a $3.4 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the fiscal\nyear ended September 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $20.4\n11", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0983036050d2cbd0fb274568158da6852e9efe3e16bcfbd9bf75249b0657588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7576c22-3e2a-4827-95f2-0606cbc6a2d1", "node_type": "1", "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n"}, "hash": "7ff8ec08b979088276fc9d073c7d441d72031c94eefb2964d98ce6c2c500ee6d", "class_name": "RelatedNodeInfo"}}, "text": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021. ", "start_char_idx": 0, "end_char_idx": 206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7576c22-3e2a-4827-95f2-0606cbc6a2d1": {"__data__": {"id_": "a7576c22-3e2a-4827-95f2-0606cbc6a2d1", "embedding": null, "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76b776b5-ce01-4272-8686-5c0e44dc0f4a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffce6a8d67cca3c3b9de4d7103a3a4cf83df6a2b414df36d4c13c6a6b02cb2b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "639567ee-9d9c-48f5-83c0-cebdf3cf86f0", "node_type": "1", "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021. ", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01de0d6712626f98ca843f3e0ef7f24382f9015df1d8e03134c0c9d1a28771c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "303777c3-48e9-4cd6-af45-6094b451d201", "node_type": "1", "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12"}, "hash": "58e564febabdd227f7f4bc2104fc1df3589852feeefb00c3039556df056292b4", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n", "start_char_idx": 206, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "303777c3-48e9-4cd6-af45-6094b451d201": {"__data__": {"id_": "303777c3-48e9-4cd6-af45-6094b451d201", "embedding": null, "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "76b776b5-ce01-4272-8686-5c0e44dc0f4a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffce6a8d67cca3c3b9de4d7103a3a4cf83df6a2b414df36d4c13c6a6b02cb2b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7576c22-3e2a-4827-95f2-0606cbc6a2d1", "node_type": "1", "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da4b54d60cb2e371114227fc8a62d0ed3785601d5e79a8dd118dc1c638bdc087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa0e4fe5-005e-4b71-b1b5-c94eea47417b", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "aa1088a999b0d93acaaf7f0e9cbeb2f5364b30f43d12f6fa1c1c8d53afb96b51", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "start_char_idx": 598, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa0e4fe5-005e-4b71-b1b5-c94eea47417b": {"__data__": {"id_": "fa0e4fe5-005e-4b71-b1b5-c94eea47417b", "embedding": null, "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "767f4fe4929ff19f86bcd0c3696fcd5ae4307d2f5607b03e7c5f18843cbe346a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "303777c3-48e9-4cd6-af45-6094b451d201", "node_type": "1", "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f93460020aae419fe0a32722c35e8bc46c347da37d8dff24f4b72c15a09b22b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6de82a6e-b765-45bf-a95c-4fd7af18927a", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n"}, "hash": "b1190367cddc59d7c7676e33c3304c0362ab4edec768ddcc7f82a0d7a3d253c1", "class_name": "RelatedNodeInfo"}}, "text": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6de82a6e-b765-45bf-a95c-4fd7af18927a": {"__data__": {"id_": "6de82a6e-b765-45bf-a95c-4fd7af18927a", "embedding": null, "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "767f4fe4929ff19f86bcd0c3696fcd5ae4307d2f5607b03e7c5f18843cbe346a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa0e4fe5-005e-4b71-b1b5-c94eea47417b", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a060da0ae1da71661d8f4fffffa55205d248bcfb8d1ff6701761437bf1dce5af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5489d13-7534-4367-bea0-2025757b1f17", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n"}, "hash": "49d0c18394c552d47edc96b61e88054e57542f1146c8bab1a657f97412d05acc", "class_name": "RelatedNodeInfo"}}, "text": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n", "start_char_idx": 589, "end_char_idx": 937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5489d13-7534-4367-bea0-2025757b1f17": {"__data__": {"id_": "e5489d13-7534-4367-bea0-2025757b1f17", "embedding": null, "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "767f4fe4929ff19f86bcd0c3696fcd5ae4307d2f5607b03e7c5f18843cbe346a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6de82a6e-b765-45bf-a95c-4fd7af18927a", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf7f9cf226cd0f8805018317de75cd992576b26f5773296c8d4497cc7eeed43d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79682d58-56d3-4317-866a-92879ff9ab19", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "fc14450a08b9f37b892190605c5fa7af49c8cb7defb301eb9945c3fa51beac5d", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n", "start_char_idx": 937, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79682d58-56d3-4317-866a-92879ff9ab19": {"__data__": {"id_": "79682d58-56d3-4317-866a-92879ff9ab19", "embedding": null, "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "767f4fe4929ff19f86bcd0c3696fcd5ae4307d2f5607b03e7c5f18843cbe346a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5489d13-7534-4367-bea0-2025757b1f17", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa8a608810c1ed79b3bb11736c49c7b0b7f1800bf8c55cfa718ae8d2cc6da279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e47925b3-561f-4112-9175-5f60e3da866d", "node_type": "1", "metadata": {"window": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\n13"}, "hash": "e6b537e274a67e942ff90746c76e6062f716341ca7647012126cf036f1208d9f", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 1135, "end_char_idx": 1312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e47925b3-561f-4112-9175-5f60e3da866d": {"__data__": {"id_": "e47925b3-561f-4112-9175-5f60e3da866d", "embedding": null, "metadata": {"window": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\n13", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "767f4fe4929ff19f86bcd0c3696fcd5ae4307d2f5607b03e7c5f18843cbe346a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79682d58-56d3-4317-866a-92879ff9ab19", "node_type": "1", "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd7b470b2a1400c02f1f2569a87d8486aa20b2360b74cfae75d6f705b333586b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00e34dec-a3d1-4442-a058-f97b5b7e3f18", "node_type": "1", "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14"}, "hash": "4527f8f4c975ce9290348fdf525fc3bd60181c2821bf65e95a7e8e538664e498", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\n13", "start_char_idx": 1312, "end_char_idx": 1344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00e34dec-a3d1-4442-a058-f97b5b7e3f18": {"__data__": {"id_": "00e34dec-a3d1-4442-a058-f97b5b7e3f18", "embedding": null, "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c59c9858-7f9e-4c22-b88c-9914022c50ea", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b1c70b0d7de971f3d223c15944845dc1d09ea982a936d14853090e9e329f269", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e47925b3-561f-4112-9175-5f60e3da866d", "node_type": "1", "metadata": {"window": "prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\n13", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34a7552583bbbbd1bc8dc84df37b0e332e4ba9a98dd3fca6bfbab7e98be5105a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "508797a5-4419-4936-afe4-0a5be987abea", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n"}, "hash": "54280f09b2ea1c56b4e7981bd994675c5afc9031b2d8f4c5e920046ed733ada2", "class_name": "RelatedNodeInfo"}}, "text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "start_char_idx": 0, "end_char_idx": 1390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "508797a5-4419-4936-afe4-0a5be987abea": {"__data__": {"id_": "508797a5-4419-4936-afe4-0a5be987abea", "embedding": null, "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "590d0d88a86acc98a3afb5c65bfa5cde899068d1f05401a417604844f471f9a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00e34dec-a3d1-4442-a058-f97b5b7e3f18", "node_type": "1", "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a81ee6a3d0eda3a2fe279e50c7144df69e682b64b03be31c70a847690f837d53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0865bd7-1ec9-4891-88a2-d82d95081f78", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n"}, "hash": "d46152af5283ded4ceb48c06513d7a6af6ea7eeb0b996ae774a892f1bae942f7", "class_name": "RelatedNodeInfo"}}, "text": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "start_char_idx": 0, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0865bd7-1ec9-4891-88a2-d82d95081f78": {"__data__": {"id_": "a0865bd7-1ec9-4891-88a2-d82d95081f78", "embedding": null, "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "590d0d88a86acc98a3afb5c65bfa5cde899068d1f05401a417604844f471f9a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "508797a5-4419-4936-afe4-0a5be987abea", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05d0f0ad8048fac6b6d821a1eec905eebd3cc9b9822cf82aeeadc4dabbd38cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f966e64b-1b18-4323-b038-4870145e9f8d", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "3 Represents a tax benefit relating to Swiss tax reform.\n"}, "hash": "4fce5835fc14de1ad9c09a08cf393021d1ffdf293312ff3b043d5101f60f8839", "class_name": "RelatedNodeInfo"}}, "text": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n", "start_char_idx": 659, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f966e64b-1b18-4323-b038-4870145e9f8d": {"__data__": {"id_": "f966e64b-1b18-4323-b038-4870145e9f8d", "embedding": null, "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "3 Represents a tax benefit relating to Swiss tax reform.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "590d0d88a86acc98a3afb5c65bfa5cde899068d1f05401a417604844f471f9a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0865bd7-1ec9-4891-88a2-d82d95081f78", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad965c5e8b895d27cd59745b9c986b8ce894ce1013363a395a87601548c89b6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee2270e3-3e6e-48a0-84d6-d6ebb109a560", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "4aff1c318e6100487bf40b7ef08f689bdd780a0617a121b59b568ef10020ee9c", "class_name": "RelatedNodeInfo"}}, "text": "3 Represents a tax benefit relating to Swiss tax reform.\n", "start_char_idx": 851, "end_char_idx": 908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee2270e3-3e6e-48a0-84d6-d6ebb109a560": {"__data__": {"id_": "ee2270e3-3e6e-48a0-84d6-d6ebb109a560", "embedding": null, "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "590d0d88a86acc98a3afb5c65bfa5cde899068d1f05401a417604844f471f9a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f966e64b-1b18-4323-b038-4870145e9f8d", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "3 Represents a tax benefit relating to Swiss tax reform.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "811c752065757514fadb116a42a155e030f0dc2f3d79a9f72bc9f2d4ac71dd6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16514a0f-d2b8-44f2-bea6-40e6355f92dc", "node_type": "1", "metadata": {"window": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15"}, "hash": "aceb3254c6392e8bc8fe42428a736ccb3de024ece5ec6a5d3dc33b5b2540884a", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 908, "end_char_idx": 1085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16514a0f-d2b8-44f2-bea6-40e6355f92dc": {"__data__": {"id_": "16514a0f-d2b8-44f2-bea6-40e6355f92dc", "embedding": null, "metadata": {"window": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "590d0d88a86acc98a3afb5c65bfa5cde899068d1f05401a417604844f471f9a0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee2270e3-3e6e-48a0-84d6-d6ebb109a560", "node_type": "1", "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b43dcdd9e3660321d62232e1e310fe4ba446c52ab46cae6590ebbd7fecbc1de6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5cc44b2-a987-4192-8ec4-f4e3209644fc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16"}, "hash": "5efae57df15b7fcb4154fb4d06e1b3781e58d8a40a01db47be24d095761b1ee2", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "start_char_idx": 1085, "end_char_idx": 1387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5cc44b2-a987-4192-8ec4-f4e3209644fc": {"__data__": {"id_": "a5cc44b2-a987-4192-8ec4-f4e3209644fc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc40b836-7413-4492-af80-8a1de5358048", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71c830bdfa852d282d62bc6493fba536ae473e136cc9a91e678035df9112b4e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16514a0f-d2b8-44f2-bea6-40e6355f92dc", "node_type": "1", "metadata": {"window": "2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2021 \u00a0\nOperating OperatingIncome\nBefor e Income TaxNet Income \n Attributable t o\nNoncontr ollingNet Income \n Attributable\ntoDilut ed \n Earnings\nPer\n15", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c77f6fcbfa06347b243892ce2b1b8efee6dd0af50c95c9055f46f054667af84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d8fb1f7-3f85-4f0e-aabe-34e375a37aaa", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "original_text": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "c7a73d0ea9c4931ff387ff513a5cd78c5aa4c65bf03950a1b8c1ce3119919a14", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "start_char_idx": 0, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d8fb1f7-3f85-4f0e-aabe-34e375a37aaa": {"__data__": {"id_": "2d8fb1f7-3f85-4f0e-aabe-34e375a37aaa", "embedding": null, "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "original_text": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5cc44b2-a987-4192-8ec4-f4e3209644fc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3aa20decf582d4b82340f6c3f34067080bf51a1c0e1098fa21dade08ad54c7db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a09f8280-8d0b-4ce7-a345-22b7b925ebb2", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n"}, "hash": "7ffcfa38258f13801afb868e037694cc71e13b62fcff788ed61a90412031e56a", "class_name": "RelatedNodeInfo"}}, "text": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a09f8280-8d0b-4ce7-a345-22b7b925ebb2": {"__data__": {"id_": "a09f8280-8d0b-4ce7-a345-22b7b925ebb2", "embedding": null, "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d8fb1f7-3f85-4f0e-aabe-34e375a37aaa", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "original_text": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8de0984cfce449608c9a33c7a1d92afe72fc690adc788a249f4da0b2c1e964e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3a5dec8-c95f-4139-b9f0-6e94a3d84b10", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n"}, "hash": "997d4fcb666129fe41224c66e9e3643d0107c72cc0ba3a5f6b0c376528ba3dde", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n", "start_char_idx": 272, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3a5dec8-c95f-4139-b9f0-6e94a3d84b10": {"__data__": {"id_": "e3a5dec8-c95f-4139-b9f0-6e94a3d84b10", "embedding": null, "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a09f8280-8d0b-4ce7-a345-22b7b925ebb2", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81f19fb0f889a828eeb26d72e122331c256868a391ba2f01925ba7de249d7899", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43b96c01-a2c1-439d-b6a1-4c8846ed396f", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n"}, "hash": "20b7e3c39e54f19c858534ebebfa82524d46fdfc98ba560a7c28f40c9a084cff", "class_name": "RelatedNodeInfo"}}, "text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "start_char_idx": 614, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43b96c01-a2c1-439d-b6a1-4c8846ed396f": {"__data__": {"id_": "43b96c01-a2c1-439d-b6a1-4c8846ed396f", "embedding": null, "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3a5dec8-c95f-4139-b9f0-6e94a3d84b10", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efc415b5a5589097ccbebdfd0adc100598be05c08e60c43ac85ce96c45c322f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eb7e837-ad70-4d2c-86bf-7b5f3aff1946", "node_type": "1", "metadata": {"window": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "4 The sum of the components does not equal the total due to rounding.\n"}, "hash": "517227aba818fde3572f462fdd008462cdfab2b6984d2a067df5452252e84682", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "start_char_idx": 784, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eb7e837-ad70-4d2c-86bf-7b5f3aff1946": {"__data__": {"id_": "9eb7e837-ad70-4d2c-86bf-7b5f3aff1946", "embedding": null, "metadata": {"window": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "4 The sum of the components does not equal the total due to rounding.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43b96c01-a2c1-439d-b6a1-4c8846ed396f", "node_type": "1", "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dd1be41dbe5b1fd5830c80544371d50ca909260b84cfe045bf7605ab99ee9e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6105568f-4de0-48a1-b53a-8308da3dc32d", "node_type": "1", "metadata": {"window": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "c5b06825602d4f427a75800942123dcbb1be0b22702d77b5a7fd5d9c18a07932", "class_name": "RelatedNodeInfo"}}, "text": "4 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 1037, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6105568f-4de0-48a1-b53a-8308da3dc32d": {"__data__": {"id_": "6105568f-4de0-48a1-b53a-8308da3dc32d", "embedding": null, "metadata": {"window": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eb7e837-ad70-4d2c-86bf-7b5f3aff1946", "node_type": "1", "metadata": {"window": "prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "4 The sum of the components does not equal the total due to rounding.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a432ccd684d0c4ee11ee170b89616adf2067c752f713fe20ab4bb2d19eff99bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa045908-b90c-4d46-8ff4-5f49aa76830c", "node_type": "1", "metadata": {"window": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17"}, "hash": "eb2d1e4d1f2d45982e678a259c3ee1e051247553b44fb10b100ba8f99a8cfd48", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 1107, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa045908-b90c-4d46-8ff4-5f49aa76830c": {"__data__": {"id_": "aa045908-b90c-4d46-8ff4-5f49aa76830c", "embedding": null, "metadata": {"window": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08357fefa08818659e357ea61ff0bae49e1fa9f490681133199492f11aef80d0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6105568f-4de0-48a1-b53a-8308da3dc32d", "node_type": "1", "metadata": {"window": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "955522090ddd017269b60c0ec24fc6ddbbda72f60ca99f318241d3ea0b984b2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c7fd279-b4e6-4776-be60-f2f2a62f2620", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18"}, "hash": "040eae1de089aeafca1942fd3d54cdfdde38522672542425d3e9caa5f22bfd90", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "start_char_idx": 1284, "end_char_idx": 1542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c7fd279-b4e6-4776-be60-f2f2a62f2620": {"__data__": {"id_": "1c7fd279-b4e6-4776-be60-f2f2a62f2620", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "page_label": "18", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ce620db9-3cff-48e6-ab98-e86564c32b56", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b3481f3c7cb794707fd1a1dbc45267c1f60fcf8cbb953e5a3c674309cb0fb91", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa045908-b90c-4d46-8ff4-5f49aa76830c", "node_type": "1", "metadata": {"window": "3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30, 2020 \u00a0\nOperating(Loss)\nIncome \nBefor e Income TaxNet Income \nAttributable toNet (Loss) \nIncome Dilut ed\n17", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6ec02dac530ee9bb7fa4600cbd1cd2e6eaa1b32d13b3f2091364370b2d9a49a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "294f697d-8893-4c72-ac81-43f29bbea85a", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n"}, "hash": "8810e07355b311f1e9da74b0fae6e9a6652b224072cb57b1b204000a75012836", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "start_char_idx": 0, "end_char_idx": 1470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "294f697d-8893-4c72-ac81-43f29bbea85a": {"__data__": {"id_": "294f697d-8893-4c72-ac81-43f29bbea85a", "embedding": null, "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5645804b34242353656190067fa5528543984db26eecc6e316284b5659e6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c7fd279-b4e6-4776-be60-f2f2a62f2620", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "page_label": "18", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59f9a6db6300f16ced5579e3aaaa1949e9cd63019a74dbfaa585718f273359fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4b8da48-d702-4913-83c1-c205998f450a", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n"}, "hash": "1543ca2be66f82cbddade680f8fd1fa37154d36aa9e0d75c22d9131f70996394", "class_name": "RelatedNodeInfo"}}, "text": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "start_char_idx": 0, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4b8da48-d702-4913-83c1-c205998f450a": {"__data__": {"id_": "c4b8da48-d702-4913-83c1-c205998f450a", "embedding": null, "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5645804b34242353656190067fa5528543984db26eecc6e316284b5659e6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "294f697d-8893-4c72-ac81-43f29bbea85a", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbbe44110eab6078587ee797786e81abd069762e40e11219f7107b5bb08633c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b38836d8-b9f5-49b8-9372-25f430d69905", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "3 Represents a tax benefit relating to Swiss tax reform.\n"}, "hash": "5e559a7ceeb22decddba88491a92a04b99bf78d13abed9f0602c9e91b1632347", "class_name": "RelatedNodeInfo"}}, "text": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n", "start_char_idx": 683, "end_char_idx": 836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b38836d8-b9f5-49b8-9372-25f430d69905": {"__data__": {"id_": "b38836d8-b9f5-49b8-9372-25f430d69905", "embedding": null, "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "3 Represents a tax benefit relating to Swiss tax reform.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5645804b34242353656190067fa5528543984db26eecc6e316284b5659e6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4b8da48-d702-4913-83c1-c205998f450a", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78f4f0920c42f97e17d2828427ebf40b848ca8e8948f3a8fe26de8845f242f8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7a057aa-58f2-41b0-bb4e-fe84bb35c2c8", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "4 The sum of the components does not equal the total due to rounding.\n"}, "hash": "ec0f1d269175d6b2a7635a56a693d2286281041cb35f5fa2fede27efa3184b9f", "class_name": "RelatedNodeInfo"}}, "text": "3 Represents a tax benefit relating to Swiss tax reform.\n", "start_char_idx": 836, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7a057aa-58f2-41b0-bb4e-fe84bb35c2c8": {"__data__": {"id_": "c7a057aa-58f2-41b0-bb4e-fe84bb35c2c8", "embedding": null, "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "4 The sum of the components does not equal the total due to rounding.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5645804b34242353656190067fa5528543984db26eecc6e316284b5659e6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b38836d8-b9f5-49b8-9372-25f430d69905", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "3 Represents a tax benefit relating to Swiss tax reform.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41231baf7f730cb393f938b640707849106e06adaf2a5cc3109237712ef13e2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15f8f8a8-73c4-484f-9b66-48c3d3121447", "node_type": "1", "metadata": {"window": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "b3d5388e579a79f9080b12fd74f619b195ec8cb87e858a62326e8f996e8673df", "class_name": "RelatedNodeInfo"}}, "text": "4 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 893, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15f8f8a8-73c4-484f-9b66-48c3d3121447": {"__data__": {"id_": "15f8f8a8-73c4-484f-9b66-48c3d3121447", "embedding": null, "metadata": {"window": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5645804b34242353656190067fa5528543984db26eecc6e316284b5659e6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7a057aa-58f2-41b0-bb4e-fe84bb35c2c8", "node_type": "1", "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "4 The sum of the components does not equal the total due to rounding.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "273d6c17e12d41f7ab60d079a479fbb0ccfd2a4b7666fac05361390f1e6a0ba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e9f9197-0747-452b-bb9c-053ca108277a", "node_type": "1", "metadata": {"window": "3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19"}, "hash": "0354864a71c9f8d1bd1dd3df2a332c92a72307e88cf9755d526fa43d507a565f", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 963, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e9f9197-0747-452b-bb9c-053ca108277a": {"__data__": {"id_": "3e9f9197-0747-452b-bb9c-053ca108277a", "embedding": null, "metadata": {"window": "3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dd5645804b34242353656190067fa5528543984db26eecc6e316284b5659e6d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15f8f8a8-73c4-484f-9b66-48c3d3121447", "node_type": "1", "metadata": {"window": "2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "294d18442720bb761c497d073af4bb0c948fd87dacfa0ac6b2cf28d0ffb45676", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b2138d6-acbc-4242-9764-5dd4b2d61df1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n"}, "hash": "2a6b8c690b8bd521d94b77e9b1c8fc199bb38132b651409c8722533354a975b2", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "start_char_idx": 1140, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b2138d6-acbc-4242-9764-5dd4b2d61df1": {"__data__": {"id_": "9b2138d6-acbc-4242-9764-5dd4b2d61df1", "embedding": null, "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e765f75-ae88-4306-bf19-6049f47eba1a", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5c15e245f55470e86d67818c6e6bcf9d146504a8d7637e2a7ff0596ea8f4051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e9f9197-0747-452b-bb9c-053ca108277a", "node_type": "1", "metadata": {"window": "3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "original_text": "AMERISOURCEBERGEN CORPORATION\nRECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP)\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended \n September 30, \u00a0Fiscal Y ear Ended \n September 30,\n19", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c2c6226ac83884860ade753de4af8cf293accba39f0df5dff4d148ab2e457b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "996fc28a-abdf-4aa3-b8e3-9057a62d31e9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "16e978c75aa272ff7aca3427cca600b27bb9683f669ebe1d859c4e1542a52535", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n", "start_char_idx": 0, "end_char_idx": 680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "996fc28a-abdf-4aa3-b8e3-9057a62d31e9": {"__data__": {"id_": "996fc28a-abdf-4aa3-b8e3-9057a62d31e9", "embedding": null, "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e765f75-ae88-4306-bf19-6049f47eba1a", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5c15e245f55470e86d67818c6e6bcf9d146504a8d7637e2a7ff0596ea8f4051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b2138d6-acbc-4242-9764-5dd4b2d61df1", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59ae1fb8803ea42dfeb7de912293c692956211724cef501fca4ec1911af1a2db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd490ae9-60d5-43f7-92f4-f70c97e744b8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20"}, "hash": "e8e872e7005f813a1aef3cc42671cba65c237767d1d6b9547142dec5c3fafe60", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 680, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd490ae9-60d5-43f7-92f4-f70c97e744b8": {"__data__": {"id_": "fd490ae9-60d5-43f7-92f4-f70c97e744b8", "embedding": null, "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e765f75-ae88-4306-bf19-6049f47eba1a", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5c15e245f55470e86d67818c6e6bcf9d146504a8d7637e2a7ff0596ea8f4051", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "996fc28a-abdf-4aa3-b8e3-9057a62d31e9", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29f37f5ad33f04902a97a03aeff7045f82a51a8164b68aac7565d1e2d684c66f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "562def7c-12a7-4afa-80c0-ed39310b829e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21"}, "hash": "966387576d6f925b6f6ba1e65905c0e87953cc741d951a148c0795f276933429", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "start_char_idx": 857, "end_char_idx": 1235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "562def7c-12a7-4afa-80c0-ed39310b829e": {"__data__": {"id_": "562def7c-12a7-4afa-80c0-ed39310b829e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8688fdb-4311-4843-b66d-47fe768eac5d", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b1b75bbf0f78c3ea2dd25f2619dae802ab302e2cd3a32ebb2df65d475449165", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd490ae9-60d5-43f7-92f4-f70c97e744b8", "node_type": "1", "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be1d3c2ff570d58a07868848fc20914122a82a674de8dd87654f1b28db058488", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ba1e67-5c8d-4832-ae51-957adffd40a2", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "11e42e6c4daafc396da6d221b6f4bd9328f15588cc32cfe25026b47b39f7ba26", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "start_char_idx": 0, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ba1e67-5c8d-4832-ae51-957adffd40a2": {"__data__": {"id_": "d0ba1e67-5c8d-4832-ae51-957adffd40a2", "embedding": null, "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b18cbb8-a73c-49a5-af6d-bd8bb3edb0ab", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2ffe18b3be61bb65092b64f48260b3980d2c2c3e13721ea1e3fc219270a5cf6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "562def7c-12a7-4afa-80c0-ed39310b829e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a4e76d1be72ffa9c8e8241ceed17c5d3d645aa93a97e6d23461abcef5b8ded7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76f3fede-d75c-4689-bb89-db5559af304d", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22"}, "hash": "93bedc4bd641df330859511fe761afcf030572ce72e420c29074041500b37784", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76f3fede-d75c-4689-bb89-db5559af304d": {"__data__": {"id_": "76f3fede-d75c-4689-bb89-db5559af304d", "embedding": null, "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3b18cbb8-a73c-49a5-af6d-bd8bb3edb0ab", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2ffe18b3be61bb65092b64f48260b3980d2c2c3e13721ea1e3fc219270a5cf6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ba1e67-5c8d-4832-ae51-957adffd40a2", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d67405a066cab0a1c0ee229e9bbb6acf3a78c6d09ce3665aa3b0f1caaebf900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f70c4d9b-9e4d-4479-9437-41f4fabead0e", "node_type": "1", "metadata": {"window": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "original_text": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23"}, "hash": "15168f43c850d7dc264e9616304f3f752a5650826fc10769e7debf7aff7de2bc", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "start_char_idx": 733, "end_char_idx": 897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f70c4d9b-9e4d-4479-9437-41f4fabead0e": {"__data__": {"id_": "f70c4d9b-9e4d-4479-9437-41f4fabead0e", "embedding": null, "metadata": {"window": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "original_text": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "page_label": "23", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c453f395-ce3c-49ff-b342-3428bb9670d3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fad9c1468d696f7a5a3b808afa234606e26b3d0d47653daf536add16fc0a46c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76f3fede-d75c-4689-bb89-db5559af304d", "node_type": "1", "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59f9ff86f91ee1bae02f556e1e0d5dbc9a1f2aabc7e3a27023d897667108fe2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47a8d986-33b6-4cf8-a829-481ca5e466a5", "node_type": "1", "metadata": {"window": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "original_text": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24"}, "hash": "2ea4bfe8ed9591c273467cc1136c3ea0f40d6ad07c002154954a2888415f98dc", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "start_char_idx": 0, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47a8d986-33b6-4cf8-a829-481ca5e466a5": {"__data__": {"id_": "47a8d986-33b6-4cf8-a829-481ca5e466a5", "embedding": null, "metadata": {"window": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "original_text": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "page_label": "24", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a6793dca-8e31-4804-866a-0cb9e551bb83", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45adc3144914babd7a5c5e5e340c9ed44cafc8d43d1afc9db54c89b237607f64", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f70c4d9b-9e4d-4479-9437-41f4fabead0e", "node_type": "1", "metadata": {"window": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "original_text": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "page_label": "23", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c8463cb8c82b846c464e0934b4d6d492de4a2e09b18e42f312a2ed583fe7649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a877893f-e1ca-4270-bbc8-b955b05e3b12", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "5bb9639f0b81675b6d392e77f6cc9f4630f47dc5d284af3fadef15ab3f3729c1", "class_name": "RelatedNodeInfo"}}, "text": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "start_char_idx": 0, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a877893f-e1ca-4270-bbc8-b955b05e3b12": {"__data__": {"id_": "a877893f-e1ca-4270-bbc8-b955b05e3b12", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d9136c-f7a8-4540-b8a1-700d7e47c8ca", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3077d082339bf05d94283481099f3e6ffd36e6d01991a693eda64dd7e98c83ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47a8d986-33b6-4cf8-a829-481ca5e466a5", "node_type": "1", "metadata": {"window": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "original_text": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "page_label": "24", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "701f415f3c791d39f0916cda7ac811df1c17c8bd9e02753102fdfe7303a8efeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c781d97d-d1f0-4d1c-b336-854e9eca14f8", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25"}, "hash": "2ec75afc8fa7dc391c22619d72cde533e75019e8e50884b7f2b6e02bf8c05441", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c781d97d-d1f0-4d1c-b336-854e9eca14f8": {"__data__": {"id_": "c781d97d-d1f0-4d1c-b336-854e9eca14f8", "embedding": null, "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c2d9136c-f7a8-4540-b8a1-700d7e47c8ca", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3077d082339bf05d94283481099f3e6ffd36e6d01991a693eda64dd7e98c83ba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a877893f-e1ca-4270-bbc8-b955b05e3b12", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5532e006f96dcdbb189d39e1400e11fd3c435aebacbe2733e30caa04011319a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "841574fb-3124-41d9-8cef-53cb2e5ceade", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26"}, "hash": "919511a40ab88f5aa558a661a52d3c039c7f11351b53368579e6297aabbcde7b", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "start_char_idx": 177, "end_char_idx": 1006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "841574fb-3124-41d9-8cef-53cb2e5ceade": {"__data__": {"id_": "841574fb-3124-41d9-8cef-53cb2e5ceade", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "page_label": "26", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e663f9e9-9ad6-485e-8eed-8b1b19b80a43", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c1ff7fe55419e96b7697e6f98a38527362fa6edec7a80b328c65381db0fb897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c781d97d-d1f0-4d1c-b336-854e9eca14f8", "node_type": "1", "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c985a1486d5eb8da05b368dadb4c35ff9b69f52a6ffec537bc8295438c7ea924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6404a2d1-e0ba-4882-82b3-afbad408a017", "node_type": "1", "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27"}, "hash": "ba4b81ec444b63bf4a311c62c2a9152bfa6d7f5d86251aed69d8996d751893d0", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "start_char_idx": 0, "end_char_idx": 938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6404a2d1-e0ba-4882-82b3-afbad408a017": {"__data__": {"id_": "6404a2d1-e0ba-4882-82b3-afbad408a017", "embedding": null, "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "page_label": "27", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ea0ee79a-7bbc-4f00-908a-1aa32781d3da", "node_type": "4", "metadata": {"page_label": "27", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbe37252290c6ce49605e6ccee2de4ea4a08db68322816849829fb27788083ec", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "841574fb-3124-41d9-8cef-53cb2e5ceade", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "page_label": "26", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4b22b60b9f58a00ec11d2808a44ecba58f35c127573b3114d3922108a6b9c5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0894117-2b1f-4275-bc3c-f6220196a222", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "original_text": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n"}, "hash": "f8ec5e655b047addf3770e9ac85377649448c4e4754f659703e6f081a101f244", "class_name": "RelatedNodeInfo"}}, "text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "start_char_idx": 0, "end_char_idx": 1336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0894117-2b1f-4275-bc3c-f6220196a222": {"__data__": {"id_": "d0894117-2b1f-4275-bc3c-f6220196a222", "embedding": null, "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "original_text": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6404a2d1-e0ba-4882-82b3-afbad408a017", "node_type": "1", "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "page_label": "27", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83d06f0d2ef1ca28278cb70109d592585453c8b4c9f1a99e1f60432bb0736abf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ca5f761-9035-4ed8-98c4-b134eb0bb36a", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n"}, "hash": "9313e45b409ed28d604087dc7dcaf4e222d9bdab4c57dd6c2d18a5861a420239", "class_name": "RelatedNodeInfo"}}, "text": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n", "start_char_idx": 0, "end_char_idx": 588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ca5f761-9035-4ed8-98c4-b134eb0bb36a": {"__data__": {"id_": "3ca5f761-9035-4ed8-98c4-b134eb0bb36a", "embedding": null, "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0894117-2b1f-4275-bc3c-f6220196a222", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "original_text": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e349f391637594c6dd372d35170d8c03a63c86126231c9ad000df79682e8f536", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30fa8b99-981f-42be-b363-d60eb0d65d47", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n"}, "hash": "b8859c5264450a6f22e631fa2d7a24165f5496f777799a3427669b311bfc670a", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n", "start_char_idx": 588, "end_char_idx": 832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30fa8b99-981f-42be-b363-d60eb0d65d47": {"__data__": {"id_": "30fa8b99-981f-42be-b363-d60eb0d65d47", "embedding": null, "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ca5f761-9035-4ed8-98c4-b134eb0bb36a", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "original_text": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0317afb23ec9d68097078cb0e1e1fa4a8d5cab6602e14ac261aef275783528b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e477d84-9a94-460b-a10d-c424e23cade3", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n"}, "hash": "530bedc47d9042597752ca8d06c24b1487bd03acbe09961b5c8012bca5ad9637", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n", "start_char_idx": 832, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e477d84-9a94-460b-a10d-c424e23cade3": {"__data__": {"id_": "5e477d84-9a94-460b-a10d-c424e23cade3", "embedding": null, "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30fa8b99-981f-42be-b363-d60eb0d65d47", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "original_text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d15f283405b544f70282d8871c78c565d50e0b5aaea73d14461f558ab2c84c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e20a4e4-3731-4729-82b6-dd181425b948", "node_type": "1", "metadata": {"window": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "1c7f073a1f3cf141100b7867f8b749fe89626f914629ccf10af1c63ec41de2ea", "class_name": "RelatedNodeInfo"}}, "text": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "start_char_idx": 1213, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e20a4e4-3731-4729-82b6-dd181425b948": {"__data__": {"id_": "8e20a4e4-3731-4729-82b6-dd181425b948", "embedding": null, "metadata": {"window": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e477d84-9a94-460b-a10d-c424e23cade3", "node_type": "1", "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd5afe509be9c97dd53d39dac407b9c475aeb827f448eeaa8ac5694ceb382ab2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fecaf29a-c268-4061-a649-beda488ee4ed", "node_type": "1", "metadata": {"window": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "d4816640b47df53960e6e2ca7dcab0d140f0cb53f220d9445176e1a0a743f760", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 1479, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fecaf29a-c268-4061-a649-beda488ee4ed": {"__data__": {"id_": "fecaf29a-c268-4061-a649-beda488ee4ed", "embedding": null, "metadata": {"window": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e20a4e4-3731-4729-82b6-dd181425b948", "node_type": "1", "metadata": {"window": "2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a6a6d878a4310d151820b742a7ed40d6a5011a9f135418f95ba6edf8302748d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c094bb-52d6-4cc2-8c66-e8d04ffd269b", "node_type": "1", "metadata": {"window": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "50b8ca11ea1dfc87c292e32c36b3ba8dabf682de841872562435ac89111c7e8d", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 1617, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c094bb-52d6-4cc2-8c66-e8d04ffd269b": {"__data__": {"id_": "c5c094bb-52d6-4cc2-8c66-e8d04ffd269b", "embedding": null, "metadata": {"window": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fecaf29a-c268-4061-a649-beda488ee4ed", "node_type": "1", "metadata": {"window": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2298c2474823f16ba04896b65505fbfd50a713ef943582ca967e430f7324d38a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7f66d7f-3a7d-4220-a3f9-a644aa709340", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "d7f41ea6e423d600cac2fbc4858ef319d95447153d4c26be00f5ad76552c02d8", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 1732, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f66d7f-3a7d-4220-a3f9-a644aa709340": {"__data__": {"id_": "e7f66d7f-3a7d-4220-a3f9-a644aa709340", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c094bb-52d6-4cc2-8c66-e8d04ffd269b", "node_type": "1", "metadata": {"window": "4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73fcd7016117d6e8ed6522c46f802f7941d3fab73931ab83894874f73848b8b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6485b98-3a65-45d0-b960-eac27f938ef8", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "ef743e9917c4c38574b06e66a7fc740673f51bd70f60740821d73e1a3a9df129", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 1872, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6485b98-3a65-45d0-b960-eac27f938ef8": {"__data__": {"id_": "f6485b98-3a65-45d0-b960-eac27f938ef8", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7f66d7f-3a7d-4220-a3f9-a644aa709340", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "777c4d3d6433da152618f4b98fd8a2f218dab1e896909efd949a4c9d3ede6898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d85ab9b-047b-4f73-9468-d6b52a33b7b6", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "1a7e87c738e4d5f43b34c9b2e3e9e00e90861640a6e5737ce94689971d326f39", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 1991, "end_char_idx": 2210, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d85ab9b-047b-4f73-9468-d6b52a33b7b6": {"__data__": {"id_": "0d85ab9b-047b-4f73-9468-d6b52a33b7b6", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6485b98-3a65-45d0-b960-eac27f938ef8", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2d30b6bd7190a182e9d7cd59f6a47a1a40215bae8c4a481e624c2cd06d9b690", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fd54a39-26cf-4815-ab9a-f6445759aa77", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "48b3d051bab9c58aded431467569d0eaba47d86c11274e05c5c7b530eb9e2d7b", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 2210, "end_char_idx": 2392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fd54a39-26cf-4815-ab9a-f6445759aa77": {"__data__": {"id_": "8fd54a39-26cf-4815-ab9a-f6445759aa77", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d85ab9b-047b-4f73-9468-d6b52a33b7b6", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "918b9522b35b8ee6af36343801db9eae2ab3cd4573a0e1b120ddce39852fb7c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "115b8cf5-0947-4dcc-8b9c-2c643804044f", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). "}, "hash": "01070aed2ec90a0bafc6084de81eb18a1da4ffd3b966956dca53055ba1647a7e", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 2392, "end_char_idx": 2673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "115b8cf5-0947-4dcc-8b9c-2c643804044f": {"__data__": {"id_": "115b8cf5-0947-4dcc-8b9c-2c643804044f", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fd54a39-26cf-4815-ab9a-f6445759aa77", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9428f1ad837bf9ba81a5211aa954d9877d761c09fe312346616b91f0ca3f729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "193d727e-98a3-4e80-8e4a-a86c40690046", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. "}, "hash": "fd2ec0e671366e7fc32b551441a1730837b89ccd847b41ff629adb2abdd46cbc", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "start_char_idx": 2673, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "193d727e-98a3-4e80-8e4a-a86c40690046": {"__data__": {"id_": "193d727e-98a3-4e80-8e4a-a86c40690046", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "115b8cf5-0947-4dcc-8b9c-2c643804044f", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\"). ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "306b43b24cabd187a0d274f6f1ff73725335effd788b748fe1c62a75fc966f01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "383756d6-f991-4743-b27d-fabfc81a4a96", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable expenses. "}, "hash": "33b3006d9a680af16c581c0dff138a459a9a70a16878cc8c9fef88e2e60053c1", "class_name": "RelatedNodeInfo"}}, "text": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. ", "start_char_idx": 3106, "end_char_idx": 3272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "383756d6-f991-4743-b27d-fabfc81a4a96": {"__data__": {"id_": "383756d6-f991-4743-b27d-fabfc81a4a96", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "193d727e-98a3-4e80-8e4a-a86c40690046", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "445b30d8156b9f41aa4a60ad0309c40df1e27bfb9c31cfbac2e28e358bc663a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2f59bfb-2db4-4c43-8130-b09fa32861db", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n"}, "hash": "c62be1bca7d77be8128701d43b8dca822b1f4f2c76117308f5cef9bd174d10f8", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they were unpredictable expenses. ", "start_char_idx": 3272, "end_char_idx": 3356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2f59bfb-2db4-4c43-8130-b09fa32861db": {"__data__": {"id_": "f2f59bfb-2db4-4c43-8130-b09fa32861db", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "383756d6-f991-4743-b27d-fabfc81a4a96", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable expenses. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b549dc0941ee3933cc168c29e402019cb04f12c2ad5f42505bc6441a68946978", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10237c77-3e51-42ab-8c08-48c192e25df1", "node_type": "1", "metadata": {"window": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. "}, "hash": "d0d69565cb471ecc928f173c53166b0f0c74fecf3f1834f782d93f89c8fe2c1d", "class_name": "RelatedNodeInfo"}}, "text": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n", "start_char_idx": 3356, "end_char_idx": 3486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10237c77-3e51-42ab-8c08-48c192e25df1": {"__data__": {"id_": "10237c77-3e51-42ab-8c08-48c192e25df1", "embedding": null, "metadata": {"window": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2f59bfb-2db4-4c43-8130-b09fa32861db", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes the\ngain from antitrust litigation settlements, LIFO expense (credit), certain PharMEDium shutdown and remediation costs, and\nthe expense related to the New York State Opioid Stewardship Act (the \"NYS Opioid Act\").  Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ac1b73ccb98c064e1e99fb43daaae73a590cad4b5dc32e01f744d979c01acf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dace65c-dcf6-421f-8d67-133c5bca885a", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "e6c056dbe1a3af3390c6379278318f87cdb125705f2c4080fecbf19a0286c472", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 3486, "end_char_idx": 3571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dace65c-dcf6-421f-8d67-133c5bca885a": {"__data__": {"id_": "2dace65c-dcf6-421f-8d67-133c5bca885a", "embedding": null, "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10237c77-3e51-42ab-8c08-48c192e25df1", "node_type": "1", "metadata": {"window": "Gain from antitrust litigation\nsettlements and LIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing\nof these items.  PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88a9f1f0045b4d69b3773d0e78778edcee4c159e83c831453cee51f66c11452d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d3cb665-08ed-4ccd-ba57-bb373ae4a631", "node_type": "1", "metadata": {"window": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28"}, "hash": "b56fefc35593e1673e9f4134c42b0822444e68a90dc2f24452d5f3e94fa2a64d", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 3571, "end_char_idx": 3728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d3cb665-08ed-4ccd-ba57-bb373ae4a631": {"__data__": {"id_": "9d3cb665-08ed-4ccd-ba57-bb373ae4a631", "embedding": null, "metadata": {"window": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fd101fee-ca25-44af-b6d5-b7121628fc51", "node_type": "4", "metadata": {"page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333a2c81a915804602139f92900523bf13f3322e2ef367853053ad4ccb8f25ac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dace65c-dcf6-421f-8d67-133c5bca885a", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable expenses.  The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "943f2dfa0e1c1f0060e0f99ab92ee3a34e4a79646084c73d6cffdc1f0d61d495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "397f9888-60e6-4b15-a1fd-dcc3e47c88cb", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "delay or prevent generic drugs from entering the market. "}, "hash": "70b2d96829f8f78045fac3e6aa09790e29788660d0472b29ee7103338c5c2d0f", "class_name": "RelatedNodeInfo"}}, "text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "start_char_idx": 3728, "end_char_idx": 3973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "397f9888-60e6-4b15-a1fd-dcc3e47c88cb": {"__data__": {"id_": "397f9888-60e6-4b15-a1fd-dcc3e47c88cb", "embedding": null, "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "delay or prevent generic drugs from entering the market. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d3cb665-08ed-4ccd-ba57-bb373ae4a631", "node_type": "1", "metadata": {"window": "The expense related\nto the NYS Opioid Act and PharMEDium shutdown costs are excluded because they were unusual and non-recurring.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.  The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "original_text": "The\ngain from antitrust litigation settlements relates to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\n28", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebae68a17c014afae23509793fd2b392e3089ae75887c650fa8db2434218cab8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a378fed4-dc18-4bff-a373-9bcd66ba5f5a", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S. "}, "hash": "d6fed0a43f26b82c921dbea5b2a6038f73fac7c349b95d01226301812bdcec0d", "class_name": "RelatedNodeInfo"}}, "text": "delay or prevent generic drugs from entering the market. ", "start_char_idx": 0, "end_char_idx": 57, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a378fed4-dc18-4bff-a373-9bcd66ba5f5a": {"__data__": {"id_": "a378fed4-dc18-4bff-a373-9bcd66ba5f5a", "embedding": null, "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "397f9888-60e6-4b15-a1fd-dcc3e47c88cb", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "delay or prevent generic drugs from entering the market. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9aa30a7d4eeed3c3bfc069155fb39c08524f5b4f1dad5b6846f3625c356979a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1c42a3e-26ed-4ac9-b454-1e021095d7bf", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "e10b857b77834b756cf6ac1666ce364ebfb05d43fe5d59470fd8418b7992dd1f", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S. ", "start_char_idx": 57, "end_char_idx": 182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1c42a3e-26ed-4ac9-b454-1e021095d7bf": {"__data__": {"id_": "b1c42a3e-26ed-4ac9-b454-1e021095d7bf", "embedding": null, "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a378fed4-dc18-4bff-a373-9bcd66ba5f5a", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. ", "original_text": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c68eb5ca3913a5168e2a423d17d5b1384cf1415772763e3c7f4db8b1fd9f435d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34a78981-3568-4de5-a989-2730a61fab67", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. ", "original_text": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. "}, "hash": "733475c577b8549c8221dbb6bb5234233683d575d96fc5157d202df2e3d36c11", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 182, "end_char_idx": 224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34a78981-3568-4de5-a989-2730a61fab67": {"__data__": {"id_": "34a78981-3568-4de5-a989-2730a61fab67", "embedding": null, "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. ", "original_text": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1c42a3e-26ed-4ac9-b454-1e021095d7bf", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7932c0a35cf9cb54075452a3234dfcf10cd921e2b20e681eb32aa3ffbcd8ca08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5773f45a-2ac1-4cf3-8248-025500f11379", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n", "original_text": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. "}, "hash": "958ccd9d5b4d86294f22b7ee3fb1a3faa770ae66e3d08d8a9c2377d1b9037aa8", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "start_char_idx": 224, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5773f45a-2ac1-4cf3-8248-025500f11379": {"__data__": {"id_": "5773f45a-2ac1-4cf3-8248-025500f11379", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n", "original_text": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34a78981-3568-4de5-a989-2730a61fab67", "node_type": "1", "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. ", "original_text": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e14600eca6115583083cc746e0495f8cf92c65e712f49551629401eae722ed50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c1fec52-749e-46aa-afe2-bf0f5912b449", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. ", "original_text": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. "}, "hash": "10ca41eed609be582479edc57f7831a5280785e0e77b12d6088ea13e977d9bbf", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. ", "start_char_idx": 339, "end_char_idx": 521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c1fec52-749e-46aa-afe2-bf0f5912b449": {"__data__": {"id_": "8c1fec52-749e-46aa-afe2-bf0f5912b449", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. ", "original_text": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5773f45a-2ac1-4cf3-8248-025500f11379", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n", "original_text": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f876aa54d3974449e35c6b42bec52fd242670a58c5b7f3a7cbec650a485eb9b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4afc920b-4e97-4b54-a1df-feb6fb9767fb", "node_type": "1", "metadata": {"window": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. "}, "hash": "fca44f015d0fd749179fac38860488402576ef8e903f004d520b6a39832106ff", "class_name": "RelatedNodeInfo"}}, "text": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. ", "start_char_idx": 521, "end_char_idx": 777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4afc920b-4e97-4b54-a1df-feb6fb9767fb": {"__data__": {"id_": "4afc920b-4e97-4b54-a1df-feb6fb9767fb", "embedding": null, "metadata": {"window": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c1fec52-749e-46aa-afe2-bf0f5912b449", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. ", "original_text": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2585b487d45e49747225da7698fa6cb47d8e9a77e5e95d0dcb6d32afe7a016af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70322c88-1422-442b-9cd3-30f0cb0478a1", "node_type": "1", "metadata": {"window": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n"}, "hash": "bf151860ba68c4366d46c1e36e0356b732522021b20f4a51eda66680551acfdb", "class_name": "RelatedNodeInfo"}}, "text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. ", "start_char_idx": 777, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70322c88-1422-442b-9cd3-30f0cb0478a1": {"__data__": {"id_": "70322c88-1422-442b-9cd3-30f0cb0478a1", "embedding": null, "metadata": {"window": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4afc920b-4e97-4b54-a1df-feb6fb9767fb", "node_type": "1", "metadata": {"window": "PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "942b74427783f73533dd73154cb13380cb0504ddd777e4ab031c2e8b1a02f0e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb2ec193-c1ce-4f67-803e-6154541df593", "node_type": "1", "metadata": {"window": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. "}, "hash": "f388212ba20b3d85ac0688a83823503e75f0cda20b8955968b5b493ece2526e0", "class_name": "RelatedNodeInfo"}}, "text": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n", "start_char_idx": 853, "end_char_idx": 1028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb2ec193-c1ce-4f67-803e-6154541df593": {"__data__": {"id_": "bb2ec193-c1ce-4f67-803e-6154541df593", "embedding": null, "metadata": {"window": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70322c88-1422-442b-9cd3-30f0cb0478a1", "node_type": "1", "metadata": {"window": "LIFO expense\n(credit) is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be\nimpacted by market and other external influences.  The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cc0cac82d8fa4a87d833150731c546b9b33846fb54dca692154cc9c44134a9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31b78c4b-fcf6-4033-a596-d98ff12c0ed4", "node_type": "1", "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. "}, "hash": "53cdc3abff308be981fa9a191b48fe757f68840638d55e74ebbd85eaa02ff11e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. ", "start_char_idx": 1028, "end_char_idx": 1395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31b78c4b-fcf6-4033-a596-d98ff12c0ed4": {"__data__": {"id_": "31b78c4b-fcf6-4033-a596-d98ff12c0ed4", "embedding": null, "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb2ec193-c1ce-4f67-803e-6154541df593", "node_type": "1", "metadata": {"window": "The NYS Opioid Act, which went into effect on July 1, 2018, established an\nannual $100 million fund and requires manufacturers, distributors, and importers to ratably share the assessment based upon\nopioids sold or distributed to or within New York state.  In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60cdc67a1f2e061473f18db5944075bc13828853b6383ffb378c9616e99bb56d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4296aa14-9ca9-4b9d-85d8-d42fc7c7022c", "node_type": "1", "metadata": {"window": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. "}, "hash": "56245b639633c0374e0e33bf26324bed995e930f6f3663f65cfa39f2956b5666", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 1395, "end_char_idx": 1491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4296aa14-9ca9-4b9d-85d8-d42fc7c7022c": {"__data__": {"id_": "4296aa14-9ca9-4b9d-85d8-d42fc7c7022c", "embedding": null, "metadata": {"window": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31b78c4b-fcf6-4033-a596-d98ff12c0ed4", "node_type": "1", "metadata": {"window": "In December 2018, the NYS Opioid Act was ruled unconstitutional by\nthe U.S.  District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5005c861e760e8d9c0ad46f8fa780ecf83e1612d695a8560583d08dd0590cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9153c390-5c09-44a4-8739-0cef40d50c8d", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. "}, "hash": "dce848f0523784f024e13b28127bf56982ebbacd1b4f9e7693c13a1c606e6aec", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "start_char_idx": 1491, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9153c390-5c09-44a4-8739-0cef40d50c8d": {"__data__": {"id_": "9153c390-5c09-44a4-8739-0cef40d50c8d", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4296aa14-9ca9-4b9d-85d8-d42fc7c7022c", "node_type": "1", "metadata": {"window": "District Court for the Southern District of New York but, in September 2020, the United States Court of Appeals for\nthe Second Circuit reversed the District Court's decision.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d019d96dc2f9d25558caf82a243040bd89ffe41267c29f53592b4f936f75b10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfb599fb-67c1-479f-a4c1-69660b00081d", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. "}, "hash": "9d5eb55bd2664409259a9a28b0b2e521af8cc940b354b3ff27e22c3a006457ed", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. ", "start_char_idx": 1653, "end_char_idx": 1766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfb599fb-67c1-479f-a4c1-69660b00081d": {"__data__": {"id_": "bfb599fb-67c1-479f-a4c1-69660b00081d", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9153c390-5c09-44a4-8739-0cef40d50c8d", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, goodwill impairment, impairment of assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c50b03daa147dfeca347edd472c823eb951ade89657fdd8c413c83904401fd57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbdaed2e-5f77-4125-bf39-133987502e5d", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n"}, "hash": "1d0f70084052d1084fbb54e12fc3a09d9e7ba3b1aba2f52344bc518a2fb55e54", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. ", "start_char_idx": 1766, "end_char_idx": 2229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbdaed2e-5f77-4125-bf39-133987502e5d": {"__data__": {"id_": "bbdaed2e-5f77-4125-bf39-133987502e5d", "embedding": null, "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfb599fb-67c1-479f-a4c1-69660b00081d", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c84df33224ce60379da95a15367ff51625fe0ee4376246bec348876ebbc7c73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e3e9974-09a8-4985-b111-c6ea42ecdba1", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "bc7de242595b002d7ba49722e448ebeeff0e8dc6778da14e1e8d9ddc5835f53b", "class_name": "RelatedNodeInfo"}}, "text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "start_char_idx": 2229, "end_char_idx": 2524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e3e9974-09a8-4985-b111-c6ea42ecdba1": {"__data__": {"id_": "4e3e9974-09a8-4985-b111-c6ea42ecdba1", "embedding": null, "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbdaed2e-5f77-4125-bf39-133987502e5d", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "394cbf1672cea4d10569602fcc1ea238d86e7b6d2b50c9f527df391a266e1a1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2611beaa-c292-4268-a19c-195c73922481", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "0faa38f23e387054d998b7a1b9f3b549abbf8a838432c79e3c3c433cd0622581", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 2524, "end_char_idx": 2773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2611beaa-c292-4268-a19c-195c73922481": {"__data__": {"id_": "2611beaa-c292-4268-a19c-195c73922481", "embedding": null, "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e3e9974-09a8-4985-b111-c6ea42ecdba1", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructurings.  We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4939d2b73e689355eab122ff3fe603dc6e378a961498890396a164a052a3ec66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e913fa32-b92c-407a-9183-ea073640fe51", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "b933454bee5627a63594033ba4ad6c8b9e69260ce839a0a5eacbf945b1edc00f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 2773, "end_char_idx": 2866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e913fa32-b92c-407a-9183-ea073640fe51": {"__data__": {"id_": "e913fa32-b92c-407a-9183-ea073640fe51", "embedding": null, "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2611beaa-c292-4268-a19c-195c73922481", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, such as the accrual related to\nopioid lawsuits and investigations, as well as PharMEDium shutdown and remediation costs, goodwill impairment, a\ncontingent consideration adjustment and the impairment of assets, that are unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature because we believe these exclusions facilitate the analysis of our ongoing operational\nperformance.  The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31ca76981b5e25a6c3814bd136495d0e534940cde957cd3d06ac2f8f0ac057b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd666e3c-e4c3-455a-ad27-063580646a55", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "31817ab1a64ad6270a3106c29bd8cda118a265779d98d76fca80ee9484f713d6", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 2866, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd666e3c-e4c3-455a-ad27-063580646a55": {"__data__": {"id_": "fd666e3c-e4c3-455a-ad27-063580646a55", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e913fa32-b92c-407a-9183-ea073640fe51", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by one of the Company\u2019s non-wholly-\nowned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous estimate of contingent\nconsideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44ad9d5fd607086c70cdbb6964d0a3cfc402da68d2ec731b0e7688e315660833", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc15ca88-ff5d-480e-8f3b-0512429b96ef", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. "}, "hash": "612056564a425bb49394da9ac7feaa11cd8486707216fa11d02431ed6bda7a72", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 3113, "end_char_idx": 3318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc15ca88-ff5d-480e-8f3b-0512429b96ef": {"__data__": {"id_": "dc15ca88-ff5d-480e-8f3b-0512429b96ef", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd666e3c-e4c3-455a-ad27-063580646a55", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f17ca53df1255c58a786524070d0b4cef76daf5dfaa1b46d43a9d08b35dc93b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d12de588-6206-437f-85a4-33c5378b20a1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n"}, "hash": "b27f333914bdea30f21cc995ab5fb0156df948d6191e343a2bbd85e31d32265f", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. ", "start_char_idx": 3318, "end_char_idx": 3607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d12de588-6206-437f-85a4-33c5378b20a1": {"__data__": {"id_": "d12de588-6206-437f-85a4-33c5378b20a1", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc15ca88-ff5d-480e-8f3b-0512429b96ef", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a53d29601872e1522920c00e3771d04605fd2ae6f8c3d2a5fd43bcb2ddb7fa45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4827243d-1722-4735-bf26-ffc6479267b5", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "9e81a9a7b49faa66e74d1398607a126ae47e80cede05d4869c6dd0450dbbcbf0", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "start_char_idx": 3607, "end_char_idx": 3772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4827243d-1722-4735-bf26-ffc6479267b5": {"__data__": {"id_": "4827243d-1722-4735-bf26-ffc6479267b5", "embedding": null, "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d12de588-6206-437f-85a4-33c5378b20a1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19bde4d3f5fea36dba34acb17a1af4b6752fa2743baba6b576e79ae8d2763197", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "288dcd51-5fa0-4ffb-9b18-a6e0d5b93bbd", "node_type": "1", "metadata": {"window": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "f4a27f459defdaf3384eb3f56efb252bf88601e511a4496955a6393b07a7d530", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 3772, "end_char_idx": 3969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "288dcd51-5fa0-4ffb-9b18-a6e0d5b93bbd": {"__data__": {"id_": "288dcd51-5fa0-4ffb-9b18-a6e0d5b93bbd", "embedding": null, "metadata": {"window": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4827243d-1722-4735-bf26-ffc6479267b5", "node_type": "1", "metadata": {"window": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a39e59ec7b72d47f425b6f976161765a5eea34ff4502524db6b8b24030d408b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b8ca618-f02f-49c1-8731-15361f7bc8c4", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "b9131938bb5cb20a371ecb87042482c2f275b8db23cedcccb15bbed435c602c8", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 3969, "end_char_idx": 4241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b8ca618-f02f-49c1-8731-15361f7bc8c4": {"__data__": {"id_": "1b8ca618-f02f-49c1-8731-15361f7bc8c4", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "288dcd51-5fa0-4ffb-9b18-a6e0d5b93bbd", "node_type": "1", "metadata": {"window": "In addition, the loss on early\nretirement of debt in fiscal 2020, gain on the remeasurement of an equity investment, and impairment of a non-customer\nnote receivable are excluded from adjusted income before income taxes because these amounts are unusual, non-operating,\nand non-recurring.  Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5be6cbcaabce44401b47da5fd5c5453c561c4d8c71037d47e409f8bff180c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8457146f-f3bd-4c8e-8dae-3c067bf17909", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. "}, "hash": "25b3b8c3f3efbd32c14a61b756f9b084ccfda6862265365156ed139e5d2ea89e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 4241, "end_char_idx": 4479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8457146f-f3bd-4c8e-8dae-3c067bf17909": {"__data__": {"id_": "8457146f-f3bd-4c8e-8dae-3c067bf17909", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b8ca618-f02f-49c1-8731-15361f7bc8c4", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it facilitates the\ncalculation of the Company\u2019s adjusted effective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dd7d67da413f5daec1bdac6d54d626602b71c816469bd7b7c2b01899e067c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33407750-be01-4054-8d48-e4f5d4629ada", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. "}, "hash": "6321059afa9e0104b6f761a0093ea1e8aa9e87c241061fdac0c04aafcf07583a", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. ", "start_char_idx": 4479, "end_char_idx": 4762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33407750-be01-4054-8d48-e4f5d4629ada": {"__data__": {"id_": "33407750-be01-4054-8d48-e4f5d4629ada", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8457146f-f3bd-4c8e-8dae-3c067bf17909", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfe5de967ef604ddbb932de372c212dcf4f51525e0e76eac8e1c634238563e9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e30a39b9-31ea-4551-bd67-027987ad5d04", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "ab0271e3533d486884ded3c53e1a19a63bc727ddd8ded0cc9b5697bf3f418f95", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. ", "start_char_idx": 4762, "end_char_idx": 5020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e30a39b9-31ea-4551-bd67-027987ad5d04": {"__data__": {"id_": "e30a39b9-31ea-4551-bd67-027987ad5d04", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33407750-be01-4054-8d48-e4f5d4629ada", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c724f2dcf1879c4582ae36be8186f9d1704a0ddf31c6cff9d0dd43332bb8677f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "748a7f51-567d-4ad8-b34b-847c1b88f988", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. "}, "hash": "e5e3e48e57b3518b0ae650ca84009525db96508fdaf3c1d6b022b4c94232b9ca", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 5020, "end_char_idx": 5265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "748a7f51-567d-4ad8-b34b-847c1b88f988": {"__data__": {"id_": "748a7f51-567d-4ad8-b34b-847c1b88f988", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e30a39b9-31ea-4551-bd67-027987ad5d04", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb609ffd4832ea96f052097ce2423855b0f22d6757a12c4db5f7db0e5e332918", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27af8bb2-74a9-48c4-b675-ccb1dde71a8e", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "cbbc50b0944064346a65d63c24877f89ec280ee26bf14e1299912a6b079e552b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "start_char_idx": 5265, "end_char_idx": 5533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27af8bb2-74a9-48c4-b675-ccb1dde71a8e": {"__data__": {"id_": "27af8bb2-74a9-48c4-b675-ccb1dde71a8e", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "748a7f51-567d-4ad8-b34b-847c1b88f988", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense.  Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "552cc71b523e51f46c9e249c4081ea7f590b6630a645305fa1a0161f80d73b17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acb01b96-6807-4a07-9d08-9fbcb03a7540", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "29"}, "hash": "5f9ae304b7c6b315127c1ad79f765636cf42426c7e181661020132e9792aae26", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 5533, "end_char_idx": 5696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acb01b96-6807-4a07-9d08-9fbcb03a7540": {"__data__": {"id_": "acb01b96-6807-4a07-9d08-9fbcb03a7540", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "29", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26", "node_type": "4", "metadata": {"page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0df8cfeaceb9681ad121c9fe3fb70f15114059e0c4a93c45299535499363bc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27af8bb2-74a9-48c4-b675-ccb1dde71a8e", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reforms in the UK and Switzerland are\nexcluded from adjusted income tax expense in fiscal 2021 and certain benefits relating to tax reform in Switzerland are\nexcluded from adjusted income tax expense in fiscal 2020.  Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4260961349c8e2a21aa654dfdbd4f55bc9211446cad21acc28a4e5c0d7de84c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "210d1984-6635-428b-a25b-b8db37a6e2d7", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "3e6be47f918112fbaf5b50f4abcc994dbc93c0f7925e50e8e00ecff9f6208165", "class_name": "RelatedNodeInfo"}}, "text": "29", "start_char_idx": 5696, "end_char_idx": 5698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "210d1984-6635-428b-a25b-b8db37a6e2d7": {"__data__": {"id_": "210d1984-6635-428b-a25b-b8db37a6e2d7", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acb01b96-6807-4a07-9d08-9fbcb03a7540", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors as a supplemental way to evaluate the Company\u2019s performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interest: Adjusted net income/loss attributable to noncontrolling\ninterest excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n 29", "original_text": "29", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4671cda9466274bf16aaddf82c055fe805d2dfa9667f87ea34df3a586eb249cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0d2380a-e050-4a9c-8a18-0b98e1b42d14", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "c2d53e72d253b4f5196808c98ee3b3ebde2f6b88d7a1620de0001c6ec1f2a388", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 0, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0d2380a-e050-4a9c-8a18-0b98e1b42d14": {"__data__": {"id_": "c0d2380a-e050-4a9c-8a18-0b98e1b42d14", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "210d1984-6635-428b-a25b-b8db37a6e2d7", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cbe2564ea00c9d0266de175db78d6296d9c55f08a0022b391a9472df31534a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01165a53-0267-43b3-99b7-ef9fdb2d7325", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. "}, "hash": "20801b10eb9fa18626b51a7d6b30451fea867e3bda9a105f569fb9e9f89e4e0d", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 169, "end_char_idx": 414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01165a53-0267-43b3-99b7-ef9fdb2d7325": {"__data__": {"id_": "01165a53-0267-43b3-99b7-ef9fdb2d7325", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0d2380a-e050-4a9c-8a18-0b98e1b42d14", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. ", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "efa86831a6ba0c2f53d58448b2e8f873ef24f67ae69448f3e6645b58f00ed6da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a452bc23-4e4a-463f-9c92-24662ea9845d", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n", "original_text": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. "}, "hash": "4f0aa6a31d2451e44286d08dac0d8895bc5ef19baccb5db0e8343944254e7d94", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 414, "end_char_idx": 1100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a452bc23-4e4a-463f-9c92-24662ea9845d": {"__data__": {"id_": "a452bc23-4e4a-463f-9c92-24662ea9845d", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n", "original_text": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01165a53-0267-43b3-99b7-ef9fdb2d7325", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f6ec3c249d54ab31c3348623f490b1d8386e52f762df071ac9a3d29760b197f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6ad2e8b-1e56-467e-8280-7a3a8bcb1857", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. "}, "hash": "c524e229d9cfe52ad6e8c53158f2ff9154317d8d87ff7719d5eb809d33f1bc05", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "start_char_idx": 1100, "end_char_idx": 1478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6ad2e8b-1e56-467e-8280-7a3a8bcb1857": {"__data__": {"id_": "e6ad2e8b-1e56-467e-8280-7a3a8bcb1857", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a452bc23-4e4a-463f-9c92-24662ea9845d", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n", "original_text": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9cbe635268bc23281f711a8e7fc94cb869db93ce974a11cb8d2d8726b2a15e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01762e21-5295-43a6-aa0d-1fe1276ba80f", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n", "original_text": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. "}, "hash": "6795814f2dfa36c12624d9c2d5955d71aea6bd1642cd2c81d219ed9bf718154d", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. ", "start_char_idx": 1478, "end_char_idx": 1832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01762e21-5295-43a6-aa0d-1fe1276ba80f": {"__data__": {"id_": "01762e21-5295-43a6-aa0d-1fe1276ba80f", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n", "original_text": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6ad2e8b-1e56-467e-8280-7a3a8bcb1857", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c507fa2b504fd2848d89b3d151f80be4f39162ad1417546f890584f2fa2bc98f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b253c9de-f4ba-409a-b1b6-cfdba6dfd869", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n"}, "hash": "b0375c89de409b1d105c7818418704c5049c301d28687c5a93384b2f896d34c7", "class_name": "RelatedNodeInfo"}}, "text": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. ", "start_char_idx": 1832, "end_char_idx": 2108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b253c9de-f4ba-409a-b1b6-cfdba6dfd869": {"__data__": {"id_": "b253c9de-f4ba-409a-b1b6-cfdba6dfd869", "embedding": null, "metadata": {"window": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01762e21-5295-43a6-aa0d-1fe1276ba80f", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n", "original_text": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d576422f52541920141fa829751d972b8da13375ffe5f32dfb2d1f151dc059ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3267d029-116e-4852-9ddb-1525a9b190ba", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. "}, "hash": "44c8ba2b3b2119fe557615d31a9129cbc45a5548f341cf5f42c0791c4af0aa84", "class_name": "RelatedNodeInfo"}}, "text": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n", "start_char_idx": 2108, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3267d029-116e-4852-9ddb-1525a9b190ba": {"__data__": {"id_": "3267d029-116e-4852-9ddb-1525a9b190ba", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b253c9de-f4ba-409a-b1b6-cfdba6dfd869", "node_type": "1", "metadata": {"window": "In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share.  Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "original_text": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2ef6d201ee43afe1b21ea400c6556e20ccee4b6c46730c8f675f41c30c99941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02c6d203-e70c-45b9-8f53-d2207a741f1b", "node_type": "1", "metadata": {"window": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n"}, "hash": "7e353d2f5357b5ea34f243e21946559878cc40a8616ca25a731634addc9736b3", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 2271, "end_char_idx": 2702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02c6d203-e70c-45b9-8f53-d2207a741f1b": {"__data__": {"id_": "02c6d203-e70c-45b9-8f53-d2207a741f1b", "embedding": null, "metadata": {"window": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3267d029-116e-4852-9ddb-1525a9b190ba", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of\nthe Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual,\nnon-operating, unpredictable, non-recurring, or non-cash nature.  Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. ", "original_text": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6c9d99f947a557b1695f4de50c90fc2d1bf6967b1fa5883dab4384c38277319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b6a5927-8fda-4b1b-8b0e-ae6a36068fda", "node_type": "1", "metadata": {"window": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "original_text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. "}, "hash": "779f4dfd047290794ac3d07459dcc40bce4663dfa99bdee3e1a221ef7b416cec", "class_name": "RelatedNodeInfo"}}, "text": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n", "start_char_idx": 2702, "end_char_idx": 2782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b6a5927-8fda-4b1b-8b0e-ae6a36068fda": {"__data__": {"id_": "5b6a5927-8fda-4b1b-8b0e-ae6a36068fda", "embedding": null, "metadata": {"window": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "original_text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02c6d203-e70c-45b9-8f53-d2207a741f1b", "node_type": "1", "metadata": {"window": "Diluted weighted average common shares outstanding has\nbeen adjusted to include the impact of the stock options and restricted stock units that were anti-dilutive for the GAAP\npresentation due to a GAAP net loss in the fourth quarter and fiscal year ended September 30, 2020.  Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "original_text": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3829011f80b83b9c2eb3b18e64963fc18971845b60909b331fc3a13d49b47cdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46d93e7c-d17c-4c6c-a8fc-e046d98f793c", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "original_text": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. "}, "hash": "ba00f861fd9992d138d6b1bc212887c4cf85724914ea156ba23eb2487003216b", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "start_char_idx": 2782, "end_char_idx": 3068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46d93e7c-d17c-4c6c-a8fc-e046d98f793c": {"__data__": {"id_": "46d93e7c-d17c-4c6c-a8fc-e046d98f793c", "embedding": null, "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "original_text": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b6a5927-8fda-4b1b-8b0e-ae6a36068fda", "node_type": "1", "metadata": {"window": "Management believes\nthat adjusted diluted shares outstanding is useful to investors because it facilitates the calculation of adjusted diluted\nearnings per share.\n In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "original_text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a005e0501540dd1d8cf7dc8c113cbd916a6719cfb7f59c71aacfe336dbbb337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb114c45-ff22-4971-b162-aa08a7b2f078", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. "}, "hash": "9e8819825ba40c976ef64adb837faa10b2b353d7d6531e92cc89aa658f975f51", "class_name": "RelatedNodeInfo"}}, "text": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. ", "start_char_idx": 3068, "end_char_idx": 3397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb114c45-ff22-4971-b162-aa08a7b2f078": {"__data__": {"id_": "fb114c45-ff22-4971-b162-aa08a7b2f078", "embedding": null, "metadata": {"window": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46d93e7c-d17c-4c6c-a8fc-e046d98f793c", "node_type": "1", "metadata": {"window": "In addition, the Company has provided non-GAAP fiscal year 2022 guidance for diluted earnings per share, operating income and\neffective income tax rate that excludes the same or similar items as those that are excluded from the historical non-GAAP financial\nmeasures, as well as significant items that are outside the control of the Company or inherently unusual, non-operating,\nunpredictable, non-recurring or non-cash in nature.  In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "original_text": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "992c875c457af8e69fc2b58f098fc55616ed70361b83d72c75d9f97446fb0a19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2d32b7c-11f9-475b-beb7-a35b1c26e5e1", "node_type": "1", "metadata": {"window": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n"}, "hash": "a09fa3246307fbd7f8b27a41c6fa9d14a6c94597b14928bd3b51ff329c887095", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 3397, "end_char_idx": 3633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2d32b7c-11f9-475b-beb7-a35b1c26e5e1": {"__data__": {"id_": "c2d32b7c-11f9-475b-beb7-a35b1c26e5e1", "embedding": null, "metadata": {"window": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb114c45-ff22-4971-b162-aa08a7b2f078", "node_type": "1", "metadata": {"window": "In addition, it has provided fiscal year 2022 adjusted free cash flow guidance.\n For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d617d968f4c261210cdb3a52440f54e1152ec1833de7110dc673faedb59a5407", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3248643f-af34-45f6-8b45-e0f32af6a0b6", "node_type": "1", "metadata": {"window": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n"}, "hash": "fb523e778601d05b33165f4436d550d278e1d93c018140a75fdb46d48e50cc1f", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "start_char_idx": 3633, "end_char_idx": 3950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3248643f-af34-45f6-8b45-e0f32af6a0b6": {"__data__": {"id_": "3248643f-af34-45f6-8b45-e0f32af6a0b6", "embedding": null, "metadata": {"window": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2d32b7c-11f9-475b-beb7-a35b1c26e5e1", "node_type": "1", "metadata": {"window": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating\nactivities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus\ncapital expenditures.  For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cd5c1908c193ddfe08f9a7732312c3844190883ca03697e3fb745d47b13e911", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aa6fccf-5abd-47a5-84a4-2ca6f40f2622", "node_type": "1", "metadata": {"window": "The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30"}, "hash": "83e9fd9c30c4639fbea585c8c28f228d7d09a333d9e21d20341fd405eef9cdb1", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "start_char_idx": 3950, "end_char_idx": 4045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aa6fccf-5abd-47a5-84a4-2ca6f40f2622": {"__data__": {"id_": "3aa6fccf-5abd-47a5-84a4-2ca6f40f2622", "embedding": null, "metadata": {"window": "The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8", "node_type": "4", "metadata": {"page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c6fdbc817de48f64fbb04ccd5c1e6959f2ccea45fffc069b653cba59305892d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3248643f-af34-45f6-8b45-e0f32af6a0b6", "node_type": "1", "metadata": {"window": "For the fiscal year ended September 30, 2021 adjusted free cash flow of $2,087.5 million consisted of net cash\nprovided by operating activities of $2,666.6 million minus capital expenditures of $438.2 million and the gains from antitrust\nlitigation settlements of $168.8 million, plus legal settlement payments of $27.9 million.  The Company does not provide forward\nlooking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9258ff266d6a1353dbca75728b91eec9d0c98798600f30d80159eee801fd4863", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20211104005236/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n30", "start_char_idx": 4045, "end_char_idx": 4295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"fb30f01d-f1da-4b6c-af85-8e350e254872": {"doc_hash": "594e42c113535404ffd4c0ff1004e67fac743ec39b9b8aca60d8e4bf8cb26ac0", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "1f7b529e-12d8-4900-b952-9073dc122dc9": {"doc_hash": "dc7520b657eb0f4781442dc43e63364046fe211aab3a5fdcf6d4b3169ad1cfc2", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "c935420a-5b2a-49d7-a67e-4b49593ccb0b": {"doc_hash": "f911794736036d3ac6618a795022fc4a04a6f16693ab156e7a3bc5dd088c72a8", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "8998fb25-1e69-4c19-a1b0-7d4ef5172064": {"doc_hash": "3fe9816cace845a6267c97d574b8681c82c88449da69831a496958ba725d0788", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "3607aeac-91ec-4d39-812c-96a8d51d323a": {"doc_hash": "b1225d4da4d3550f1d01543840b1aaf7438722658bee5274958cc548a08cb093", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "f63d75c4-d735-4983-98ec-e655c9d3ca3d": {"doc_hash": "bae15cc6d478b2dc570bec6c8e67fe15ea0b498388d0c57616c1fee8b1f21bcf", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "3cb7553f-8fbb-4ed1-8189-d1c168cac871": {"doc_hash": "f8c12b883da51cd6ee88f7b9f67b09b526ccbd058a720efb50bd98a4e3a94532", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "4d4b2432-0911-4127-a716-5bc41001bac3": {"doc_hash": "ce531fa48ba2b070a2837889db8ded5ce13a8ebdcf9476cd97432aa22ef37ee7", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "fbd13a51-c9d3-4545-85ca-d93b0a927887": {"doc_hash": "9aaa016b6deaf45253314fdff84cce442574f976b5ddbdf1ac026792feeea25e", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "3e9303fe-4dde-493b-ad56-86c67d9bad00": {"doc_hash": "42876d0fe3c33a82866d76229835bc396045e3dd2daaecc3c7362435473ee33c", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "cf807aaf-a818-44cf-95e7-065c6667df16": {"doc_hash": "18dda8be73653b0005333e030d63c4287228483e1d59b2e9a701c33409c7c5ba", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "790778c9-d0de-49a5-9472-56818c0dd008": {"doc_hash": "6ef826fdd66a408092dbe92e3e37fc951dc4760c3d1d92dba089fca0fdab7df7", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "09101624-2e97-4fcd-bf5a-539db64fbd57": {"doc_hash": "8b06c3c3b93f4a44f3a738b39578807531010cb82eab77e768c23714f94bbc91", "ref_doc_id": "867b5a13-688e-4a45-97ba-c3feb7565389"}, "3c920032-d067-417e-b8f3-bd9e316ac195": {"doc_hash": "14bcd4e0f3e059a03728d3b032cbcdebe6330a05a678fb2b8a34c5619e03a76a", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "e78cd766-657e-48b7-94a8-8a978c260eb6": {"doc_hash": "a1fb7e27615c70b4f6db60911ec2fea5573dffb857544106b159c3c4ea3c2946", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "379d1b3e-41ca-4e49-8b27-314ef8a01980": {"doc_hash": "ad66f5663f51abef849dbd86f0f05da2cb1e9b4a3df0e817d8a28663ad3acfda", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "7244cccb-bb8f-4ceb-a1d3-3ecfecb506eb": {"doc_hash": "b00397bbd86264e28450ac896f0124eded1c46fe5fb29d16155362237254e3fa", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "965afa94-7a1c-4230-bfdc-510ed048ff49": {"doc_hash": "6ec7cb3bdacb31fb6c672da1c1c384303715188d3cc2b9b53ca903e11e20c8cc", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "e19e0b62-bc01-44ff-acb3-a9f7ddf999ae": {"doc_hash": "bfefc1f14545ac915a2e7f5cdfbca9a7697da0417d8e3fb6652547184092ce43", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "f9d74e9b-cec7-435b-9c0f-aa44fba55d19": {"doc_hash": "68afeb572ee097d4ddb79f5771315dff4efc10adb78bf141a61f2afed029c236", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "8eed55b2-7c3c-4403-9c7e-fe6c7bd1cc8d": {"doc_hash": "50d7de1596560f2a76ba86405312c7129a742fe84a05b54546ec14cc5e85de6e", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "cc57206b-b2af-4130-a874-898b9f690cf0": {"doc_hash": "1c372770ab3ef276c9b044ecad87c92ca69396cc2f58c97c24a8fa5c1e5a8d26", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "3ab6b56c-eeff-45ee-9267-5489473452bd": {"doc_hash": "c8b43fe1e9103ad8b8a28114d36c8083bfeff0e727f5bedeb32d5dc9e13a6cba", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "4a47c259-7683-4031-b5f9-fad81f6a2dce": {"doc_hash": "71a6d632b549afdf4bffd215369cc25061dd15c12f367c0fd12f0c0af7b37e7a", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "13d6a852-721d-4705-b93d-fbac9bc16fe3": {"doc_hash": "e8db0d2734cd4c47ab97dfbf23b3dbb0a491303fee1db46c79843fe1c08e69c9", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "f062024a-ae59-440c-af9f-545fc7adfb18": {"doc_hash": "3390816f3993185da2dadb8eaae5eeb4f7e1dc1c234954848555c1941748b796", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "d996dcea-f310-428a-b81c-ea8dca640ceb": {"doc_hash": "f4cdfaf5e2b4fca048949c80aef4942ad552be8c55e7874bc5213721d019c3b3", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "8c37dd9b-c67a-41c5-ba86-f56c91c4b431": {"doc_hash": "139211c5e9e2fc6f26d23cbfedf2c7eea93f3e1a0038205b15e81b1e0bac6e3e", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "8d7e85db-b14d-42ad-a425-0f2efea7487f": {"doc_hash": "303d47e4ea1fbd0efc386d5ed9f06d349b2945df1e36adc2444d632f08644da7", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "be3f9295-d91a-441b-9428-e4e5db0ff4da": {"doc_hash": "c8d7d7e578b8b425b12e18ed0d653b2cd7ee18af9cd4afe6dce3b44291965446", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "e192c913-6afb-4f10-9cb4-99ea22052f07": {"doc_hash": "77541aa9f629f0cafe2cc3b673978560bf02b761b31df84c93e4732a68a64c4c", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "e86c5902-6762-4d25-a692-2cd8e20f3d92": {"doc_hash": "da4752444dd16c79308e1b91b96ee0884a7b779e497f20cede3db878a21696a7", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "e3d7f4c8-1097-40c5-ad0c-1ab503243bb9": {"doc_hash": "8a0e8c9892650c7c28f7412254c6933ffaf24c034fc287adaadbc822b2cfd0ba", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "561543e4-57eb-4dc2-ae35-fafb4fea2386": {"doc_hash": "6149d071cf051923222ddb10dc545b8ccd9e762244f732f5210af78ee85e3f4c", "ref_doc_id": "ef133143-d754-4537-a987-836ab2b9b35f"}, "756efeac-0cb4-48eb-8e77-4c6154a8b486": {"doc_hash": "431f4006dafa8a032f4eb59d8a2a5c222f58f9c2728a085bb43f4d2698526df4", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "4fe18875-008d-4559-b668-9ecf60062442": {"doc_hash": "f7f625377a3e9925b34d2eae223f6ef1ce3b3a7560bff5249034d86c3ba08a7a", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "5d48a009-df3b-440c-9275-2b5e079ec444": {"doc_hash": "8eea98182cbd8b302e18ffc7f0bfdcd50d2f9182a2e5bba88e6402eb41d35e94", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "207d9c4b-9dc7-4ffe-b3da-6391f8c5a28f": {"doc_hash": "046b7cc57d01b14c71e8ab6aed5fa9978a19dfabdd2febfb4a6112187b78b09a", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "084b6942-30fc-4756-b411-428ed01fe9af": {"doc_hash": "c258bd457f8d45b8184b99ef8094b9205457a8abdd7be8a3a282c581b0897395", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "aef7bca5-028c-4f72-9962-5de4ae26b43d": {"doc_hash": "dbb05eff04c435033737bfcfeab125aaff49b304527260b20e284c8450705521", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "b0fbecbb-bcee-4f98-ad9f-58ed67e70ea7": {"doc_hash": "7ae84e6b192906c559cb04cd945136e85eba4d2a06a9c4fa7563e55dbf11fc05", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "9af23843-2920-4ed9-995e-3052c019dcb0": {"doc_hash": "244dfe660c0cb48ee68df71ccd0b89bb3fe74c9752554bc845599550d0adb5e8", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "d02beb8c-7177-4768-864d-ba41f9e38fba": {"doc_hash": "fc388b95d21eda60ebf47ea5922d10398dcc4c7b0046d1a52b118d27520b9bb1", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "3f326c2a-aeb5-425c-a770-b0bc83b90be5": {"doc_hash": "35bed031b01a349504b97c773926ced039ed8c4046453d4fc4d7506235e29611", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "c84c170f-8da4-4c98-8cb1-3fed24c6c5dd": {"doc_hash": "f9e6cb4fb054bb40c67eda67dcba50ff26daf7b754940286452f17d39aebad43", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "4c10f97f-cb4f-49b5-b83e-5c0649c6a3db": {"doc_hash": "437a10dc4fe219549e5dffc117cbd9dbfad251661278792c6be75499c4a12761", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "2f5a4254-8529-43c4-ae60-f130339d9c55": {"doc_hash": "09145f82922da357a1aff7db6c1cd66b5e51e73cce059486b1297282d12115d1", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "d35afe02-f45c-4362-85a5-ed9233d4d6d0": {"doc_hash": "8d10af6ea5784cf275364ebf6850571e47bafa1e1d0ce136465682a2443e737d", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "384803c5-197d-460c-b65e-00191d4880aa": {"doc_hash": "1ca865184abb652170ff648f94f709bcda75d2ff54b8d605121bc522ce2ceb6e", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "d1d0f6ef-590d-4cf9-980b-111d3f00d96d": {"doc_hash": "3427bcee89c894d2a3ac466c6ccff73fc85094c6f58089b5fbe08f2aaf418a88", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "aad6b1da-2478-43c4-87f1-965bcf57e72e": {"doc_hash": "7460a7af9f20555c08f64a108b0be02004721d5bf70396fe46f3618b443e74ee", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "875239ee-3226-4c2a-9732-011b840b509e": {"doc_hash": "88b835a977d13d658359585fef1527d06e7f063e3c3b2affd9a8f34fcd5b2897", "ref_doc_id": "967f1b71-9d13-4871-aa8d-f288ecbf315f"}, "3e5b973f-40d1-45bd-a92c-0463c88fe21d": {"doc_hash": "d79697ab6a3edb91f4f0db41479cf2051c4dccbd972d469feef5940823e16a06", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "9ebd2cd2-4c90-4aac-bc9c-323419faa1d5": {"doc_hash": "96885db339ca0d0edde8480ffe4fd9136a627146c4ed7f92747a11b6d8217fea", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "31794ee6-9386-4bd8-9a44-403ca2874b10": {"doc_hash": "cea04415a9425f49c999dca83b1f7bd974bd180ca8f612bfc092931843c68b2a", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "54a4b724-3b44-41c5-a7ad-a90aad28e4ee": {"doc_hash": "3fbbe9723772dcf0a9a00c5564c0873967a5e654d8533e930a01c87a5186f171", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "6706c029-ff73-457a-835b-e9f981d44962": {"doc_hash": "ac30fd3ae41a17c080c5c9224205eace833c1b2eac49e0833c83817806e79369", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "0ec78b49-8624-4ca1-882f-2684358d889e": {"doc_hash": "96b34ed9c2a282fbc2a2cced4d535834898c4fa0762f4107642477534cc9757e", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "ef08a182-1208-44d4-99d8-ecb5329e9645": {"doc_hash": "70d49885b92434f883eb49d4427ce6bf6dc8a8708309c1a81f957e0bbcee5b70", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "53ae9695-3a38-4960-9b51-78e356d9e94f": {"doc_hash": "29b49c8f8712026fc3f8978c32f253dfefe12c1a7b9663bd68c2878d946ddff9", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "dc0362f0-477c-4742-890e-f231a740f8df": {"doc_hash": "889bf53131f71321c313d2dcdef1f8a75e849fbe9fc14a375fe6230a363390d5", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "b4dc5b5b-f95d-43f8-bed7-9f433dc6a186": {"doc_hash": "cf878592ac07fa62071b8d5244dee3b86218c68998b83e166c5fe3a1853e1c8c", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "99307616-cfba-4bd7-a402-44cc95de6c03": {"doc_hash": "860ddfc829af44856f4f9ce3a3ab890e34062b17583f596c8289c19c6777c7d6", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "8f70ed0d-cef5-40af-af94-d4a359622daf": {"doc_hash": "dd7a7839caae34db401960cea88998899e20b7503fcdaeb4851da0e956baf37c", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "ee0a1cc0-d4a4-40bf-9753-8bd4e9a26e3b": {"doc_hash": "cd6c663f5ce40a060233075a20da3f7f68c6a559762c8f71947115e7a81b845a", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "43024462-fd14-4eaf-b70a-dde807c655ac": {"doc_hash": "0d57bfb9a64844190bafd4eb4b3513f0631e427db75d51e7cd0ccf23a64e0a84", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "120c3c89-fc3e-4d70-abf6-8fa4c8465ea1": {"doc_hash": "da31d50e42294c92e3bef75549f66b9e4875911870fd26844eeada4637feb1c9", "ref_doc_id": "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c"}, "9e1b2584-254d-4682-9222-f17693a6a6a6": {"doc_hash": "4fc73e2a3991397730f5b917fb7fd107fc10e8a6e72d1a2dc02264f5b869aa7a", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "6c55ba0a-3c1d-4c7b-bbc4-5dfe5bb15b17": {"doc_hash": "ec962f45fc68a08e735d576343d681fff6dfcd00757d308b735c8c76a7321829", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "bd76d5d5-6bbb-438f-a38f-2c8c540d76c6": {"doc_hash": "980eaa90183f23ebb396b1f531fc41239ecf2796a92e8dd1af9f797090efc9b6", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "fa7306db-b25b-4060-a4ba-cc6e143ac726": {"doc_hash": "8bce0f4b2cc5d3ce83133191185867af240e121a7fb9ea9eaf4beb10af12e68c", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "8fdf6ccc-0030-4195-a743-81aa10d81caa": {"doc_hash": "5d29348a8c19e897cdd7551542c2f73db40be24d75a3b17364b7d5b025b0780f", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "9762429a-5182-4ec7-bfbc-6de5ac38af73": {"doc_hash": "b441a6832715efc78c3e3d6f16ecdb286441db49967720920011d590eda8fb7f", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "e97e069b-a11e-4f06-862d-6b47f84aa8ed": {"doc_hash": "6d2036261516b2b3b8362612f56a98f3bfc4dc6c2603f80c477ab380ca301d0e", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "7354e0e3-fc85-4b71-affb-265d0dc5a18b": {"doc_hash": "b5df0101b289a7e25c98be7ba5c3a265e491c1fbf26e433006b7d91a239800c3", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "4fba6cd3-5990-416a-9dbf-53815e60ee72": {"doc_hash": "7ad7f6ef7d83a6289250021bbd3cf5bcc3a3e6a512ddc20a055f438a2c603903", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "ab98b000-1edd-4533-ad9d-6f19e2bb8230": {"doc_hash": "88891445d30008f3a500a3400a8c886c6c82db5a5f3db8d7cfdfc0fbd6364aa7", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "ce3a1be3-958f-45f5-b271-e29b1a4fef68": {"doc_hash": "bffad5cf2b00682039de52601085a4158782a8b46dd3bc39974148e24eed06f3", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "cb1d23e9-9184-4308-b208-981f88fe29b3": {"doc_hash": "a1f190af04c545e3dc76c6c129c6347a1e20dfde51785a503dff8315d17019b3", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "56c00853-cc51-46db-a4c9-2efd0f78e5ec": {"doc_hash": "f73f522a1af3bfa91c08d152042682a7ba3a1c6d2d27c7ed014e63f148cf5394", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "2b047f95-bb82-47de-8572-c2fd2e3913b1": {"doc_hash": "88b752f348c9e15542ccad0969cd0ecbe01922855a6b777aadf0339d95b59463", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "f6353406-e8d1-426f-b6d5-d4663107d977": {"doc_hash": "3d0fb90e7546950fc049d453d1585e00a51fa716d0513e29275f27d4929014e4", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "d5e5f054-e22c-4bbe-af01-53d9bb0be147": {"doc_hash": "281ea96f2695201884ae8a5953236da415d9b92a2ca63ba3c1a69e1f06e3a3b6", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "4b279f48-9eba-4908-9cbe-0b25a454c44e": {"doc_hash": "c66eca93307e7cf6cc543ecb4450becc3d2300924a7bc673b475b0ef7faf3f81", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "42f8a8ee-e3d4-46c9-8000-e3926f469077": {"doc_hash": "170178b1df77c3d0d52b90f9cf0321bdd0a385dd15267ce0198017ae43b64494", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "d74637ad-a228-477e-891b-56441e50467e": {"doc_hash": "3279987c321433ba5bbbdc8344da64494bf06b48a2950caf2d6c06eaab5a70f0", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "a758d1f9-73ee-48dd-9238-357ea32d5adc": {"doc_hash": "9713b9b63502307bfe369773b1845b4525b75c70ff074e1b24fca305c1320fc5", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "fb79b495-32fc-482b-90aa-598d0eb81639": {"doc_hash": "49c0ebde439933a75fa4dd09e85b078802757e8a0c52dd44db4373c28452d8d3", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "95eff09d-de36-415f-8385-b84687fa7538": {"doc_hash": "4cc9c480832c276870acd6c84a61910c9867cc6a94b17db16ea421be17dfc33d", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "94a0e509-3b4f-4a0f-88f4-c5bb82800bf5": {"doc_hash": "54c5f97e13462dfa3c073246b2f54ac797f07b59ece21c0e4404674b93b98291", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "f3e5d2bb-92cd-440d-a18f-fd9a9c386e64": {"doc_hash": "a9073c31054600cd5c76450c879673f38f7a57dc720c8a5081d75030bcd93ae5", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "586fe25b-3095-4963-a638-495dad6cef1d": {"doc_hash": "fd56304db29a6be3d3c1fc283209c3f491a7e75e46990c29920b008b00608aa2", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "e0c15b22-2847-42d1-ba9a-7cb63e1afb27": {"doc_hash": "5f7414bfc190b6e4ab08eb8f5692f167d72d9ffbf98a063077a98f1c15a0220f", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "ee7cd545-8cc2-4442-820e-4be4818d245e": {"doc_hash": "654d27ac2f84ad120b06628c2835315c47e71d54d6712f9283873eb3003895a8", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "425c26b9-a8f8-4e7d-b59a-49589dd2eea9": {"doc_hash": "09c1c7fa916720db59eb28a7636e9639f10a681a2eb5bcab104e784eccf54317", "ref_doc_id": "449fa554-fa5e-44de-99aa-9b1f9d4024fd"}, "fd654a60-fa27-4868-9ba1-525a1478d578": {"doc_hash": "d13c3f6f8c4aee95187b48e5c38caaef729e331f8df03d0719b51edc63591cd1", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "6a6d7d22-08ab-4223-8914-f59f09f4c6f7": {"doc_hash": "75778c87c4065600583f7cc50cb5881bf8a71f71ae08b07a95bbbc330ab3b2bc", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "a5fe2589-59ba-4bf4-ba5d-9bfe8743837b": {"doc_hash": "61ed3a85a483738fd676c427e209da7ca3b4999eae226a48551382dbedae3c41", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "dcf5d784-5565-423b-a71d-31330ef9199a": {"doc_hash": "13461f0c6cfefdbcb7277dfa3ac5641bb3290c05ab2db25b5c6675995da56be6", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "4d478b7e-8506-43ad-bdc0-115a218f0ad1": {"doc_hash": "42f4b278581a414bc2785111287f2fb6c5cd41135842722621b86f4fb8f0cabe", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "7fb2257e-7424-4382-b47e-673ee1acb1de": {"doc_hash": "298f1a2e4fd748cf21d35d7f73af91fe4e13ae8443620273b916a186052d3f9b", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "cec75c9b-d2f3-44af-aa08-c0bbcd18a5e7": {"doc_hash": "734c2fef42bb084be333ad89bec94f83d6c1a2ddd374e0549638d5844c236412", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "db114988-20ec-4923-8d39-55f9c600cf41": {"doc_hash": "2a5bbd0e2a84934c5db0ac9814a2d1e6fa434f118985d059ee653159a9fc42ec", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "7b957e00-d98b-4f26-af45-5ecdd245522c": {"doc_hash": "57d37305409153a477e15d31b42d09d5f35c912aeaebf175db96188593a67b54", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "3a0ed1b9-9cda-4e36-989c-b4be2d08ab5f": {"doc_hash": "48ed5e7c845f9542ed9bb56cc03d52fab5febad78a89a72a182a492d21279aa7", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "c27b4d15-1441-4d37-9627-943c9a548f43": {"doc_hash": "733d802fbdad04c923ed2e00fb82c9c3ec0713faf05dbc8e989126b302305708", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "1fe81fe2-f846-4e36-a57e-695a13057a4d": {"doc_hash": "a1c908fb84abca8309bfb72a1549b8e71e2dcb40067a464ea947ada0b0582d56", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "aaa9c401-ba7e-4747-b819-71afd4032103": {"doc_hash": "71e7ad5110a0efec4a358d6d6aa8c2befb5052319066a58af02a40b5d36b6794", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "9ed10240-e264-4bb9-872f-5b322d59bc6c": {"doc_hash": "948ca1784a87b0ae518c80068e74e0fa63d33955ec12ce2fbe2ed9dd06a57d12", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "64807305-2729-4c90-93c6-b1130a4db588": {"doc_hash": "06e408431c00b85621a8b02b67b890a9da59179e2a54278f06b850fa142ba7b4", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "66858b7d-a8fc-44c7-ab73-90c3deee1c89": {"doc_hash": "d25ba6ee43a508cf32f19c0930ed559a724b32550fc68b09ee574a252dd0b420", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "ffe44d94-ff88-460d-9eb9-25e274c392a4": {"doc_hash": "967f5a1eaebe5defd6eabeaf81877032e9ffc09bde7dd9728f22de2aa25d4475", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "ded6f19e-bdda-451c-a161-e3460d5c3edc": {"doc_hash": "f3369a45272821134bbd2e02548708498c5024f432efcfb97cf69994b8863845", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "4ad14ae5-78c1-4c1b-b1e1-697306b57784": {"doc_hash": "424e3920fddaead2e6a488a39aef5ce04896428167e37e7c40498ea583eb5dc6", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "1881e8ea-dd61-42ae-9a89-4b650383dd40": {"doc_hash": "dfe037fa2fda17964ce8543e200c213fc0a3c0c755cb458dbf2923588c4d9b14", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "f139b735-fe95-4d3a-a9d4-d917a3c2328c": {"doc_hash": "004c961a16720852536012ef061aa577d0782bb85f0a994f32c20c63a9a5564e", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "d2323456-5a46-4b34-9972-32b9c345b4ef": {"doc_hash": "688cc24013066067f7f368be74102823f063b8683df1fea9f784bcefe725264d", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "2b9ff6c8-5bc1-49b4-a1fe-713d6aa44f3f": {"doc_hash": "31d246757951d56e31cca5b373db3844eb7c72a7278b6a4cf7c925c2c39ed715", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "47a56e1c-24dd-4f2d-a075-275294d92258": {"doc_hash": "8f0002bbeea75a962d21e8dbbdebe743d2c54dc7edcd789fcf79270ee03d3415", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "22b88bf0-5ce6-4704-b47f-4740a7510825": {"doc_hash": "991178cf1a1116141651ad2818735622df3ce0dcb113bbc0c71eb433fdfec9f1", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "0b625300-9268-49e4-9c10-ceb3bdb7e621": {"doc_hash": "a12c249c62f0ef917e37a8c1d1c6de854e17504158758d09221a4e3f0c70f807", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "d2932a82-b061-4a94-bc2f-5e72a0f4942b": {"doc_hash": "9cf49c8bea36fd5bbee1a791761bd669851c086b67a4478173c5c2d17c00ed36", "ref_doc_id": "82a918f5-ce90-40db-ae39-8a1966dfe496"}, "ec1ac552-5033-4a20-8a42-81889826bdc5": {"doc_hash": "58009914b277c65a726bbfe55bfd3f1f02fe2bdfa0d2d4805acd41270551854e", "ref_doc_id": "4178326e-7085-471d-b59a-0a763f409150"}, "bb097874-cd20-4354-a0ba-aa7298b5cf69": {"doc_hash": "389adf2c9fe34ae9be39eebade41ee0bfb94cb74ccc7bcfe9af4c757dbf9e743", "ref_doc_id": "4178326e-7085-471d-b59a-0a763f409150"}, "b892b8fa-976e-45e5-8b18-9993047d4a52": {"doc_hash": "da39fb200c1f32142036fa033f6c04589b191ca27cbe03a24cb91f5599fda886", "ref_doc_id": "4178326e-7085-471d-b59a-0a763f409150"}, "98a8f0f4-d3f9-4631-a82d-4e4cdabd68a3": {"doc_hash": "7541acf82041f6d4cda79c25db2f46b417070388dfa713303eded078eba9187b", "ref_doc_id": "4178326e-7085-471d-b59a-0a763f409150"}, "51f7506e-ce6a-4e07-9634-a7cb36562ded": {"doc_hash": "592727795ecbb4f8aabd6098ad27c54a427f1b0e4a7f878fa40fe5cd8d007662", "ref_doc_id": "4178326e-7085-471d-b59a-0a763f409150"}, "1181f044-904a-4630-a399-d806fb2ee26a": {"doc_hash": "7ea5c2658d2958e3ba3cecd94fbced703a3c05e901fa81ca33fea7f6a0de3f6a", "ref_doc_id": "4178326e-7085-471d-b59a-0a763f409150"}, "7751b9b7-0e73-4092-ab5c-8de8386dcebc": {"doc_hash": "41fc0e3075a5926d3ca2c06ffdaf8c8cea5db04e01b6a75e23da23e7be39940d", "ref_doc_id": "3c8bd45b-ac5e-4397-ba2c-82a897ddb832"}, "e3b7e517-1edc-4af8-8b79-d133f45427c2": {"doc_hash": "9de934409c3da008008ffe23b81984d02bbe6af824b254927eb1bdd501999f22", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "49d971d2-88a4-48e0-a56c-d29a8d3e96a6": {"doc_hash": "93bb3b56a32c7a4409ed95a96178b75a058fcb6af6db79463cda64ed2189f2b3", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "5f68b27f-cd78-408f-94e7-b66e66c5216b": {"doc_hash": "3817a4f9bffdaed8a56009547a991c706cf1f88dc6643f7bb5564d36bf6b4b39", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "7ca99a91-9ec2-4547-9c52-a19d609a876d": {"doc_hash": "63448c01719e8f0e9120a62d289374234d5eef80fd0d5c12155ee6facdb08aad", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "f0642ca7-fdb7-474b-8686-8e7c35b4f139": {"doc_hash": "552576feda9a312dfef73cd9df69877bc71f81ab1ef5af6628bb4c32334678db", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "4c397fe2-faba-44ed-9362-c5e521721e3d": {"doc_hash": "23e18335c6cd4a8c4bd8e4c4086cb78507e69f352a2b3efd7bd59c0ebebdad13", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "fbbcd649-aaf5-4715-9389-3fca9e3ac58f": {"doc_hash": "03f5ec303fd1adee43087aec251c837cfcbebd77beb151cbca2577d93708f0f2", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "36463de1-266f-4432-b9c3-62289a600f09": {"doc_hash": "7b6a48c362857b1fc7b35b4555bcb53323019bf06c84a99f3583d500261602e2", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "76b77dcf-d40f-421c-a554-e978625ca37a": {"doc_hash": "216c6ed7db0d2126b7fe4097e6a5b84e76c5f6d1e18661e7bd9df1a758279609", "ref_doc_id": "df6e7762-f404-4def-be69-c71cef041775"}, "f17d447d-76fd-401d-a53b-fdd9945d43ee": {"doc_hash": "bc64872949cfda0e983651b86175fb68653506b18e7c468a9e7dd21e61b40867", "ref_doc_id": "8e17dd7f-08e3-40f8-be90-86760ea4bebb"}, "4fb806e9-54d6-40df-84d1-718f4b40021f": {"doc_hash": "66861369cefe15edf6e8217e21708a2f244c1575015839504d7ec50ad12cb513", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "6c397843-1f60-4c93-8e72-2f120f53d7d3": {"doc_hash": "3a56d9ccc4e41761326def3c7f53f1123b7fcb81a97ec0bc1cc68a2d940637a7", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "c316e041-05af-494d-a229-244a1396dfd4": {"doc_hash": "3066ed26b22d2510e53622aa90d22f87e7a181cbd14a5122d478ce5ccc16f009", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "490c4b03-ac21-4581-9729-6c2b488a80f2": {"doc_hash": "d3b8fb836aa2cbe7235c2e279ab0b9fad581ee4ed7f0beac333d9d36f07124d2", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "52f058f3-2c0a-4aaf-acc0-d4e7a545c275": {"doc_hash": "e2673ac9180944187705a849a4720c7c7836dddbb52d13937fae6ae61300eec2", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "7c5d9cd3-7aec-4ac6-bf66-af8eea8fd1e3": {"doc_hash": "b54cbb11829299c1ad38c4e99164650a7ec6a90a8f050c4255da2fc1693f4445", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "a1f44901-7ffa-40d3-aabf-d364b0085ad8": {"doc_hash": "a0983036050d2cbd0fb274568158da6852e9efe3e16bcfbd9bf75249b0657588", "ref_doc_id": "e6b7304f-5a55-4ef8-a202-1040e2e69013"}, "639567ee-9d9c-48f5-83c0-cebdf3cf86f0": {"doc_hash": "01de0d6712626f98ca843f3e0ef7f24382f9015df1d8e03134c0c9d1a28771c9", "ref_doc_id": "76b776b5-ce01-4272-8686-5c0e44dc0f4a"}, "a7576c22-3e2a-4827-95f2-0606cbc6a2d1": {"doc_hash": "da4b54d60cb2e371114227fc8a62d0ed3785601d5e79a8dd118dc1c638bdc087", "ref_doc_id": "76b776b5-ce01-4272-8686-5c0e44dc0f4a"}, "303777c3-48e9-4cd6-af45-6094b451d201": {"doc_hash": "f93460020aae419fe0a32722c35e8bc46c347da37d8dff24f4b72c15a09b22b1", "ref_doc_id": "76b776b5-ce01-4272-8686-5c0e44dc0f4a"}, "fa0e4fe5-005e-4b71-b1b5-c94eea47417b": {"doc_hash": "a060da0ae1da71661d8f4fffffa55205d248bcfb8d1ff6701761437bf1dce5af", "ref_doc_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1"}, "6de82a6e-b765-45bf-a95c-4fd7af18927a": {"doc_hash": "bf7f9cf226cd0f8805018317de75cd992576b26f5773296c8d4497cc7eeed43d", "ref_doc_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1"}, "e5489d13-7534-4367-bea0-2025757b1f17": {"doc_hash": "aa8a608810c1ed79b3bb11736c49c7b0b7f1800bf8c55cfa718ae8d2cc6da279", "ref_doc_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1"}, "79682d58-56d3-4317-866a-92879ff9ab19": {"doc_hash": "fd7b470b2a1400c02f1f2569a87d8486aa20b2360b74cfae75d6f705b333586b", "ref_doc_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1"}, "e47925b3-561f-4112-9175-5f60e3da866d": {"doc_hash": "34a7552583bbbbd1bc8dc84df37b0e332e4ba9a98dd3fca6bfbab7e98be5105a", "ref_doc_id": "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1"}, "00e34dec-a3d1-4442-a058-f97b5b7e3f18": {"doc_hash": "a81ee6a3d0eda3a2fe279e50c7144df69e682b64b03be31c70a847690f837d53", "ref_doc_id": "c59c9858-7f9e-4c22-b88c-9914022c50ea"}, "508797a5-4419-4936-afe4-0a5be987abea": {"doc_hash": "05d0f0ad8048fac6b6d821a1eec905eebd3cc9b9822cf82aeeadc4dabbd38cbe", "ref_doc_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f"}, "a0865bd7-1ec9-4891-88a2-d82d95081f78": {"doc_hash": "ad965c5e8b895d27cd59745b9c986b8ce894ce1013363a395a87601548c89b6d", "ref_doc_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f"}, "f966e64b-1b18-4323-b038-4870145e9f8d": {"doc_hash": "811c752065757514fadb116a42a155e030f0dc2f3d79a9f72bc9f2d4ac71dd6c", "ref_doc_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f"}, "ee2270e3-3e6e-48a0-84d6-d6ebb109a560": {"doc_hash": "b43dcdd9e3660321d62232e1e310fe4ba446c52ab46cae6590ebbd7fecbc1de6", "ref_doc_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f"}, "16514a0f-d2b8-44f2-bea6-40e6355f92dc": {"doc_hash": "4c77f6fcbfa06347b243892ce2b1b8efee6dd0af50c95c9055f46f054667af84", "ref_doc_id": "1d4d83e5-ad60-4401-9163-dc510f0c875f"}, "a5cc44b2-a987-4192-8ec4-f4e3209644fc": {"doc_hash": "3aa20decf582d4b82340f6c3f34067080bf51a1c0e1098fa21dade08ad54c7db", "ref_doc_id": "cc40b836-7413-4492-af80-8a1de5358048"}, "2d8fb1f7-3f85-4f0e-aabe-34e375a37aaa": {"doc_hash": "8de0984cfce449608c9a33c7a1d92afe72fc690adc788a249f4da0b2c1e964e1", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "a09f8280-8d0b-4ce7-a345-22b7b925ebb2": {"doc_hash": "81f19fb0f889a828eeb26d72e122331c256868a391ba2f01925ba7de249d7899", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "e3a5dec8-c95f-4139-b9f0-6e94a3d84b10": {"doc_hash": "efc415b5a5589097ccbebdfd0adc100598be05c08e60c43ac85ce96c45c322f8", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "43b96c01-a2c1-439d-b6a1-4c8846ed396f": {"doc_hash": "6dd1be41dbe5b1fd5830c80544371d50ca909260b84cfe045bf7605ab99ee9e0", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "9eb7e837-ad70-4d2c-86bf-7b5f3aff1946": {"doc_hash": "a432ccd684d0c4ee11ee170b89616adf2067c752f713fe20ab4bb2d19eff99bc", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "6105568f-4de0-48a1-b53a-8308da3dc32d": {"doc_hash": "955522090ddd017269b60c0ec24fc6ddbbda72f60ca99f318241d3ea0b984b2f", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "aa045908-b90c-4d46-8ff4-5f49aa76830c": {"doc_hash": "f6ec02dac530ee9bb7fa4600cbd1cd2e6eaa1b32d13b3f2091364370b2d9a49a", "ref_doc_id": "bb4fdbb9-341a-49fd-bc42-adff7066b683"}, "1c7fd279-b4e6-4776-be60-f2f2a62f2620": {"doc_hash": "59f9a6db6300f16ced5579e3aaaa1949e9cd63019a74dbfaa585718f273359fa", "ref_doc_id": "ce620db9-3cff-48e6-ab98-e86564c32b56"}, "294f697d-8893-4c72-ac81-43f29bbea85a": {"doc_hash": "bbbe44110eab6078587ee797786e81abd069762e40e11219f7107b5bb08633c1", "ref_doc_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031"}, "c4b8da48-d702-4913-83c1-c205998f450a": {"doc_hash": "78f4f0920c42f97e17d2828427ebf40b848ca8e8948f3a8fe26de8845f242f8e", "ref_doc_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031"}, "b38836d8-b9f5-49b8-9372-25f430d69905": {"doc_hash": "41231baf7f730cb393f938b640707849106e06adaf2a5cc3109237712ef13e2a", "ref_doc_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031"}, "c7a057aa-58f2-41b0-bb4e-fe84bb35c2c8": {"doc_hash": "273d6c17e12d41f7ab60d079a479fbb0ccfd2a4b7666fac05361390f1e6a0ba0", "ref_doc_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031"}, "15f8f8a8-73c4-484f-9b66-48c3d3121447": {"doc_hash": "294d18442720bb761c497d073af4bb0c948fd87dacfa0ac6b2cf28d0ffb45676", "ref_doc_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031"}, "3e9f9197-0747-452b-bb9c-053ca108277a": {"doc_hash": "5c2c6226ac83884860ade753de4af8cf293accba39f0df5dff4d148ab2e457b5", "ref_doc_id": "f3e87af4-1d6f-4b76-b64b-b57691f46031"}, "9b2138d6-acbc-4242-9764-5dd4b2d61df1": {"doc_hash": "59ae1fb8803ea42dfeb7de912293c692956211724cef501fca4ec1911af1a2db", "ref_doc_id": "0e765f75-ae88-4306-bf19-6049f47eba1a"}, "996fc28a-abdf-4aa3-b8e3-9057a62d31e9": {"doc_hash": "29f37f5ad33f04902a97a03aeff7045f82a51a8164b68aac7565d1e2d684c66f", "ref_doc_id": "0e765f75-ae88-4306-bf19-6049f47eba1a"}, "fd490ae9-60d5-43f7-92f4-f70c97e744b8": {"doc_hash": "be1d3c2ff570d58a07868848fc20914122a82a674de8dd87654f1b28db058488", "ref_doc_id": "0e765f75-ae88-4306-bf19-6049f47eba1a"}, "562def7c-12a7-4afa-80c0-ed39310b829e": {"doc_hash": "9a4e76d1be72ffa9c8e8241ceed17c5d3d645aa93a97e6d23461abcef5b8ded7", "ref_doc_id": "c8688fdb-4311-4843-b66d-47fe768eac5d"}, "d0ba1e67-5c8d-4832-ae51-957adffd40a2": {"doc_hash": "5d67405a066cab0a1c0ee229e9bbb6acf3a78c6d09ce3665aa3b0f1caaebf900", "ref_doc_id": "3b18cbb8-a73c-49a5-af6d-bd8bb3edb0ab"}, "76f3fede-d75c-4689-bb89-db5559af304d": {"doc_hash": "59f9ff86f91ee1bae02f556e1e0d5dbc9a1f2aabc7e3a27023d897667108fe2c", "ref_doc_id": "3b18cbb8-a73c-49a5-af6d-bd8bb3edb0ab"}, "f70c4d9b-9e4d-4479-9437-41f4fabead0e": {"doc_hash": "9c8463cb8c82b846c464e0934b4d6d492de4a2e09b18e42f312a2ed583fe7649", "ref_doc_id": "c453f395-ce3c-49ff-b342-3428bb9670d3"}, "47a8d986-33b6-4cf8-a829-481ca5e466a5": {"doc_hash": "701f415f3c791d39f0916cda7ac811df1c17c8bd9e02753102fdfe7303a8efeb", "ref_doc_id": "a6793dca-8e31-4804-866a-0cb9e551bb83"}, "a877893f-e1ca-4270-bbc8-b955b05e3b12": {"doc_hash": "b5532e006f96dcdbb189d39e1400e11fd3c435aebacbe2733e30caa04011319a", "ref_doc_id": "c2d9136c-f7a8-4540-b8a1-700d7e47c8ca"}, "c781d97d-d1f0-4d1c-b336-854e9eca14f8": {"doc_hash": "c985a1486d5eb8da05b368dadb4c35ff9b69f52a6ffec537bc8295438c7ea924", "ref_doc_id": "c2d9136c-f7a8-4540-b8a1-700d7e47c8ca"}, "841574fb-3124-41d9-8cef-53cb2e5ceade": {"doc_hash": "b4b22b60b9f58a00ec11d2808a44ecba58f35c127573b3114d3922108a6b9c5f", "ref_doc_id": "e663f9e9-9ad6-485e-8eed-8b1b19b80a43"}, "6404a2d1-e0ba-4882-82b3-afbad408a017": {"doc_hash": "83d06f0d2ef1ca28278cb70109d592585453c8b4c9f1a99e1f60432bb0736abf", "ref_doc_id": "ea0ee79a-7bbc-4f00-908a-1aa32781d3da"}, "d0894117-2b1f-4275-bc3c-f6220196a222": {"doc_hash": "e349f391637594c6dd372d35170d8c03a63c86126231c9ad000df79682e8f536", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "3ca5f761-9035-4ed8-98c4-b134eb0bb36a": {"doc_hash": "0317afb23ec9d68097078cb0e1e1fa4a8d5cab6602e14ac261aef275783528b4", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "30fa8b99-981f-42be-b363-d60eb0d65d47": {"doc_hash": "8d15f283405b544f70282d8871c78c565d50e0b5aaea73d14461f558ab2c84c3", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "5e477d84-9a94-460b-a10d-c424e23cade3": {"doc_hash": "dd5afe509be9c97dd53d39dac407b9c475aeb827f448eeaa8ac5694ceb382ab2", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "8e20a4e4-3731-4729-82b6-dd181425b948": {"doc_hash": "2a6a6d878a4310d151820b742a7ed40d6a5011a9f135418f95ba6edf8302748d", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "fecaf29a-c268-4061-a649-beda488ee4ed": {"doc_hash": "2298c2474823f16ba04896b65505fbfd50a713ef943582ca967e430f7324d38a", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "c5c094bb-52d6-4cc2-8c66-e8d04ffd269b": {"doc_hash": "73fcd7016117d6e8ed6522c46f802f7941d3fab73931ab83894874f73848b8b9", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "e7f66d7f-3a7d-4220-a3f9-a644aa709340": {"doc_hash": "777c4d3d6433da152618f4b98fd8a2f218dab1e896909efd949a4c9d3ede6898", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "f6485b98-3a65-45d0-b960-eac27f938ef8": {"doc_hash": "e2d30b6bd7190a182e9d7cd59f6a47a1a40215bae8c4a481e624c2cd06d9b690", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "0d85ab9b-047b-4f73-9468-d6b52a33b7b6": {"doc_hash": "918b9522b35b8ee6af36343801db9eae2ab3cd4573a0e1b120ddce39852fb7c4", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "8fd54a39-26cf-4815-ab9a-f6445759aa77": {"doc_hash": "f9428f1ad837bf9ba81a5211aa954d9877d761c09fe312346616b91f0ca3f729", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "115b8cf5-0947-4dcc-8b9c-2c643804044f": {"doc_hash": "306b43b24cabd187a0d274f6f1ff73725335effd788b748fe1c62a75fc966f01", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "193d727e-98a3-4e80-8e4a-a86c40690046": {"doc_hash": "445b30d8156b9f41aa4a60ad0309c40df1e27bfb9c31cfbac2e28e358bc663a5", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "383756d6-f991-4743-b27d-fabfc81a4a96": {"doc_hash": "b549dc0941ee3933cc168c29e402019cb04f12c2ad5f42505bc6441a68946978", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "f2f59bfb-2db4-4c43-8130-b09fa32861db": {"doc_hash": "1ac1b73ccb98c064e1e99fb43daaae73a590cad4b5dc32e01f744d979c01acf2", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "10237c77-3e51-42ab-8c08-48c192e25df1": {"doc_hash": "88a9f1f0045b4d69b3773d0e78778edcee4c159e83c831453cee51f66c11452d", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "2dace65c-dcf6-421f-8d67-133c5bca885a": {"doc_hash": "943f2dfa0e1c1f0060e0f99ab92ee3a34e4a79646084c73d6cffdc1f0d61d495", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "9d3cb665-08ed-4ccd-ba57-bb373ae4a631": {"doc_hash": "ebae68a17c014afae23509793fd2b392e3089ae75887c650fa8db2434218cab8", "ref_doc_id": "fd101fee-ca25-44af-b6d5-b7121628fc51"}, "397f9888-60e6-4b15-a1fd-dcc3e47c88cb": {"doc_hash": "9aa30a7d4eeed3c3bfc069155fb39c08524f5b4f1dad5b6846f3625c356979a8", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "a378fed4-dc18-4bff-a373-9bcd66ba5f5a": {"doc_hash": "c68eb5ca3913a5168e2a423d17d5b1384cf1415772763e3c7f4db8b1fd9f435d", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "b1c42a3e-26ed-4ac9-b454-1e021095d7bf": {"doc_hash": "7932c0a35cf9cb54075452a3234dfcf10cd921e2b20e681eb32aa3ffbcd8ca08", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "34a78981-3568-4de5-a989-2730a61fab67": {"doc_hash": "e14600eca6115583083cc746e0495f8cf92c65e712f49551629401eae722ed50", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "5773f45a-2ac1-4cf3-8248-025500f11379": {"doc_hash": "f876aa54d3974449e35c6b42bec52fd242670a58c5b7f3a7cbec650a485eb9b8", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "8c1fec52-749e-46aa-afe2-bf0f5912b449": {"doc_hash": "2585b487d45e49747225da7698fa6cb47d8e9a77e5e95d0dcb6d32afe7a016af", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "4afc920b-4e97-4b54-a1df-feb6fb9767fb": {"doc_hash": "942b74427783f73533dd73154cb13380cb0504ddd777e4ab031c2e8b1a02f0e5", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "70322c88-1422-442b-9cd3-30f0cb0478a1": {"doc_hash": "4cc0cac82d8fa4a87d833150731c546b9b33846fb54dca692154cc9c44134a9f", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "bb2ec193-c1ce-4f67-803e-6154541df593": {"doc_hash": "60cdc67a1f2e061473f18db5944075bc13828853b6383ffb378c9616e99bb56d", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "31b78c4b-fcf6-4033-a596-d98ff12c0ed4": {"doc_hash": "c5005c861e760e8d9c0ad46f8fa780ecf83e1612d695a8560583d08dd0590cc6", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "4296aa14-9ca9-4b9d-85d8-d42fc7c7022c": {"doc_hash": "5d019d96dc2f9d25558caf82a243040bd89ffe41267c29f53592b4f936f75b10", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "9153c390-5c09-44a4-8739-0cef40d50c8d": {"doc_hash": "c50b03daa147dfeca347edd472c823eb951ade89657fdd8c413c83904401fd57", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "bfb599fb-67c1-479f-a4c1-69660b00081d": {"doc_hash": "4c84df33224ce60379da95a15367ff51625fe0ee4376246bec348876ebbc7c73", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "bbdaed2e-5f77-4125-bf39-133987502e5d": {"doc_hash": "394cbf1672cea4d10569602fcc1ea238d86e7b6d2b50c9f527df391a266e1a1c", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "4e3e9974-09a8-4985-b111-c6ea42ecdba1": {"doc_hash": "4939d2b73e689355eab122ff3fe603dc6e378a961498890396a164a052a3ec66", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "2611beaa-c292-4268-a19c-195c73922481": {"doc_hash": "31ca76981b5e25a6c3814bd136495d0e534940cde957cd3d06ac2f8f0ac057b0", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "e913fa32-b92c-407a-9183-ea073640fe51": {"doc_hash": "44ad9d5fd607086c70cdbb6964d0a3cfc402da68d2ec731b0e7688e315660833", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "fd666e3c-e4c3-455a-ad27-063580646a55": {"doc_hash": "8f17ca53df1255c58a786524070d0b4cef76daf5dfaa1b46d43a9d08b35dc93b", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "dc15ca88-ff5d-480e-8f3b-0512429b96ef": {"doc_hash": "a53d29601872e1522920c00e3771d04605fd2ae6f8c3d2a5fd43bcb2ddb7fa45", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "d12de588-6206-437f-85a4-33c5378b20a1": {"doc_hash": "19bde4d3f5fea36dba34acb17a1af4b6752fa2743baba6b576e79ae8d2763197", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "4827243d-1722-4735-bf26-ffc6479267b5": {"doc_hash": "a39e59ec7b72d47f425b6f976161765a5eea34ff4502524db6b8b24030d408b8", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "288dcd51-5fa0-4ffb-9b18-a6e0d5b93bbd": {"doc_hash": "d5be6cbcaabce44401b47da5fd5c5453c561c4d8c71037d47e409f8bff180c7b", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "1b8ca618-f02f-49c1-8731-15361f7bc8c4": {"doc_hash": "9dd7d67da413f5daec1bdac6d54d626602b71c816469bd7b7c2b01899e067c6b", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "8457146f-f3bd-4c8e-8dae-3c067bf17909": {"doc_hash": "dfe5de967ef604ddbb932de372c212dcf4f51525e0e76eac8e1c634238563e9c", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "33407750-be01-4054-8d48-e4f5d4629ada": {"doc_hash": "c724f2dcf1879c4582ae36be8186f9d1704a0ddf31c6cff9d0dd43332bb8677f", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "e30a39b9-31ea-4551-bd67-027987ad5d04": {"doc_hash": "eb609ffd4832ea96f052097ce2423855b0f22d6757a12c4db5f7db0e5e332918", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "748a7f51-567d-4ad8-b34b-847c1b88f988": {"doc_hash": "552cc71b523e51f46c9e249c4081ea7f590b6630a645305fa1a0161f80d73b17", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "27af8bb2-74a9-48c4-b675-ccb1dde71a8e": {"doc_hash": "4260961349c8e2a21aa654dfdbd4f55bc9211446cad21acc28a4e5c0d7de84c9", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "acb01b96-6807-4a07-9d08-9fbcb03a7540": {"doc_hash": "4671cda9466274bf16aaddf82c055fe805d2dfa9667f87ea34df3a586eb249cb", "ref_doc_id": "bf004786-7343-4c2d-928b-7d6ad10c2b26"}, "210d1984-6635-428b-a25b-b8db37a6e2d7": {"doc_hash": "2cbe2564ea00c9d0266de175db78d6296d9c55f08a0022b391a9472df31534a4", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "c0d2380a-e050-4a9c-8a18-0b98e1b42d14": {"doc_hash": "efa86831a6ba0c2f53d58448b2e8f873ef24f67ae69448f3e6645b58f00ed6da", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "01165a53-0267-43b3-99b7-ef9fdb2d7325": {"doc_hash": "5f6ec3c249d54ab31c3348623f490b1d8386e52f762df071ac9a3d29760b197f", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "a452bc23-4e4a-463f-9c92-24662ea9845d": {"doc_hash": "c9cbe635268bc23281f711a8e7fc94cb869db93ce974a11cb8d2d8726b2a15e2", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "e6ad2e8b-1e56-467e-8280-7a3a8bcb1857": {"doc_hash": "c507fa2b504fd2848d89b3d151f80be4f39162ad1417546f890584f2fa2bc98f", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "01762e21-5295-43a6-aa0d-1fe1276ba80f": {"doc_hash": "d576422f52541920141fa829751d972b8da13375ffe5f32dfb2d1f151dc059ca", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "b253c9de-f4ba-409a-b1b6-cfdba6dfd869": {"doc_hash": "d2ef6d201ee43afe1b21ea400c6556e20ccee4b6c46730c8f675f41c30c99941", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "3267d029-116e-4852-9ddb-1525a9b190ba": {"doc_hash": "c6c9d99f947a557b1695f4de50c90fc2d1bf6967b1fa5883dab4384c38277319", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "02c6d203-e70c-45b9-8f53-d2207a741f1b": {"doc_hash": "3829011f80b83b9c2eb3b18e64963fc18971845b60909b331fc3a13d49b47cdd", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "5b6a5927-8fda-4b1b-8b0e-ae6a36068fda": {"doc_hash": "9a005e0501540dd1d8cf7dc8c113cbd916a6719cfb7f59c71aacfe336dbbb337", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "46d93e7c-d17c-4c6c-a8fc-e046d98f793c": {"doc_hash": "992c875c457af8e69fc2b58f098fc55616ed70361b83d72c75d9f97446fb0a19", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "fb114c45-ff22-4971-b162-aa08a7b2f078": {"doc_hash": "d617d968f4c261210cdb3a52440f54e1152ec1833de7110dc673faedb59a5407", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "c2d32b7c-11f9-475b-beb7-a35b1c26e5e1": {"doc_hash": "4cd5c1908c193ddfe08f9a7732312c3844190883ca03697e3fb745d47b13e911", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "3248643f-af34-45f6-8b45-e0f32af6a0b6": {"doc_hash": "9258ff266d6a1353dbca75728b91eec9d0c98798600f30d80159eee801fd4863", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}, "3aa6fccf-5abd-47a5-84a4-2ca6f40f2622": {"doc_hash": "851e45de93e8a994fdcf26ebc6587125f0c121fa5ae34a194c32ae487dc4858b", "ref_doc_id": "c238faa8-711d-4721-ae81-ec0d1f5154d8"}}, "docstore/ref_doc_info": {"867b5a13-688e-4a45-97ba-c3feb7565389": {"node_ids": ["fb30f01d-f1da-4b6c-af85-8e350e254872", "1f7b529e-12d8-4900-b952-9073dc122dc9", "c935420a-5b2a-49d7-a67e-4b49593ccb0b", "8998fb25-1e69-4c19-a1b0-7d4ef5172064", "3607aeac-91ec-4d39-812c-96a8d51d323a", "f63d75c4-d735-4983-98ec-e655c9d3ca3d", "3cb7553f-8fbb-4ed1-8189-d1c168cac871", "4d4b2432-0911-4127-a716-5bc41001bac3", "fbd13a51-c9d3-4545-85ca-d93b0a927887", "3e9303fe-4dde-493b-ad56-86c67d9bad00", "cf807aaf-a818-44cf-95e7-065c6667df16", "790778c9-d0de-49a5-9472-56818c0dd008", "09101624-2e97-4fcd-bf5a-539db64fbd57"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion.  Revenue increased 12.7 percent to $214.0\nbillion for the fiscal year.  On the basis of U.S.  generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was\n$2.08 for the September quarter of fiscal 2021, compared to $(23.74) in the prior year quarter. ", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Four th Quar ter and Y ear End R esults\n11/4/2021\nRevenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase \n Fourth Quarter GAAP Diluted EPS of $2.08 and Adjusted Diluted EPS of $2.39 \n Revenue of $214.0 Billion for Fiscal Year 2021, a 12.7 Percent Year-Over-Year Increase \n Fiscal Year 2021 GAAP Diluted EPS of $7.39 and Adjusted Diluted EPS of $9.26\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2021\nfourth quarter ended September 30, 2021, revenue increased 19.6 percent to $58.9 billion. ", "page_label": "1", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ef133143-d754-4537-a987-836ab2b9b35f": {"node_ids": ["3c920032-d067-417e-b8f3-bd9e316ac195", "e78cd766-657e-48b7-94a8-8a978c260eb6", "379d1b3e-41ca-4e49-8b27-314ef8a01980", "7244cccb-bb8f-4ceb-a1d3-3ecfecb506eb", "965afa94-7a1c-4230-bfdc-510ed048ff49", "e19e0b62-bc01-44ff-acb3-a9f7ddf999ae", "f9d74e9b-cec7-435b-9c0f-aa44fba55d19", "8eed55b2-7c3c-4403-9c7e-fe6c7bd1cc8d", "cc57206b-b2af-4130-a874-898b9f690cf0", "3ab6b56c-eeff-45ee-9267-5489473452bd", "4a47c259-7683-4031-b5f9-fad81f6a2dce", "13d6a852-721d-4705-b93d-fbac9bc16fe3", "f062024a-ae59-440c-af9f-545fc7adfb18", "d996dcea-f310-428a-b81c-ea8dca640ceb", "8c37dd9b-c67a-41c5-ba86-f56c91c4b431", "8d7e85db-b14d-42ad-a425-0f2efea7487f", "be3f9295-d91a-441b-9428-e4e5db0ff4da", "e192c913-6afb-4f10-9cb4-99ea22052f07", "e86c5902-6762-4d25-a692-2cd8e20f3d92", "e3d7f4c8-1097-40c5-ad0c-1ab503243bb9", "561543e4-57eb-4dc2-ae35-fafb4fea2386"], "metadata": {"window": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results.  In the tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information\nrelated to non-GAAP financial measures, including adjustments made in the periods presented, please refer to the Supplemental\nInformation Regarding non-GAAP Financial Measures following the tables.\n Four th Quar ter GAAP R esults\nRevenue:  In the fourth quarter of fiscal 2021, revenue was $58.9 billion, up 19.6 percent compared to the same quarter in the\nprevious fiscal year, reflecting an 8.4 percent increase in Pharmaceutical Distribution Services revenue and a 286.8 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Dilut ed Earnings P er Shar e $2.08 $2.39\nDilut ed Shar es Outstanding 210.8M 210.8M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly and fiscal\nyear results. ", "page_label": "2", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "967f1b71-9d13-4871-aa8d-f288ecbf315f": {"node_ids": ["756efeac-0cb4-48eb-8e77-4c6154a8b486", "4fe18875-008d-4559-b668-9ecf60062442", "5d48a009-df3b-440c-9275-2b5e079ec444", "207d9c4b-9dc7-4ffe-b3da-6391f8c5a28f", "084b6942-30fc-4756-b411-428ed01fe9af", "aef7bca5-028c-4f72-9962-5de4ae26b43d", "b0fbecbb-bcee-4f98-ad9f-58ed67e70ea7", "9af23843-2920-4ed9-995e-3052c019dcb0", "d02beb8c-7177-4768-864d-ba41f9e38fba", "3f326c2a-aeb5-425c-a770-b0bc83b90be5", "c84c170f-8da4-4c98-8cb1-3fed24c6c5dd", "4c10f97f-cb4f-49b5-b83e-5c0649c6a3db", "2f5a4254-8529-43c4-ae60-f130339d9c55", "d35afe02-f45c-4362-85a5-ed9233d4d6d0", "384803c5-197d-460c-b65e-00191d4880aa", "d1d0f6ef-590d-4cf9-980b-111d3f00d96d", "aad6b1da-2478-43c4-87f1-965bcf57e72e", "875239ee-3226-4c2a-9732-011b840b509e"], "metadata": {"window": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the fourth quarter of fiscal 2021, adjusted operating expenses were $1.3 billion, an increase\nof 64.9 percent compared to the same period in the previous fiscal year primarily due to the operating expenses of Alliance\nHealthcare and an increase in payroll-related operating costs to support the Company's current and future revenue growth.\n Adjusted operating expenses as a percentage of revenue in the fiscal 2021 fourth quarter was 2.23 percent, an increase of 61\nbasis points when compared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 fourth quarter, adjusted operating income of $694.1 million increased 31.0\npercent from the prior year quarter due to a 113.6 percent increase in operating income within Other and a 10.9 percent\nincrease in Pharmaceutical Distribution Services' operating income. ", "original_text": "the prior year quarter primarily driven by the Alliance Healthcare acquisition, an increase in sales of specialty products in\nPharmaceutical Distribution Services and growth in some of the Company's higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2cad8c3c-0bd8-4ef8-9efb-d9d244a7ce2c": {"node_ids": ["3e5b973f-40d1-45bd-a92c-0463c88fe21d", "9ebd2cd2-4c90-4aac-bc9c-323419faa1d5", "31794ee6-9386-4bd8-9a44-403ca2874b10", "54a4b724-3b44-41c5-a7ad-a90aad28e4ee", "6706c029-ff73-457a-835b-e9f981d44962", "0ec78b49-8624-4ca1-882f-2684358d889e", "ef08a182-1208-44d4-99d8-ecb5329e9645", "53ae9695-3a38-4960-9b51-78e356d9e94f", "dc0362f0-477c-4742-890e-f231a740f8df", "b4dc5b5b-f95d-43f8-bed7-9f433dc6a186", "99307616-cfba-4bd7-a402-44cc95de6c03", "8f70ed0d-cef5-40af-af94-d4a359622daf", "ee0a1cc0-d4a4-40bf-9753-8bd4e9a26e3b", "43024462-fd14-4eaf-b70a-dde807c655ac", "120c3c89-fc3e-4d70-abf6-8fa4c8465ea1"], "metadata": {"window": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year.  Revenue increased 12.7 percent from\nlast fiscal year to $214.0 billion.  Gross profit increased 33.7 percent to $6.9 billion primarily due to increases in gross profit within\nOther, including the impact of the June 2021 Alliance Healthcare acquisition, a $203.0 million LIFO credit in the current fiscal year, a\n$159.7 million increase in antitrust litigation settlements over the prior fiscal year and Pharmaceutical Distribution Services.\n Operating expenses decreased 55.6 percent primarily due to the legal expense accrual recorded in the prior fiscal year, partially\noffset by an increase in expenses as a result of the June 2021 acquisition of Alliance Healthcare. ", "original_text": "\u00a0GAAP Adjust ed (non-\nGAAP)\nRevenue $214.0B $214.0B\nGross Pr ofit $6.9B $6.6B\nOperating Expenses $4.6B $3.9B\nOperating Income $2.4B $2.6B\nInterest Expense, Net $174M $174M\nEffectiv e Tax Rat e 30.5% 21.3%\nNet Income A ttributable t o\nABC $1.5B $1.9B\nDilut ed Earnings P er Shar e $7.39 $9.26\nDilut ed Shar es Outstanding 208.5M 208.5M\nSummary Fiscal Year GAAP Results\nIn fiscal year 2021, GAAP diluted EPS was $7.39 compared to a loss of $16.65 in the prior year. ", "page_label": "4", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "449fa554-fa5e-44de-99aa-9b1f9d4024fd": {"node_ids": ["9e1b2584-254d-4682-9222-f17693a6a6a6", "6c55ba0a-3c1d-4c7b-bbc4-5dfe5bb15b17", "bd76d5d5-6bbb-438f-a38f-2c8c540d76c6", "fa7306db-b25b-4060-a4ba-cc6e143ac726", "8fdf6ccc-0030-4195-a743-81aa10d81caa", "9762429a-5182-4ec7-bfbc-6de5ac38af73", "e97e069b-a11e-4f06-862d-6b47f84aa8ed", "7354e0e3-fc85-4b71-affb-265d0dc5a18b", "4fba6cd3-5990-416a-9dbf-53815e60ee72", "ab98b000-1edd-4533-ad9d-6f19e2bb8230", "ce3a1be3-958f-45f5-b271-e29b1a4fef68", "cb1d23e9-9184-4308-b208-981f88fe29b3", "56c00853-cc51-46db-a4c9-2efd0f78e5ec", "2b047f95-bb82-47de-8572-c2fd2e3913b1", "f6353406-e8d1-426f-b6d5-d4663107d977", "d5e5f054-e22c-4bbe-af01-53d9bb0be147", "4b279f48-9eba-4908-9cbe-0b25a454c44e", "42f8a8ee-e3d4-46c9-8000-e3926f469077", "d74637ad-a228-477e-891b-56441e50467e", "a758d1f9-73ee-48dd-9238-357ea32d5adc", "fb79b495-32fc-482b-90aa-598d0eb81639", "95eff09d-de36-415f-8385-b84687fa7538", "94a0e509-3b4f-4a0f-88f4-c5bb82800bf5", "f3e5d2bb-92cd-440d-a18f-fd9a9c386e64", "586fe25b-3095-4963-a638-495dad6cef1d", "e0c15b22-2847-42d1-ba9a-7cb63e1afb27", "ee7cd545-8cc2-4442-820e-4be4818d245e", "425c26b9-a8f8-4e7d-b59a-49589dd2eea9"], "metadata": {"window": "Silver certification for the headquarters.  At the building's ribbon cutting ceremony, AmerisourceBergen leadership also\nannounced the company had been recognized as a Great Place to Work\u00ae for a third year.\n AmerisourceBergen furthered its diversity, equity, and inclusion efforts with the rollout of new Employee Resource Groups\nand diverse candidate slate objectives.  AmerisourceBergen also unveiled its leadership competency model that will\nstrengthen efforts to support and develop talent. ", "original_text": "Silver certification for the headquarters. ", "page_label": "5", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "82a918f5-ce90-40db-ae39-8a1966dfe496": {"node_ids": ["fd654a60-fa27-4868-9ba1-525a1478d578", "6a6d7d22-08ab-4223-8914-f59f09f4c6f7", "a5fe2589-59ba-4bf4-ba5d-9bfe8743837b", "dcf5d784-5565-423b-a71d-31330ef9199a", "4d478b7e-8506-43ad-bdc0-115a218f0ad1", "7fb2257e-7424-4382-b47e-673ee1acb1de", "cec75c9b-d2f3-44af-aa08-c0bbcd18a5e7", "db114988-20ec-4923-8d39-55f9c600cf41", "7b957e00-d98b-4f26-af45-5ecdd245522c", "3a0ed1b9-9cda-4e36-989c-b4be2d08ab5f", "c27b4d15-1441-4d37-9627-943c9a548f43", "1fe81fe2-f846-4e36-a57e-695a13057a4d", "aaa9c401-ba7e-4747-b819-71afd4032103", "9ed10240-e264-4bb9-872f-5b322d59bc6c", "64807305-2729-4c90-93c6-b1130a4db588", "66858b7d-a8fc-44c7-ab73-90c3deee1c89", "ffe44d94-ff88-460d-9eb9-25e274c392a4", "ded6f19e-bdda-451c-a161-e3460d5c3edc", "4ad14ae5-78c1-4c1b-b1e1-697306b57784", "1881e8ea-dd61-42ae-9a89-4b650383dd40", "f139b735-fe95-4d3a-a9d4-d917a3c2328c", "d2323456-5a46-4b34-9972-32b9c345b4ef", "2b9ff6c8-5bc1-49b4-a1fe-713d6aa44f3f", "47a56e1c-24dd-4f2d-a075-275294d92258", "22b88bf0-5ce6-4704-b47f-4740a7510825", "0b625300-9268-49e4-9c10-ceb3bdb7e621", "d2932a82-b061-4a94-bc2f-5e72a0f4942b"], "metadata": {"window": "U.S.  Healthcare Solutions segment operating income to be in the range of $2.325 to $2.4 billion, representing growth\nof 3% to 6%;\nInternational Healthcare solutions segment operating income to be in the range of $685 to $715 million;\nInterest expense growth to be in the mid-teens percent range;\nAdjusted effective tax rate to be approximately 21 percent to 22 percent;\nAdjusted free cash flow to be approximately $2 to $2.5 billion;\nCapital expenditures in the $500 million range; and\nWeighted average diluted shares are expected to be approximately 212 million for the fiscal year.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on November 4, 2021. ", "original_text": "U.S. ", "page_label": "6", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4178326e-7085-471d-b59a-0a763f409150": {"node_ids": ["ec1ac552-5033-4a20-8a42-81889826bdc5", "bb097874-cd20-4354-a0ba-aa7298b5cf69", "b892b8fa-976e-45e5-8b18-9993047d4a52", "98a8f0f4-d3f9-4631-a82d-4e4cdabd68a3", "51f7506e-ce6a-4e07-9634-a7cb36562ded", "1181f044-904a-4630-a399-d806fb2ee26a"], "metadata": {"window": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated.  Among the factors that could cause actual results to differ materially from those projected,\nanticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or\nfrequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in\nincreasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\ngovernmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time\nconsuming or costly than expected; the Company's or Alliance Healthcare's failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between WBA and the Company, including with respect to the pharmaceutical distribution agreement and/or the global\ngeneric purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; managing foreign\nexpansion, including non-compliance with the U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import\nlaws and regulations; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a\nmajor customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of\nCOVID-19; financial market volatility and disruption; financial and other impacts of COVID-19 on our operations or business\ncontinuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate\nas designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, or the inability to capture\nall of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the\nCompany's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its\nstockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic\nconditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational\nfactors affecting the Company's business generally.  Certain additional factors that management believes could cause actual\noutcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\nFactors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary\nmaterially from those indicated. ", "page_label": "7", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3c8bd45b-ac5e-4397-ba2c-82a897ddb832": {"node_ids": ["7751b9b7-0e73-4092-ab5c-8de8386dcebc"], "metadata": {"window": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "\u00a0 \u00a0Three \nMonths Ended \nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$58,912,421 \u00a0\u00a0\u00a0 \u00a0$49,244,768 \u00a0\u00a0\u00a0 \u00a019.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a056,843,010 \u00a0\u00a0\u00a0 \u00a047,897,921 \u00a0\u00a0\u00a0 \u00a018.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a02,069,411 \u00a0\u00a03.51% \u00a01,346,847 \u00a0\u00a02.74% \u00a053.6%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a01,215,688 \u00a0\u00a02.06% \u00a0720,966 \u00a0\u00a01.46% \u00a068.6%\nDepreciation and amortization \u00a0177,721 \u00a0\u00a00.30% \u00a097,337 \u00a0\u00a00.20% \u00a082.6%\nEmployee severance, litigation, and other 3 \u00a096,410 \u00a0\u00a0\u00a0 \u00a06,641,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,507,516 \u00a0\u00a02.56% \u00a07,459,984 \u00a0\u00a015.15% \u00a0(79.8)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a0561,895 \u00a0\u00a00.95% \u00a0(6,113,137) \u00a0\u00a0(12.41)% \u00a0109.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net 4 \u00a0(46,637) \u00a0\u00a0\u00a0 \u00a0(4,387) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a054,596 \u00a0\u00a0\u00a0 \u00a034,707 \u00a0\u00a0\u00a0 \u00a057.3%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a0553,936 \u00a0\u00a00.94% \u00a0(6,143,457) \u00a0\u00a0(12.48)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0117,488 \u00a0\u00a0\u00a0 \u00a0(1,298,952) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a0436,448 \u00a0\u00a00.74% \u00a0(4,844,505) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "df6e7762-f404-4def-be69-c71cef041775": {"node_ids": ["e3b7e517-1edc-4af8-8b79-d133f45427c2", "49d971d2-88a4-48e0-a56c-d29a8d3e96a6", "5f68b27f-cd78-408f-94e7-b66e66c5216b", "7ca99a91-9ec2-4547-9c52-a19d609a876d", "f0642ca7-fdb7-474b-8686-8e7c35b4f139", "4c397fe2-faba-44ed-9362-c5e521721e3d", "fbbcd649-aaf5-4715-9389-3fca9e3ac58f", "36463de1-266f-4432-b9c3-62289a600f09", "76b77dcf-d40f-421c-a554-e978625ca37a"], "metadata": {"window": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021.  Includes a $35.8 million LIFO credit, an estimated $14.8 million assessment relating to the New York State\nOpioid Stewardship Act (for the period covering January 1, 2017 through December 31, 2018), and $0.5 million of gains from\nantitrust litigation settlements in the three months ended September 30, 2020.\n 2 Includes a $2.2 million credit of PharMEDium shutdown costs in the three months ended September 30, 2020.\n 3 Includes $7.0 million of employee severance, a $6.3 million legal accrual related to opioid litigation settlements, $39.0 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $44.1 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the three months ended September 30, 2021. ", "original_text": "Net loss (income) attributable to noncontrolling\ninterests \u00a01,250 \u00a0\u00a0\u00a0 \u00a0(1,567) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$437,698 \u00a0\u00a00.74% \u00a0$(4,846,072) \u00a0\u00a0(9.84)% \u00a0109.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.11 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.9%\nDiluted \u00a0$2.08 \u00a0\u00a0\u00a0 \u00a0$(23.74) \u00a0\u00a0\u00a0 \u00a0108.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0207,900 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a01.9%\nDiluted \u00a0210,810 \u00a0\u00a0\u00a0 \u00a0204,094 \u00a0\u00a0\u00a0 \u00a03.3%\n________________________________________\n1 Includes a $42.5 million LIFO credit and $21.4 million of gains from antitrust litigation settlements in the three months ended\nSeptember 30, 2021. ", "page_label": "9", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8e17dd7f-08e3-40f8-be90-86760ea4bebb": {"node_ids": ["f17d447d-76fd-401d-a53b-fdd9945d43ee"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(In thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended\nSeptember 30,\n2021 \u00a0% of \n Revenue \u00a0Fiscal Y ear Ended\nSeptember 30,\n2020 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$213,988,843 \u00a0\u00a0\u00a0 \u00a0$189,893,926 \u00a0\u00a0\u00a0 \u00a012.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0207,045,615 \u00a0\u00a0\u00a0 \u00a0184,702,042 \u00a0\u00a0\u00a0 \u00a012.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a06,943,228 \u00a0\u00a03.24% \u00a05,191,884 \u00a0\u00a02.73% \u00a033.7%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a03,594,251 \u00a0\u00a01.68% \u00a02,767,217 \u00a0\u00a01.46% \u00a029.9%\nDepreciation and amortization \u00a0505,172 \u00a0\u00a00.24% \u00a0391,062 \u00a0\u00a00.21% \u00a029.2%\nEmployee severance, litigation, and other 3 \u00a0471,911 \u00a0\u00a0\u00a0 \u00a06,807,307 \u00a0\u00a0\u00a0 \u00a0\u00a0\nGoodwill impairment \u00a06,373 \u00a0\u00a0\u00a0 \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a011,324 \u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a04,589,031 \u00a0\u00a02.14% \u00a010,327,238 \u00a0\u00a05.44% \u00a0(55.6)%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income (loss) \u00a02,354,197 \u00a0\u00a01.10% \u00a0(5,135,354) \u00a0\u00a0(2.70)% \u00a0145.8%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther income, net  4 \u00a0(41,736) \u00a0\u00a0\u00a0 \u00a0(1,581) \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0174,074 \u00a0\u00a0\u00a0 \u00a0137,883 \u00a0\u00a0\u00a0 \u00a026.2%\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome (loss) before income taxes \u00a02,221,859 \u00a0\u00a01.04% \u00a0(5,293,831) \u00a0\u00a0(2.79)% \u00a0142.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0677,251 \u00a0\u00a0\u00a0 \u00a0(1,894,273) \u00a0\u00a0\u00a0 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e6b7304f-5a55-4ef8-a202-1040e2e69013": {"node_ids": ["4fb806e9-54d6-40df-84d1-718f4b40021f", "6c397843-1f60-4c93-8e72-2f120f53d7d3", "c316e041-05af-494d-a229-244a1396dfd4", "490c4b03-ac21-4581-9729-6c2b488a80f2", "52f058f3-2c0a-4aaf-acc0-d4e7a545c275", "7c5d9cd3-7aec-4ac6-bf66-af8eea8fd1e3", "a1f44901-7ffa-40d3-aabf-d364b0085ad8"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021.  Includes an estimated $14.8 million assessment relating to the New York State Opioid Stewardship Act (for the\nperiod covering January 1, 2017 through December 31, 2018), $12.6 million of PharMEDium shutdown and remediation costs, $9.1\nmillion of gains from antitrust litigation settlements, and a $7.4 million LIFO expense in the fiscal year ended September 30, 2020.\n 2 Includes $46.8 million of PharMEDium shutdown and remediation costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the fiscal year ended September\n30, 2020.\n 3 Includes $13.7 million of employee severance, a $147.7 million legal accrual related to opioid litigation settlements, $124.9 million\nrelated to legal fees and opioid-related costs in connection with opioid lawsuits and investigations, and $185.6 million of other costs\nin connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring initiatives\nin the fiscal year ended September 30, 2021. ", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) \u00a01,544,608 \u00a0\u00a00.72% \u00a0(3,399,558) \u00a0\u00a0(1.79)% \u00a0145.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(4,676) \u00a0\u00a0\u00a0 \u00a0(9,158) \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income (loss) attributable to AmerisourceBergen\nCorporation \u00a0$1,539,932 \u00a0\u00a00.72% \u00a0$(3,408,716) \u00a0\u00a0(1.80)% \u00a0145.2%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$7.48 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.9%\nDiluted \u00a0$7.39 \u00a0\u00a0\u00a0 \u00a0$(16.65) \u00a0\u00a0\u00a0 \u00a0144.4%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,919 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a00.6%\nDiluted \u00a0208,465 \u00a0\u00a0\u00a0 \u00a0204,783 \u00a0\u00a0\u00a0 \u00a01.8%\n________________________________________\n1 Includes a $203.0 million LIFO credit and $168.8 million of gains from antitrust litigation settlements in the fiscal year ended\nSeptember 30, 2021. ", "page_label": "11", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "76b776b5-ce01-4272-8686-5c0e44dc0f4a": {"node_ids": ["639567ee-9d9c-48f5-83c0-cebdf3cf86f0", "a7576c22-3e2a-4827-95f2-0606cbc6a2d1", "303777c3-48e9-4cd6-af45-6094b451d201"], "metadata": {"window": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021.  Includes a $1,078.6 million tax benefit relating\nto the $6.6 billion legal expense accrual in connection with opioid lawsuits, $720.6 million of discrete tax benefits primarily\nattributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business, and a $360.7\nmillion tax benefit relating to Swiss tax reform in the fiscal year ended September 30, 2020.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income T ax\nExpense \u00a0Net Loss \n (Income) \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$2,069,411 \u00a0\u00a0$1,507,516 \u00a0\u00a0$561,895 \u00a0\u00a0$553,936 \u00a0\u00a0$117,488 \u00a0\u00a0$1,250 \u00a0\u00a0$437,698 \u00a0\u00a0$2.08\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(21,362) \u00a0\u00a0\u2014 \u00a0\u00a0(21,362) \u00a0\u00a0(21,362) \u00a0\u00a0(32,251) \u00a0\u00a0\u2014 \u00a0\u00a010,889 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(42,463) \u00a0\u00a0\u2014 \u00a0\u00a0(42,463) \u00a0\u00a0(42,463) \u00a0\u00a0(40,529) \u00a0\u00a0\u2014 \u00a0\u00a0(1,934) \u00a0\u00a0(0.01) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(81,932) \u00a0\u00a081,932 \u00a0\u00a081,932 \u00a0\u00a043,830 \u00a0\u00a0(5,734) \u00a0\u00a032,368 \u00a0\u00a00.15 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(96,410) \u00a0\u00a096,410 \u00a0\u00a096,410 \u00a0\u00a050,802 \u00a0\u00a0\u2014 \u00a0\u00a045,608 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\n12", "original_text": "million adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the fiscal year ended September 30, 2021. ", "page_label": "12", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1d9e34ec-8834-4b3e-b1a3-c77447dbdfa1": {"node_ids": ["fa0e4fe5-005e-4b71-b1b5-c94eea47417b", "6de82a6e-b765-45bf-a95c-4fd7af18927a", "e5489d13-7534-4367-bea0-2025757b1f17", "79682d58-56d3-4317-866a-92879ff9ab19", "e47925b3-561f-4112-9175-5f60e3da866d"], "metadata": {"window": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year\nquarter \u00a051.3 %\u00a064.9 %\u00a031.0 %\u00a027.6 %\u00a019.3 %\u00a0\u00a0 \u00a029.4 %\u00a026.5 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.51% \u00a03.40%\nOperating expenses \u00a02.56% \u00a02.23%\nOperating income \u00a00.95% \u00a01.18%\n________________________________________\n1 Includes a $6.3 million legal expense accrual related to opioid litigation settlements.\n 2 Includes $9.8 million of expense relating to Swiss tax reform and a $2.3 million loss on the currency remeasurement of the related\ndeferred tax assets, which is recorded within Other Income, Net.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "remeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a02,276 \u00a0\u00a0(9,784) \u00a0\u00a0\u2014 \u00a0\u00a012,060 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$2,005,586 \u00a0\u00a0$1,311,477 \u00a0\u00a0$694,109 \u00a0\u00a0$637,705 \u00a0\u00a0$129,556 \u00a0\u00a0$(4,484) \u00a0\u00a0$503,665 \u00a0\u00a0$2.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "13", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c59c9858-7f9e-4c22-b88c-9914022c50ea": {"node_ids": ["00e34dec-a3d1-4442-a058-f97b5b7e3f18"], "metadata": {"window": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "original_text": "GAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0 \u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0(Loss)\nIncome \n Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net (Loss) \n Income \n Attributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,346,847 \u00a0\u00a0$7,459,984 \u00a0\u00a0$(6,113,137 )\u00a0$(6,143,457 )\u00a0$(1,298,952 )\u00a0$(1,567 )\u00a0$(4,846,072 )\u00a0$(23.74 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(530 )\u00a0\u2014 \u00a0\u00a0(530 )\u00a0(530 )\u00a0112 \u00a0\u00a0\u2014 \u00a0\u00a0(642 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(35,773 )\u00a0\u2014 \u00a0\u00a0(35,773 )\u00a0(35,773 )\u00a0(8,989 )\u00a0\u2014 \u00a0\u00a0(26,784 )\u00a0(0.13 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0(2,200 )\u00a0(2,200 )\u00a0(2,132 )\u00a0\u2014 \u00a0\u00a0(68 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(25,133 )\u00a025,133 \u00a0\u00a025,133 \u00a0\u00a03,213 \u00a0\u00a0(437 )\u00a021,483 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,641,681 )\u00a06,641,681 \u00a0\u00a06,641,681 \u00a0\u00a01,081,721 \u00a0\u00a0\u2014 \u00a0\u00a05,559,960 \u00a0\u00a027.20 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(9,700 )\u00a0\u2014 \u00a0\u00a09,700 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n14", "page_label": "14", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1d4d83e5-ad60-4401-9163-dc510f0c875f": {"node_ids": ["508797a5-4419-4936-afe4-0a5be987abea", "a0865bd7-1ec9-4891-88a2-d82d95081f78", "f966e64b-1b18-4323-b038-4870145e9f8d", "ee2270e3-3e6e-48a0-84d6-d6ebb109a560", "16514a0f-d2b8-44f2-bea6-40e6355f92dc"], "metadata": {"window": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents an adjustment to discrete tax benefits previously recognized primarily attributable to the income tax deductions\nresulting from the permanent shutdown of the PharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Other \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(268 )\u00a0189 \u00a0457 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a00.10 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745 )\u00a0(1.75 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,325,344 \u00a0\u00a0$795,370 \u00a0\u00a0$529,974 \u00a0\u00a0$499,654 \u00a0\u00a0$108,565 \u00a0\u00a0$(1,815 )\u00a0$389,274 \u00a0\u00a0$1.89 \u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.74% \u00a02.69%\nOperating expenses \u00a015.15% \u00a01.62%\nOperating (loss) income \u00a0(12.41)% \u00a01.08%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "page_label": "15", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cc40b836-7413-4492-af80-8a1de5358048": {"node_ids": ["a5cc44b2-a987-4192-8ec4-f4e3209644fc"], "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "original_text": "\u00a0 \u00a0Gross Pr ofit \u00a0Operating \n Expenses \u00a0Operating\nIncome \u00a0Befor e \n Income T axes\u00a0Income T ax\nExpense \u00a0Noncontr olling\nInterests \u00a0to \n ABC \u00a0Per\nShare \u00a0\nGAAP \u00a0$6,943,228 \u00a0\u00a0$4,589,031 \u00a0\u00a0$2,354,197 \u00a0\u00a0$2,221,859 \u00a0\u00a0$677,251 \u00a0\u00a0$(4,676) \u00a0\u00a0$1,539,932 \u00a0\u00a0$7.39\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(168,794) \u00a0\u00a0\u2014 \u00a0\u00a0(168,794) \u00a0\u00a0(168,794) \u00a0\u00a0(47,517) \u00a0\u00a0\u2014 \u00a0\u00a0(121,277) \u00a0\u00a0(0.58) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(203,028) \u00a0\u00a0\u2014 \u00a0\u00a0(203,028) \u00a0\u00a0(203,028) \u00a0\u00a0(57,154) \u00a0\u00a0\u2014 \u00a0\u00a0(145,874) \u00a0\u00a0(0.70) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(176,221) \u00a0\u00a0176,221 \u00a0\u00a0176,221 \u00a0\u00a046,873 \u00a0\u00a0(7,498) \u00a0\u00a0121,850 \u00a0\u00a00.58 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother 1 \u00a0\u2014 \u00a0\u00a0(471,911) \u00a0\u00a0471,911 \u00a0\u00a0471,911 \u00a0\u00a087,304 \u00a0\u00a0\u2014 \u00a0\u00a0384,607 \u00a0\u00a01.84 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nnon-customer\nnote receivable \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a014,000 \u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGain on\nremeasurement\nof equity\ninvestment \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(64,721) \u00a0\u00a0(0.31) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGoodwill\nimpairment \u00a0\u2014 \u00a0\u00a0(6,373) \u00a0\u00a06,373 \u00a0\u00a06,373 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a06,373 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nassets \u00a0\u2014 \u00a0\u00a0(11,324) \u00a0\u00a011,324 \u00a0\u00a011,324 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a011,324 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain discrete\ntax benefits 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425) \u00a0\u00a0(0.10) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n16", "page_label": "16", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bb4fdbb9-341a-49fd-bc42-adff7066b683": {"node_ids": ["2d8fb1f7-3f85-4f0e-aabe-34e375a37aaa", "a09f8280-8d0b-4ce7-a345-22b7b925ebb2", "e3a5dec8-c95f-4139-b9f0-6e94a3d84b10", "43b96c01-a2c1-439d-b6a1-4c8846ed396f", "9eb7e837-ad70-4d2c-86bf-7b5f3aff1946", "6105568f-4de0-48a1-b53a-8308da3dc32d", "aa045908-b90c-4d46-8ff4-5f49aa76830c"], "metadata": {"window": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a025.9 %\u00a030.2 %\u00a020.1 %\u00a019.4 %\u00a022.0 %\u00a0\u00a0 \u00a018.3 %\u00a017.2 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.24% \u00a03.07%\nOperating expenses \u00a02.14% \u00a01.83%\nOperating income \u00a01.10% \u00a01.24%\n________________________________________\n1 Includes a $147.7 million legal expense accrual related to opioid litigation settlements.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $73.8 million of expense relating to Swiss tax reform, and a $3.4\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Income, Net.\n", "original_text": "Tax reform 3 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a03,362 \u00a0\u00a0(201,391) \u00a0\u00a0\u2014 \u00a0\u00a0204,753 \u00a0\u00a00.98 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$6,571,406 \u00a0\u00a0$3,923,202 \u00a0\u00a0$2,648,204 \u00a0\u00a0$2,468,507 \u00a0\u00a0$525,791 \u00a0\u00a0$(12,174) \u00a0\u00a0$1,930,542 \u00a0\u00a0$9.26\u00a04\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "17", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ce620db9-3cff-48e6-ab98-e86564c32b56": {"node_ids": ["1c7fd279-b4e6-4776-be60-f2f2a62f2620"], "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n (Loss)\nIncome \u00a0Befor e\nIncome \n Taxes \u00a0Income T ax \n (Benefit) \n Expense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP \u00a0$5,191,884 \u00a0\u00a0$10,327,238 \u00a0\u00a0$(5,135,354) \u00a0\u00a0$(5,293,831) \u00a0\u00a0$(1,894,273) \u00a0\u00a0$(9,158) \u00a0\u00a0$(3,408,716) \u00a0\u00a0$(16.65) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(9,076) \u00a0\u00a0\u2014 \u00a0\u00a0(9,076) \u00a0\u00a0(9,076) \u00a0\u00a0(1,988) \u00a0\u00a0\u2014 \u00a0\u00a0(7,088) \u00a0\u00a0(0.03) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a07,422 \u00a0\u00a0\u2014 \u00a0\u00a07,422 \u00a0\u00a07,422 \u00a0\u00a01,625 \u00a0\u00a0\u2014 \u00a0\u00a05,797 \u00a0\u00a00.03 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\nand\nremediation\ncosts \u00a012,556 \u00a0\u00a0(46,815) \u00a0\u00a059,371 \u00a0\u00a059,371 \u00a0\u00a012,996 \u00a0\u00a0\u2014 \u00a0\u00a046,375 \u00a0\u00a00.22 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nNew York\nState Opioid\nStewardship\nAct \u00a014,800 \u00a0\u00a0\u2014 \u00a0\u00a014,800 \u00a0\u00a014,800 \u00a0\u00a03,240 \u00a0\u00a0\u2014 \u00a0\u00a011,560 \u00a0\u00a00.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(110,478) \u00a0\u00a0110,478 \u00a0\u00a0110,478 \u00a0\u00a024,184 \u00a0\u00a0(1,745) \u00a0\u00a084,549 \u00a0\u00a00.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(6,807,307) \u00a0\u00a06,807,307 \u00a0\u00a06,807,307 \u00a0\u00a01,122,417 \u00a0\u00a0\u2014 \u00a0\u00a05,684,890 \u00a0\u00a027.66 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u2014 \u00a0\u00a0(361,652) \u00a0\u00a0361,652 \u00a0\u00a0361,652 \u00a0\u00a079,165 \u00a0\u00a0\u2014 \u00a0\u00a0282,487 \u00a0\u00a01.37 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0(12,153) \u00a0\u00a0(12,153) \u00a0\u00a0(2,660) \u00a0\u00a05,867 \u00a0\u00a0(3,626) \u00a0\u00a0(0.02) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndb\n18", "page_label": "18", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f3e87af4-1d6f-4b76-b64b-b57691f46031": {"node_ids": ["294f697d-8893-4c72-ac81-43f29bbea85a", "c4b8da48-d702-4913-83c1-c205998f450a", "b38836d8-b9f5-49b8-9372-25f430d69905", "c7a057aa-58f2-41b0-bb4e-fe84bb35c2c8", "15f8f8a8-73c4-484f-9b66-48c3d3121447", "3e9f9197-0747-452b-bb9c-053ca108277a"], "metadata": {"window": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n 2 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the\nPharMEDium business.\n 3 Represents a tax benefit relating to Swiss tax reform.\n 4 The sum of the components does not equal the total due to rounding.\n", "original_text": "debt \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a022,175 \u00a0\u00a04,854 \u00a0\u00a0\u2014 \u00a0\u00a017,321 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0720,590 \u00a0\u00a0\u2014 \u00a0\u00a0(720,590) \u00a0\u00a0(3.49) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0360,745 \u00a0\u00a0\u2014 \u00a0\u00a0(360,745) \u00a0\u00a0(1.75) \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$5,217,586 \u00a0\u00a0$3,013,139 \u00a0\u00a0$2,204,447 \u00a0\u00a0$2,068,145 \u00a0\u00a0$430,895 \u00a0\u00a0$(5,036) \u00a0\u00a0$1,632,214 \u00a0\u00a0$7.90 \u00a04\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.73% \u00a02.75%\nOperating expenses \u00a05.44% \u00a01.59%\nOperating (loss) income \u00a0(2.70)% \u00a01.16%\n________________________________________\n1 Includes a $6.6 billion legal expense accrual in connection with opioid lawsuits.\n", "page_label": "19", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0e765f75-ae88-4306-bf19-6049f47eba1a": {"node_ids": ["9b2138d6-acbc-4242-9764-5dd4b2d61df1", "996fc28a-abdf-4aa3-b8e3-9057a62d31e9", "fd490ae9-60d5-43f7-92f4-f70c97e744b8"], "metadata": {"window": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution\nServices \u00a0$51,247,348 \u00a0\u00a0$47,288,572 \u00a0\u00a08.4%\nOther \u00a07,701,487 \u00a0\u00a01,990,992 \u00a0\u00a0286.8%\nIntersegment\neliminations \u00a0(36,414) \u00a0\u00a0(34,796) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$58,912,421 \u00a0\u00a0$49,244,768 \u00a0\u00a019.6%\n20", "original_text": "\u00a0 \u00a02021 \u00a02020 \u00a02021 \u00a02020\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic shares outstanding \u00a0207,900 \u00a0\u00a0204,094 \u00a0\u00a0205,919 \u00a0204,783\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution \u00a02,910 \u00a0\u00a0\u2014 \u00a0\u00a02,546 \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0204,094 \u00a0\u00a0208,465 \u00a0\u00a0204,783 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nStock option and restricted stock unit dilution 1 \u00a0\u2014 \u00a0\u00a02,262 \u00a0\u00a0\u2014 \u00a0\u00a01,839 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNon-GAAP diluted shares outstanding \u00a0210,810 \u00a0\u00a0206,356 \u00a0\u00a0208,465 \u00a0\u00a0206,622 \u00a0\n1 For the non-GAAP presentation, diluted weighted average common shares outstanding has been adjusted to include the impact\nof the stock options and restricted stock units that were anti-dilutive for the GAAP presentation.\n", "page_label": "20", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c8688fdb-4311-4843-b66d-47fe768eac5d": {"node_ids": ["562def7c-12a7-4afa-80c0-ed39310b829e"], "metadata": {"window": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "original_text": "\u00a0 \u00a0Three Months Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$472,058 \u00a0\u00a0$425,567 \u00a0\u00a010.9%\nOther \u00a0223,277 \u00a0\u00a0104,525 \u00a0\u00a0113.6%\nIntersegment\neliminations \u00a0(1,226) \u00a0\u00a0(118) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a0694,109\u00a0\n\u00a0529,974\u00a0\n\u00a031.0%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a021,362 \u00a0\u00a0530 \u00a0\u00a0\u00a0\nLIFO credit \u00a042,463 \u00a0\u00a035,773 \u00a0\u00a0\u00a0\nPharMEDium shutdown\ncosts \u00a0\u2014 \u00a0\u00a02,200 \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(81,932) \u00a0\u00a0(25,133) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(96,410) \u00a0\u00a0(6,641,681) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$561,895 \u00a0\u00a0$(6,113,137) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.10% \u00a02.05% \u00a0\u00a0\n21", "page_label": "21", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3b18cbb8-a73c-49a5-af6d-bd8bb3edb0ab": {"node_ids": ["d0ba1e67-5c8d-4832-ae51-957adffd40a2", "76f3fede-d75c-4689-bb89-db5559af304d"], "metadata": {"window": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(dollars in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nRevenue \u00a02021 \u00a02020 \u00a0%\nChange\n22", "original_text": "Operating expenses \u00a01.18% \u00a01.15% \u00a0\u00a0\nOperating income \u00a00.92% \u00a00.90% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a012.09% \u00a018.08% \u00a0\u00a0\nOperating expenses \u00a09.19% \u00a012.83% \u00a0\u00a0\nOperating income \u00a02.90% \u00a05.25% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.51% \u00a02.74% \u00a0\u00a0\nOperating expenses \u00a02.56% \u00a015.15% \u00a0\u00a0\nOperating income\n(loss) \u00a00.95% \u00a0(12.41)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.40% \u00a02.69% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a02.23% \u00a01.62% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.18% \u00a01.08% \u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "22", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c453f395-ce3c-49ff-b342-3428bb9670d3": {"node_ids": ["f70c4d9b-9e4d-4479-9437-41f4fabead0e"], "metadata": {"window": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "original_text": "Pharmaceutical\nDistribution\nServices \u00a0$198,153,202 \u00a0\u00a0$182,467,189 \u00a0\u00a08.6%\nOther \u00a015,974,799 \u00a0\u00a07,525,102 \u00a0\u00a0112.3%\nIntersegment\neliminations \u00a0(139,158) \u00a0\u00a0(98,365) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$213,988,843 \u00a0\u00a0$189,893,926 \u00a0\u00a012.7%\n\u00a0 \u00a0Fiscal Y ear Ended Sept ember 30,\nOperating income\n(loss) \u00a02021 \u00a02020 \u00a0%\nChange\nPharmaceutical\nDistribution Services \u00a0$2,041,072 \u00a0\u00a0$1,807,001 \u00a0\u00a013.0%\nOther \u00a0614,973 \u00a0\u00a0400,139 \u00a0\u00a053.7%\nIntersegment\neliminations \u00a0(7,841) \u00a0\u00a0(2,693) \u00a0\u00a0\u00a0\nTotal segment\noperating income \u00a02,648,204\u00a0\n\u00a02,204,447\u00a0\n\u00a020.1%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust\nlitigation settlements \u00a0168,794 \u00a0\u00a09,076 \u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0203,028 \u00a0\u00a0(7,422) \u00a0\u00a0\u00a0\nPharMEDium\nshutdown and\nremediation costs \u00a0\u2014 \u00a0\u00a0(59,371) \u00a0\u00a0\u00a0\nNew York State Opioid\nStewardship Act \u00a0\u2014 \u00a0\u00a0(14,800) \u00a0\u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0(176,221) \u00a0\u00a0(110,478) \u00a0\u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0(471,911) \u00a0\u00a0(6,807,307) \u00a0\u00a0\u00a0\nGoodwill impairment \u00a0(6,373) \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nImpairment of assets \u00a0(11,324) \u00a0\u00a0(361,652) \u00a0\u00a0\u00a0\nContingent\n23", "page_label": "23", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a6793dca-8e31-4804-866a-0cb9e551bb83": {"node_ids": ["47a8d986-33b6-4cf8-a829-481ca5e466a5"], "metadata": {"window": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "original_text": "consideration\nadjustment \u00a0\u2014 \u00a0\u00a012,153 \u00a0\u00a0\u00a0\nOperating\nincome (loss) \u00a0$2,354,197 \u00a0\u00a0$(5,135,354) \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of\nrevenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical\nDistribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.17% \u00a02.10% \u00a0\u00a0\nOperating expenses \u00a01.14% \u00a01.11% \u00a0\u00a0\nOperating income \u00a01.03% \u00a00.99% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a014.32% \u00a018.60% \u00a0\u00a0\nOperating expenses \u00a010.47% \u00a013.28% \u00a0\u00a0\nOperating income \u00a03.85% \u00a05.32% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.24% \u00a02.73% \u00a0\u00a0\nOperating expenses \u00a02.14% \u00a05.44% \u00a0\u00a0\nOperating income\n(loss) \u00a01.10% \u00a0(2.70)% \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen\nCorporation (Non-\nGAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.07% \u00a02.75% \u00a0\u00a0\nAdjusted operating\nexpenses \u00a01.83% \u00a01.59% \u00a0\u00a0\nAdjusted operating\nincome \u00a01.24% \u00a01.16% \u00a0\u00a0\n24", "page_label": "24", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c2d9136c-f7a8-4540-b8a1-700d7e47c8ca": {"node_ids": ["a877893f-e1ca-4270-bbc8-b955b05e3b12", "c781d97d-d1f0-4d1c-b336-854e9eca14f8"], "metadata": {"window": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Fiscal Y ear Ended Sept ember 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,547,142 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 18,167,175 \u00a0\u00a013,846,301 \u00a0\nInventories 15,368,352 \u00a0\u00a012,589,278 \u00a0\nRight to recover asset 1,271,557 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 221,875 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 1,226,508 \u00a0\u00a0189,300 \u00a0\nTotal current assets 38,802,609 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,162,961 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,287,458 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 290,791 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,793,986 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0 \u00a0\u00a0\n25", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "25", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e663f9e9-9ad6-485e-8eed-8b1b19b80a43": {"node_ids": ["841574fb-3124-41d9-8cef-53cb2e5ceade"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,009,954 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 3,048,474 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 300,213 \u00a0\u00a0501,259 \u00a0\nTotal current liabilities 41,358,641 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,383,711 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 281,070 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,685,296 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,082,723 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 5,961,953 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 584,411 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $57,337,805 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0Fiscal Y ear Ended\nSeptember 30,\n\u00a0 2021 \u00a02020\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income (loss) $1,544,608 \u00a0\u00a0$(3,399,558) \u00a0\nAdjustments to reconcile net income (loss) to net cash provided by operating activities 1 754,656 \u00a0\u00a0(662,430) \u00a0\n26", "page_label": "26", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ea0ee79a-7bbc-4f00-908a-1aa32781d3da": {"node_ids": ["6404a2d1-e0ba-4882-82b3-afbad408a017"], "metadata": {"window": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "original_text": "Changes in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (930,078) \u00a0\u00a0(1,628,991) \u00a0\nInventories (1,116,344) \u00a0\u00a0(1,621,143) \u00a0\nAccounts payable 2,049,167 \u00a0\u00a03,300,832 \u00a0\nOther, net 2 364,577 \u00a0\u00a06,218,330 \u00a0\nNet cash provided by operating activities 2,666,586 \u00a0\u00a02,207,040 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (438,217) \u00a0\u00a0(369,677) \u00a0\nCost of acquired companies, net of cash acquired (5,563,040) \u00a0\u00a0\u2014 \u00a0\nCost of equity investments (162,620) \u00a0\u00a0(56,080) \u00a0\nOther 22,300 \u00a0\u00a045,886 \u00a0\nNet cash used in investing activities (6,141,577) \u00a0\u00a0(379,871) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,216,552 \u00a0\u00a0(32,006) \u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0(21,448) \u00a0\nPurchases of common stock (82,150) \u00a0\u00a0(420,449) \u00a0\nExercises of stock options 198,750 \u00a0\u00a0159,533 \u00a0\nCash dividends on common stock (366,648) \u00a0\u00a0(343,578) \u00a0\nOther (13,655) \u00a0\u00a054,331 \u00a0\nNet cash provided by (used in) financing activities 1,952,849 \u00a0\u00a0(603,617) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash (3,725) \u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash, cash equivalents, and restricted cash, including cash classified within\nassets held for sale (1,525,867) \u00a0\u00a01,223,552 \u00a0\nLess: Increase in cash classified within assets held for sale (1,751) \u00a0\u00a0\u2014 \u00a0\n27", "page_label": "27", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fd101fee-ca25-44af-b6d5-b7121628fc51": {"node_ids": ["d0894117-2b1f-4275-bc3c-f6220196a222", "3ca5f761-9035-4ed8-98c4-b134eb0bb36a", "30fa8b99-981f-42be-b363-d60eb0d65d47", "5e477d84-9a94-460b-a10d-c424e23cade3", "8e20a4e4-3731-4729-82b6-dd181425b948", "fecaf29a-c268-4061-a649-beda488ee4ed", "c5c094bb-52d6-4cc2-8c66-e8d04ffd269b", "e7f66d7f-3a7d-4220-a3f9-a644aa709340", "f6485b98-3a65-45d0-b960-eac27f938ef8", "0d85ab9b-047b-4f73-9468-d6b52a33b7b6", "8fd54a39-26cf-4815-ab9a-f6445759aa77", "115b8cf5-0947-4dcc-8b9c-2c643804044f", "193d727e-98a3-4e80-8e4a-a86c40690046", "383756d6-f991-4743-b27d-fabfc81a4a96", "f2f59bfb-2db4-4c43-8130-b09fa32861db", "10237c77-3e51-42ab-8c08-48c192e25df1", "2dace65c-dcf6-421f-8d67-133c5bca885a", "9d3cb665-08ed-4ccd-ba57-bb373ae4a631"], "metadata": {"window": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n 2 Includes a $6.6 billion expense accrual in connection with opioid lawsuits and a $482.6 million increase in income tax receivable\nprimarily as a result of recognizing certain discrete tax benefits in the fiscal year ended September 30, 2020.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\nnotes, and a $500 million term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare,\noffset in part by a $250 million repayment of the above-mentioned term loan in the fiscal year ended September 30, 2021.\n 4 Includes $2,547.1 million of Cash and Cash Equivalents, $463.0 million of restricted cash in Prepaid Expenses and Other, and $60.0\nmillion of restricted cash in Other Long-Term Assets on the Company's Condensed Consolidated Balance Sheet as of September 30,\n2021.\n", "original_text": "(Decrease) increase in cash, cash equivalents, and restricted cash (1,527,618) \u00a0\u00a01,223,552 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of year 4,597,746 \u00a0\u00a03,374,194 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of year 4 $3,070,128 \u00a0\u00a0$4,597,746 \u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million and a $1,545.0 million benefit for deferred income taxes primarily\nattributable to Swiss tax reform and a legal accrual in connection with opioid lawsuits in the fiscal year ended September 30, 2020.\n", "page_label": "28", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bf004786-7343-4c2d-928b-7d6ad10c2b26": {"node_ids": ["397f9888-60e6-4b15-a1fd-dcc3e47c88cb", "a378fed4-dc18-4bff-a373-9bcd66ba5f5a", "b1c42a3e-26ed-4ac9-b454-1e021095d7bf", "34a78981-3568-4de5-a989-2730a61fab67", "5773f45a-2ac1-4cf3-8248-025500f11379", "8c1fec52-749e-46aa-afe2-bf0f5912b449", "4afc920b-4e97-4b54-a1df-feb6fb9767fb", "70322c88-1422-442b-9cd3-30f0cb0478a1", "bb2ec193-c1ce-4f67-803e-6154541df593", "31b78c4b-fcf6-4033-a596-d98ff12c0ed4", "4296aa14-9ca9-4b9d-85d8-d42fc7c7022c", "9153c390-5c09-44a4-8739-0cef40d50c8d", "bfb599fb-67c1-479f-a4c1-69660b00081d", "bbdaed2e-5f77-4125-bf39-133987502e5d", "4e3e9974-09a8-4985-b111-c6ea42ecdba1", "2611beaa-c292-4268-a19c-195c73922481", "e913fa32-b92c-407a-9183-ea073640fe51", "fd666e3c-e4c3-455a-ad27-063580646a55", "dc15ca88-ff5d-480e-8f3b-0512429b96ef", "d12de588-6206-437f-85a4-33c5378b20a1", "4827243d-1722-4735-bf26-ffc6479267b5", "288dcd51-5fa0-4ffb-9b18-a6e0d5b93bbd", "1b8ca618-f02f-49c1-8731-15361f7bc8c4", "8457146f-f3bd-4c8e-8dae-3c067bf17909", "33407750-be01-4054-8d48-e4f5d4629ada", "e30a39b9-31ea-4551-bd67-027987ad5d04", "748a7f51-567d-4ad8-b34b-847c1b88f988", "27af8bb2-74a9-48c4-b675-ccb1dde71a8e", "acb01b96-6807-4a07-9d08-9fbcb03a7540"], "metadata": {"window": "delay or prevent generic drugs from entering the market.  The PharMEDium remediation costs related to costs incurred in\nconnection with suspended production activities following U.S.  Food and Drug Administration inspections.  PharMEDium\nshutdown costs are costs incurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "delay or prevent generic drugs from entering the market. ", "page_label": "29", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c238faa8-711d-4721-ae81-ec0d1f5154d8": {"node_ids": ["210d1984-6635-428b-a25b-b8db37a6e2d7", "c0d2380a-e050-4a9c-8a18-0b98e1b42d14", "01165a53-0267-43b3-99b7-ef9fdb2d7325", "a452bc23-4e4a-463f-9c92-24662ea9845d", "e6ad2e8b-1e56-467e-8280-7a3a8bcb1857", "01762e21-5295-43a6-aa0d-1fe1276ba80f", "b253c9de-f4ba-409a-b1b6-cfdba6dfd869", "3267d029-116e-4852-9ddb-1525a9b190ba", "02c6d203-e70c-45b9-8f53-d2207a741f1b", "5b6a5927-8fda-4b1b-8b0e-ae6a36068fda", "46d93e7c-d17c-4c6c-a8fc-e046d98f793c", "fb114c45-ff22-4971-b162-aa08a7b2f078", "c2d32b7c-11f9-475b-beb7-a35b1c26e5e1", "3248643f-af34-45f6-8b45-e0f32af6a0b6", "3aa6fccf-5abd-47a5-84a4-2ca6f40f2622"], "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gain from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs; the\nexpense related to the NYS Opioid Act; acquisition-related intangibles amortization; employee severance, litigation, and\nother; impairment of assets; a contingent consideration adjustment; loss on early retirement of debt; goodwill impairment;\ngain on remeasurement of an equity investment; and impairment of a non-customer note receivable, in each case net of the\ntax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of certain discrete\ntax benefits primarily attributable to the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the CARES Act and the per share impact of certain benefits and expenses relating to tax reforms in\nSwitzerland and the UK are also excluded from adjusted diluted earnings per share. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "30", "file_name": "CEN-Q4-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q4-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 245069, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}